{"PMC7508198": [["A 33-year-old obese patient (body mass index=32.7), without other comorbidities, wasadmitted to our hospital with complaints of severe low back pain radiating to thehypogastric region.", [["body", "ANATOMY", 29, 33], ["back", "ANATOMY", 139, 143], ["thehypogastric region", "ANATOMY", 162, 183], ["low back pain", "DISEASE", 135, 148], ["patient", "ORGANISM", 20, 27], ["body", "ORGANISM_SUBDIVISION", 29, 33], ["patient", "SPECIES", 20, 27], ["body mass index", "TEST", 29, 44], ["other comorbidities", "PROBLEM", 60, 79], ["severe low back pain", "PROBLEM", 128, 148], ["33-", "OBSERVATION_MODIFIER", 2, 5], ["severe", "OBSERVATION_MODIFIER", 128, 134], ["low", "OBSERVATION_MODIFIER", 135, 138], ["back", "ANATOMY", 139, 143], ["pain", "OBSERVATION", 144, 148], ["thehypogastric", "ANATOMY", 162, 176], ["region", "ANATOMY_MODIFIER", 177, 183]]], ["The pain had started about 8 hours before admission.", [["pain", "DISEASE", 4, 8], ["The pain", "PROBLEM", 0, 8]]], ["Additionally,11 days before admission, he had experienced dry cough, a fever of 38.2\u00b0C, and fatigueand was diagnosed with SARS-CoV-2 infection by nasopharyngeal swab testing.", [["nasopharyngeal swab", "ANATOMY", 146, 165], ["dry cough", "DISEASE", 58, 67], ["fever", "DISEASE", 71, 76], ["fatigueand", "DISEASE", 92, 102], ["SARS-CoV-2 infection", "DISEASE", 122, 142], ["nasopharyngeal swab", "MULTI-TISSUE_STRUCTURE", 146, 165], ["dry cough", "PROBLEM", 58, 67], ["a fever", "PROBLEM", 69, 76], ["fatigueand", "PROBLEM", 92, 102], ["SARS", "PROBLEM", 122, 126], ["CoV", "PROBLEM", 127, 130], ["2 infection", "PROBLEM", 131, 142], ["nasopharyngeal swab testing", "TEST", 146, 173], ["cough", "OBSERVATION", 62, 67], ["infection", "OBSERVATION", 133, 142], ["nasopharyngeal", "ANATOMY", 146, 160]]]], "PMC7312488": [], "de73cb5959ef98692db693d16b4740ff771205b4": [["The ancient Greeks identified 4 different kinds of knowledge.", [["4 different kinds", "OBSERVATION_MODIFIER", 30, 47]]], ["Two of them, episteme and techne, are dominant in medical research.", [["dominant", "OBSERVATION_MODIFIER", 38, 46]]], ["Its methods are deduction and generalization; it is the basis for modern science and appears in medicine as the quest for methodological rigor.", [["methodological rigor", "PROBLEM", 122, 142]]], ["Its most muscular manifestation is the evidence-based medicine movement.", [["muscular", "ANATOMY", 9, 17], ["most muscular", "OBSERVATION_MODIFIER", 4, 17], ["medicine movement", "OBSERVATION", 54, 71]]], ["Its goals are the development and testing of \"recipes\"; it is the basis for modern engineering and appears in medicine largely in the form of numeric reasoning, such as applied statistical inference.", [["modern engineering", "TREATMENT", 76, 94]]]], "da0c22f3aee161f1b6414a7940c24705370636ce": [["Hence, not only the average but also the distribution of the measured parameter can be obtained, which provides a direct insight into the structure, function, and dynamics of the investigated molecule or particle and into the mechanisms behind the processes the molecule or the particle is involved in.", [["particle", "OBSERVATION_MODIFIER", 278, 286]]], ["Investigation of molecules and particles one by one has particular significance in biological systems, considering that in a living cell often there are only a handful of molecules of the same species present.", [["cell", "ANATOMY", 132, 136], ["cell", "CELL", 132, 136], ["molecules", "OBSERVATION", 17, 26], ["particles", "OBSERVATION_MODIFIER", 31, 40]]], ["Although particles, in the biological sense, are usually supramolecular assemblies and therefore are composed of a number of molecules, similar methodological principles can be applied to them as to single molecules.", [["particles", "OBSERVATION_MODIFIER", 9, 18], ["supramolecular assemblies", "OBSERVATION", 57, 82]]]], "58b271e61f06e148dd80d5dbf0c037118dcc9963": [["BackgroundGiven the structure of the genetic code synonymous codons will yield distinct amino acid changes upon mutation.", [["amino acid", "CHEMICAL", 88, 98], ["amino acid", "CHEMICAL", 88, 98], ["amino acid", "AMINO_ACID", 88, 98], ["distinct amino acid changes upon mutation", "PROBLEM", 79, 120], ["synonymous codons", "OBSERVATION", 50, 67], ["amino acid", "OBSERVATION", 88, 98]]], ["The extraordinarily large number of possible encodings in natural genes is to some extent restricted by two encoding biases referred to as codon bias [1, 2] and codon pair bias [3] .", [["natural genes", "DNA", 58, 71], ["encodings in natural genes", "PROBLEM", 45, 71], ["codon pair bias", "TEST", 161, 176], ["extraordinarily", "OBSERVATION_MODIFIER", 4, 19], ["large", "OBSERVATION_MODIFIER", 20, 25], ["number", "OBSERVATION_MODIFIER", 26, 32], ["possible", "UNCERTAINTY", 36, 44], ["encodings", "OBSERVATION", 45, 54], ["natural genes", "OBSERVATION", 58, 71]]], ["The remarkable nucleotide composition of the human immunodeficiency virus type 1 (HIV-1) genome with an above average percentage of A nucleotides results in a codon composition that is different from that of the human genome [4] .", [["nucleotide", "CHEMICAL", 15, 25], ["human immunodeficiency virus", "DISEASE", 45, 73], ["nucleotide", "CHEMICAL", 15, 25], ["nucleotides", "CHEMICAL", 134, 145], ["human immunodeficiency virus type 1", "ORGANISM", 45, 80], ["HIV-1", "ORGANISM", 82, 87], ["human", "ORGANISM", 212, 217], ["human immunodeficiency virus type 1 (HIV-1) genome", "DNA", 45, 95], ["human genome", "DNA", 212, 224], ["human", "SPECIES", 45, 50], ["immunodeficiency virus type 1", "SPECIES", 51, 80], ["HIV-1", "SPECIES", 82, 87], ["human", "SPECIES", 212, 217], ["human immunodeficiency virus type 1", "SPECIES", 45, 80], ["HIV-1", "SPECIES", 82, 87], ["human", "SPECIES", 212, 217], ["the human immunodeficiency virus type", "PROBLEM", 41, 78], ["A nucleotides", "TREATMENT", 132, 145], ["a codon composition", "TREATMENT", 157, 176]]], ["Especially the more flexible third codon positions are preferentially occupied by A-nucleotides [5] , which induces ribosome pausing and inefficient translation [6] .", [["ribosome", "ANATOMY", 116, 124], ["ribosome", "CELLULAR_COMPONENT", 116, 124], ["flexible third codon positions", "DNA", 20, 50], ["ribosome pausing", "OBSERVATION", 116, 132]]], ["The bias of A-rich codons in HIV-1 is thought to be the action of host enzymes of the APOBEC3 family.", [["HIV-1", "ORGANISM", 29, 34], ["APOBEC3", "GENE_OR_GENE_PRODUCT", 86, 93], ["A-rich codons", "DNA", 12, 25], ["host enzymes", "PROTEIN", 66, 78], ["APOBEC3 family", "PROTEIN", 86, 100], ["HIV-1", "SPECIES", 29, 34], ["HIV-1", "SPECIES", 29, 34], ["A-rich codons in HIV", "PROBLEM", 12, 32], ["A-rich codons", "OBSERVATION", 12, 25]]], ["On the contrary, it has been shown that the HIV-1 A-rich sequence is not merely an evolutionary artefact of enzyme-induced hypermutations, and that HIV-1 has adapted to rely on A-rich RNA sequences to support the synthesis of viral cDNA during reverse transcription [7] .", [["HIV-1", "ORGANISM", 44, 49], ["HIV-1", "ORGANISM", 148, 153], ["HIV-1 A-rich sequence", "DNA", 44, 65], ["enzyme", "PROTEIN", 108, 114], ["A-rich RNA sequences", "DNA", 177, 197], ["viral cDNA", "DNA", 226, 236], ["HIV-1", "SPECIES", 44, 49], ["HIV-1", "SPECIES", 44, 49], ["HIV-1", "SPECIES", 148, 153], ["A-rich sequence", "TEST", 50, 65], ["enzyme", "TEST", 108, 114], ["induced hypermutations", "PROBLEM", 115, 137], ["A-rich RNA sequences", "TREATMENT", 177, 197], ["viral cDNA", "PROBLEM", 226, 236]]], ["Recent data have identified a novel antiviral mechanism within the innate immune response, in which human SLFN11 selectively inhibits viral protein synthesis in HIV-infected cells by means of codon-bias discrimination [8] .", [["cells", "ANATOMY", 174, 179], ["SLFN11", "CHEMICAL", 106, 112], ["HIV-infected", "DISEASE", 161, 173], ["human", "ORGANISM", 100, 105], ["SLFN11", "GENE_OR_GENE_PRODUCT", 106, 112], ["HIV", "ORGANISM", 161, 164], ["cells", "CELL", 174, 179], ["human SLFN11", "PROTEIN", 100, 112], ["HIV-infected cells", "CELL_TYPE", 161, 179], ["human", "SPECIES", 100, 105], ["HIV", "SPECIES", 161, 164], ["human", "SPECIES", 100, 105], ["HIV", "SPECIES", 161, 164], ["a novel antiviral mechanism", "PROBLEM", 28, 55], ["viral protein synthesis", "PROBLEM", 134, 157], ["HIV", "PROBLEM", 161, 164], ["infected cells", "PROBLEM", 165, 179], ["codon", "TEST", 192, 197]]], ["Synonymous substitutions optimizing for human cell expression reduces the antiviral activity of SLFN11 [8] .", [["cell", "ANATOMY", 46, 50], ["human", "ORGANISM", 40, 45], ["cell", "CELL", 46, 50], ["human", "SPECIES", 40, 45], ["human", "SPECIES", 40, 45], ["Synonymous substitutions", "TREATMENT", 0, 24], ["human cell expression", "TREATMENT", 40, 61]]], ["Synonymous mutation is thought to be selectively neutral.", [["Synonymous mutation", "PROBLEM", 0, 19], ["thought to be", "UNCERTAINTY", 23, 36]]], ["However, previous work demonstrated that synonymous substitutions can negatively affect the replication capacity of several RNA viruses [9] , including HIV-1 [10] .BackgroundRecently, a new approach, termed synthetic attenuated virus engineering (SAVE), was used to rationally design live attenuated poliovirus and influenza virus vaccines [3, 11] .", [["influenza virus", "DISEASE", 315, 330], ["HIV-1", "ORGANISM", 152, 157], ["poliovirus", "ORGANISM", 300, 310], ["influenza virus", "ORGANISM", 315, 330], ["HIV-1", "SPECIES", 152, 157], ["influenza virus", "SPECIES", 315, 330], ["HIV-1", "SPECIES", 152, 157], ["poliovirus", "SPECIES", 300, 310], ["synonymous substitutions", "PROBLEM", 41, 65], ["the replication capacity", "PROBLEM", 88, 112], ["several RNA viruses", "PROBLEM", 116, 135], ["HIV", "TEST", 152, 155], ["a new approach", "TREATMENT", 184, 198], ["termed synthetic attenuated virus engineering", "TREATMENT", 200, 245], ["live attenuated poliovirus", "TREATMENT", 284, 310], ["influenza virus vaccines", "TREATMENT", 315, 339], ["synonymous substitutions", "OBSERVATION", 41, 65], ["several", "OBSERVATION_MODIFIER", 116, 123], ["RNA viruses", "OBSERVATION", 124, 135]]], ["SAVE works by recoding and synthesizing the viral genome; the wild-type amino acid sequence is preserved, but the existing synonymous codons are rearranged to create a suboptimal arrangement of codon pairs [3] .", [["amino acid", "CHEMICAL", 72, 82], ["amino acid", "CHEMICAL", 72, 82], ["amino acid", "AMINO_ACID", 72, 82], ["SAVE", "PROTEIN", 0, 4], ["viral genome", "DNA", 44, 56], ["wild-type amino acid sequence", "DNA", 62, 91], ["the viral genome", "PROBLEM", 40, 56], ["the wild-type amino acid sequence", "TEST", 58, 91], ["the existing synonymous codons", "PROBLEM", 110, 140], ["codon pairs", "PROBLEM", 194, 205], ["viral genome", "OBSERVATION", 44, 56], ["synonymous codons", "OBSERVATION", 123, 140]]], ["Although the reasons are still not well understood, some codon pairs occur more frequently, and others less frequently, than expected [12] .", [["codon pairs", "DNA", 57, 68], ["some codon pairs", "PROBLEM", 52, 68]]], ["The overall codon usage in a genome can differ dramatically among species, although less so among closely related species [13] .", [["dramatically among species", "PROBLEM", 47, 73], ["codon usage", "OBSERVATION", 12, 23]]], ["It is unclear why some codon pairs are under-or overrepresented.", [["codon pairs", "DNA", 23, 34], ["some codon pairs", "PROBLEM", 18, 34], ["unclear why", "UNCERTAINTY", 6, 17], ["codon", "OBSERVATION", 23, 28]]], ["It has been suggested that structural features that regulate tRNA geometry within the ribosome may govern genomic codon pair patterns, driving enhanced translational fidelity and/or rate [14] .", [["ribosome", "ANATOMY", 86, 94], ["ribosome", "CELLULAR_COMPONENT", 86, 94], ["structural features", "PROBLEM", 27, 46], ["tRNA geometry", "PROBLEM", 61, 74], ["tRNA geometry", "OBSERVATION", 61, 74], ["genomic codon", "OBSERVATION", 106, 119]]], ["For example, as described by Coleman et al., the amino acid pair Ala-Glu is expected to be encoded by GCCGAA and GCAGAG approximately equally as often.", [["amino acid", "CHEMICAL", 49, 59], ["Ala-Glu", "CHEMICAL", 65, 72], ["amino acid", "CHEMICAL", 49, 59], ["Ala-Glu", "CHEMICAL", 65, 72], ["amino acid", "AMINO_ACID", 49, 59], ["Ala-Glu", "AMINO_ACID", 65, 72], ["GCCGAA", "GENE_OR_GENE_PRODUCT", 102, 108], ["GCCGAA", "PROTEIN", 102, 108], ["GCAGAG", "PROTEIN", 113, 119], ["the amino acid pair Ala", "TEST", 45, 68]]], ["However, the codon pair GCCGAA is strongly underrepresented and is used only one-seventh as often as GCAGAG [3] .BackgroundSAVE was used previously to recode poliovirus and influenza virus genomes so that they include infrequently used codon pairs, which led to the generation of highly attenuated viruses [3, 11] .", [["influenza virus", "ORGANISM", 173, 188], ["codon pair GCCGAA", "DNA", 13, 30], ["codon pairs", "DNA", 236, 247], ["influenza virus", "SPECIES", 173, 188], ["influenza virus", "SPECIES", 173, 188], ["the codon pair GCCGAA", "TEST", 9, 30], ["poliovirus", "PROBLEM", 158, 168], ["influenza virus genomes", "PROBLEM", 173, 196], ["codon pairs", "PROBLEM", 236, 247], ["highly attenuated viruses", "PROBLEM", 280, 305], ["attenuated", "OBSERVATION_MODIFIER", 287, 297], ["viruses", "OBSERVATION", 298, 305]]], ["Mice immunized with recoded attenuated polioviruses were found to have protective immunity when they were challenged with wild-type poliovirus [3] .", [["Mice", "ORGANISM", 0, 4], ["polioviruses", "ORGANISM", 39, 51], ["wild-type poliovirus", "ORGANISM", 122, 142], ["Mice", "SPECIES", 0, 4], ["attenuated polioviruses", "PROBLEM", 28, 51]]], ["The mechanism of attenuation is unclear, but it has been suggested that translation is affected [3, 11] .", [["attenuation", "OBSERVATION", 17, 28]]], ["Since codon-pair deoptimization is the result of tens, hundreds, or even thousands of nucleotide substitutions, it has been also suggested that reversion to virulence is unlikely to occur.", [["nucleotide", "CHEMICAL", 86, 96], ["nucleotide", "CHEMICAL", 86, 96], ["nucleotide substitutions", "PROBLEM", 86, 110], ["virulence", "PROBLEM", 157, 166]]], ["Furthermore, attenuation may be fine tuned by adjusting the extent of codon-pair deoptimization [3] .BackgroundIn contrast to poliovirus and influenza virus, after retrotranscription of its genomic RNA into a proviral intermediate, HIV-1 (a retrovirus belonging to the Lentiviridae family) DNA is permanently integrated into the host cell genome and transcribed by the host RNA polymerase II [15] .", [["cell", "ANATOMY", 334, 338], ["influenza virus", "DISEASE", 141, 156], ["poliovirus", "ORGANISM", 126, 136], ["influenza virus", "ORGANISM", 141, 156], ["HIV-1", "ORGANISM", 232, 237], ["retrovirus", "ORGANISM", 241, 251], ["Lentiviridae", "GENE_OR_GENE_PRODUCT", 269, 281], ["DNA", "CELLULAR_COMPONENT", 290, 293], ["host cell", "CELL", 329, 338], ["RNA polymerase II", "GENE_OR_GENE_PRODUCT", 374, 391], ["genomic RNA", "RNA", 190, 201], ["Lentiviridae family) DNA", "DNA", 269, 293], ["host cell genome", "DNA", 329, 345], ["host RNA polymerase II", "PROTEIN", 369, 391], ["influenza virus", "SPECIES", 141, 156], ["HIV-1", "SPECIES", 232, 237], ["influenza virus", "SPECIES", 141, 156], ["HIV-1", "SPECIES", 232, 237], ["codon-pair deoptimization", "TREATMENT", 70, 95], ["BackgroundIn contrast", "TREATMENT", 101, 122], ["poliovirus", "PROBLEM", 126, 136], ["influenza virus", "PROBLEM", 141, 156], ["HIV", "PROBLEM", 232, 235], ["a retrovirus", "TREATMENT", 239, 251], ["may be", "UNCERTAINTY", 25, 31], ["influenza virus", "OBSERVATION", 141, 156], ["host cell genome", "OBSERVATION", 329, 345]]], ["Moreover, HIV-1 can initiate translation either by the classical cap-dependent mechanism or by internal recruitment of the ribosome through RNA domains called IRESs (internal ribosome entry sites) [16] .", [["ribosome", "ANATOMY", 123, 131], ["HIV-1", "ORGANISM", 10, 15], ["ribosome", "CELLULAR_COMPONENT", 123, 131], ["IRESs", "GENE_OR_GENE_PRODUCT", 159, 164], ["RNA domains", "DNA", 140, 151], ["IRESs", "PROTEIN", 159, 164], ["internal ribosome entry sites", "DNA", 166, 195], ["HIV-1", "SPECIES", 10, 15], ["HIV-1", "SPECIES", 10, 15], ["HIV", "PROBLEM", 10, 13], ["IRESs (internal ribosome entry sites", "TREATMENT", 159, 195], ["internal", "OBSERVATION_MODIFIER", 95, 103], ["recruitment", "OBSERVATION", 104, 115]]], ["To explore whether recoding synonymous codon pairs will generate viruses with altered replication capacity, we redesigned different parts of the HIV-1 genome.", [["HIV-1", "ORGANISM", 145, 150], ["synonymous codon pairs", "DNA", 28, 50], ["HIV-1 genome", "DNA", 145, 157], ["HIV-1", "SPECIES", 145, 150], ["HIV-1", "SPECIES", 145, 150], ["recoding synonymous codon pairs", "PROBLEM", 19, 50], ["altered replication capacity", "PROBLEM", 78, 106], ["synonymous codon", "OBSERVATION", 28, 44]]], ["To phenotypically modify the replicative properties of HIV-1, we recoded the gag and protease (contained within the pol gene) coding regions by introducing optimized or deoptimized codon pairs without altering the amino acid sequence.", [["amino acid", "CHEMICAL", 214, 224], ["amino acid", "CHEMICAL", 214, 224], ["HIV-1", "ORGANISM", 55, 60], ["gag", "GENE_OR_GENE_PRODUCT", 77, 80], ["pol", "GENE_OR_GENE_PRODUCT", 116, 119], ["amino acid", "AMINO_ACID", 214, 224], ["gag", "DNA", 77, 80], ["protease", "PROTEIN", 85, 93], ["pol gene", "DNA", 116, 124], ["deoptimized codon pairs", "DNA", 169, 192], ["amino acid sequence", "PROTEIN", 214, 233], ["HIV-1", "SPECIES", 55, 60], ["HIV-1", "SPECIES", 55, 60], ["HIV", "PROBLEM", 55, 58], ["protease", "TREATMENT", 85, 93], ["deoptimized codon pairs", "TREATMENT", 169, 192], ["the amino acid sequence", "TEST", 210, 233]]], ["Gag and protease coding regions were chosen in order to explore proteins with different function, structural and enzymatic, respectively.", [["Gag", "GENE_OR_GENE_PRODUCT", 0, 3], ["Gag and protease coding regions", "DNA", 0, 31], ["Gag and protease coding regions", "PROBLEM", 0, 31]]], ["When redesigned gag and protease fragments were recombined with HIV-1 infectious clones that lacked gag or protease, the resulting viruses showed significantly modified viral replication capacity in MT-4 cells and peripheral blood mononuclear cells (PBMCs).Construction of synthetically recoded HIV-1 with modified codon-pair biasWe recoded the HIV-1 protease and gag coding regions by introducing different codon pairs.", [["MT-4 cells", "ANATOMY", 199, 209], ["peripheral blood mononuclear cells", "ANATOMY", 214, 248], ["PBMCs", "ANATOMY", 250, 255], ["gag", "GENE_OR_GENE_PRODUCT", 16, 19], ["HIV-1", "ORGANISM", 64, 69], ["clones", "CELL", 81, 87], ["gag", "GENE_OR_GENE_PRODUCT", 100, 103], ["MT-4 cells", "CELL", 199, 209], ["peripheral blood mononuclear cells", "CELL", 214, 248], ["PBMCs", "CELL", 250, 255], ["HIV-1", "ORGANISM", 295, 300], ["HIV-1 protease", "GENE_OR_GENE_PRODUCT", 345, 359], ["redesigned gag and protease fragments", "DNA", 5, 42], ["protease", "PROTEIN", 107, 115], ["MT-4 cells", "CELL_LINE", 199, 209], ["peripheral blood mononuclear cells", "CELL_TYPE", 214, 248], ["PBMCs", "CELL_TYPE", 250, 255], ["HIV-1", "DNA", 295, 300], ["modified codon-pair biasWe", "DNA", 306, 332], ["HIV-1 protease", "DNA", 345, 359], ["gag coding regions", "DNA", 364, 382], ["codon pairs", "DNA", 408, 419], ["HIV-1", "SPECIES", 64, 69], ["HIV-1", "SPECIES", 295, 300], ["HIV-1", "SPECIES", 345, 350], ["HIV-1", "SPECIES", 64, 69], ["HIV-1", "SPECIES", 295, 300], ["HIV-1", "SPECIES", 345, 350], ["redesigned gag and protease fragments", "PROBLEM", 5, 42], ["HIV", "PROBLEM", 64, 67], ["1 infectious clones", "PROBLEM", 68, 87], ["gag or protease", "PROBLEM", 100, 115], ["the resulting viruses", "PROBLEM", 117, 138], ["significantly modified viral replication capacity", "PROBLEM", 146, 195], ["peripheral blood mononuclear cells", "TEST", 214, 248], ["PBMCs", "TEST", 250, 255], ["modified codon", "TREATMENT", 306, 320], ["gag coding regions", "PROBLEM", 364, 382], ["viral replication capacity", "OBSERVATION", 169, 195], ["peripheral", "ANATOMY_MODIFIER", 214, 224], ["blood", "ANATOMY", 225, 230], ["mononuclear cells", "OBSERVATION", 231, 248], ["codon pairs", "OBSERVATION", 408, 419]]], ["The virus was recoded to use codon pairs that are underrepresented or overrepresented relative to the human genome by means of a previously described algorithm [3] .", [["human", "ORGANISM", 102, 107], ["codon pairs", "DNA", 29, 40], ["human genome", "DNA", 102, 114], ["human", "SPECIES", 102, 107], ["human", "SPECIES", 102, 107], ["The virus", "PROBLEM", 0, 9], ["codon pairs", "TREATMENT", 29, 40], ["virus", "OBSERVATION", 4, 9]]], ["Only synonymous substitutions were introduced.", [["synonymous substitutions", "TREATMENT", 5, 29], ["synonymous substitutions", "OBSERVATION", 5, 29]]], ["Recoded segments had the same amino acid sequence as the wild-type segments, but different pairwise arrangements of synonymous codons.", [["amino acid", "CHEMICAL", 30, 40], ["amino acid", "CHEMICAL", 30, 40], ["amino acid", "AMINO_ACID", 30, 40], ["amino acid sequence", "PROTEIN", 30, 49], ["wild-type segments", "DNA", 57, 75], ["the same amino acid sequence", "PROBLEM", 21, 49], ["synonymous codons", "PROBLEM", 116, 133], ["synonymous codons", "OBSERVATION", 116, 133]]], ["Codon bias and the folding free energy of the RNA were also controlled (Additional file 1: Table S1 , Additional file 2: Figure S1 ).", [["Codon bias", "PROBLEM", 0, 10], ["the folding free energy of the RNA", "PROBLEM", 15, 49]]], ["Recoded fragments were chemically synthesized, recombined with an infectious HIV-1 DNA clone in which protease or gag had been deleted and the resulting viral stocks sequenced.", [["fragments", "ANATOMY", 8, 17], ["HIV-1", "ORGANISM", 77, 82], ["gag", "GENE_OR_GENE_PRODUCT", 114, 117], ["infectious HIV-1 DNA clone", "DNA", 66, 92], ["protease", "PROTEIN", 102, 110], ["HIV-1", "SPECIES", 77, 82], ["HIV-1", "SPECIES", 77, 82], ["Recoded fragments", "PROBLEM", 0, 17], ["an infectious HIV", "PROBLEM", 63, 80], ["DNA clone", "PROBLEM", 83, 92], ["gag", "PROBLEM", 114, 117], ["the resulting viral stocks", "PROBLEM", 139, 165], ["infectious", "OBSERVATION", 66, 76], ["viral stocks", "OBSERVATION", 153, 165]]], ["To avoid that recombination was prevented by the mutations, no substitutions were introduced in the recombination regions.Construction of synthetically recoded HIV-1 with modified codon-pair biasWe first designed and constructed an entire deoptimized protease gene, HIV-Pmin, as well as an optimized protease gene, HIV-Pmax ( Figure 1 ).", [["HIV-1", "ORGANISM", 160, 165], ["HIV-Pmin", "ORGANISM", 266, 274], ["recombination regions", "DNA", 100, 121], ["modified codon-pair biasWe", "DNA", 171, 197], ["deoptimized protease gene", "DNA", 239, 264], ["HIV-Pmin", "DNA", 266, 274], ["protease gene", "DNA", 300, 313], ["HIV-1", "SPECIES", 160, 165], ["HIV", "SPECIES", 266, 269], ["HIV-1", "SPECIES", 160, 165], ["HIV-Pmin", "SPECIES", 266, 274], ["substitutions", "PROBLEM", 63, 76], ["modified codon", "TREATMENT", 171, 185], ["an entire deoptimized protease gene", "TREATMENT", 229, 264], ["an optimized protease gene", "TREATMENT", 287, 313]]], ["Of the 297 nucleotides that encode the HIV-1 protease, HIV-Pmin and HIV-Pmax contain 57 and 38 synonymous substitutions, respectively (Table 1) .", [["nucleotides", "CHEMICAL", 11, 22], ["HIV-1", "ORGANISM", 39, 44], ["HIV-Pmin", "ORGANISM", 55, 63], ["HIV-Pmax", "ORGANISM", 68, 76], ["HIV-1 protease", "PROTEIN", 39, 53], ["HIV-1", "SPECIES", 39, 44], ["HIV", "SPECIES", 55, 58], ["HIV", "SPECIES", 68, 71], ["HIV-1", "SPECIES", 39, 44], ["HIV-Pmin", "SPECIES", 55, 63], ["HIV-Pmax", "SPECIES", 68, 76], ["the HIV", "TEST", 35, 42], ["HIV", "TEST", 55, 58], ["HIV", "TEST", 68, 71]]], ["HIV-Pmin has a codon pair-bias score (see Methods) much lower than that of human genes, while HIV-Pmax has a codon pair-bias score much higher than that of human genes ( Table 1 ).", [["HIV-Pmin", "ORGANISM", 0, 8], ["human", "ORGANISM", 75, 80], ["HIV-Pmax", "ORGANISM", 94, 102], ["human", "ORGANISM", 156, 161], ["Pmin", "DNA", 4, 8], ["codon pair", "DNA", 15, 25], ["human genes", "DNA", 75, 86], ["codon pair", "DNA", 109, 119], ["human genes", "DNA", 156, 167], ["HIV", "SPECIES", 0, 3], ["human", "SPECIES", 75, 80], ["human", "SPECIES", 156, 161], ["HIV", "SPECIES", 0, 3], ["human", "SPECIES", 75, 80], ["HIV", "SPECIES", 94, 97], ["human", "SPECIES", 156, 161], ["bias score", "PROBLEM", 120, 130]]], ["The percentage of As in the HIV-Pmin sequence decreased from 0.36 to 0.30, and the percentage of Gs increased from 0.23 to 0.27.", [["HIV", "ORGANISM", 28, 31], ["Gs", "GENE_OR_GENE_PRODUCT", 97, 99], ["HIV-Pmin sequence", "DNA", 28, 45], ["Gs", "PROTEIN", 97, 99], ["HIV", "SPECIES", 28, 31], ["HIV-Pmin", "SPECIES", 28, 36], ["the HIV-Pmin sequence", "TEST", 24, 45], ["Gs", "TEST", 97, 99], ["percentage", "OBSERVATION_MODIFIER", 4, 14]]], ["In contrast, the percentage of As in the HIV-Pmax sequence slightly increased to 0.38 and the percentage of Gs, 0.22, was almost identical to that of the wild-type sequence.", [["As", "CHEMICAL", 31, 33], ["HIV", "ORGANISM", 41, 44], ["Gs", "GENE_OR_GENE_PRODUCT", 108, 110], ["HIV-Pmax sequence", "DNA", 41, 58], ["Gs", "PROTEIN", 108, 110], ["wild-type sequence", "DNA", 154, 172], ["HIV", "SPECIES", 41, 44], ["the HIV-Pmax sequence", "TEST", 37, 58], ["Gs", "TEST", 108, 110], ["percentage", "OBSERVATION_MODIFIER", 17, 27], ["increased", "OBSERVATION_MODIFIER", 68, 77]]], ["After recombination of these two synthetic constructs with an HIV-1 infectious clone, no viable virus could be isolated from MT-4 cells transfected with HIV-Pmin, even after five blind passages.", [["MT-4 cells", "ANATOMY", 125, 135], ["HIV-1", "ORGANISM", 62, 67], ["clone", "CELL", 79, 84], ["MT-4 cells", "CELL", 125, 135], ["HIV-Pmin", "ORGANISM", 153, 161], ["MT-4 cells", "CELL_LINE", 125, 135], ["HIV-1", "SPECIES", 62, 67], ["HIV", "SPECIES", 153, 156], ["HIV-1", "SPECIES", 62, 67], ["HIV-Pmin", "SPECIES", 153, 161], ["these two synthetic constructs", "PROBLEM", 23, 53], ["an HIV-1 infectious clone", "PROBLEM", 59, 84], ["viable virus", "PROBLEM", 89, 101]]], ["As expected, HIV-Pmax yielded a viable virus that was titrated and replicated.", [["HIV-Pmax", "ORGANISM", 13, 21], ["HIV", "SPECIES", 13, 16], ["HIV", "SPECIES", 13, 16], ["HIV-Pmax", "TEST", 13, 21], ["a viable virus", "PROBLEM", 30, 44]]], ["When the replication capacity of HIV-Pmax was assayed in MT-4 cells and PBMCs, HIV-Pmax was as fit as the wild-type virus in both cell types ( Figure 2) .Construction of synthetically recoded HIV-1 with modified codon-pair biasTo obtain deoptimized viable virus, we reduced the number of underrepresented pair codons present in HIV-Pmin ( Figure 1 ).", [["MT-4 cells", "ANATOMY", 57, 67], ["PBMCs", "ANATOMY", 72, 77], ["cell", "ANATOMY", 130, 134], ["HIV-Pmax", "ORGANISM", 33, 41], ["MT-4 cells", "CELL", 57, 67], ["PBMCs", "CELL", 72, 77], ["HIV-Pmax", "ORGANISM", 79, 87], ["wild-type virus", "ORGANISM", 106, 121], ["cell", "CELL", 130, 134], ["HIV-1", "ORGANISM", 192, 197], ["MT-4 cells", "CELL_LINE", 57, 67], ["PBMCs", "CELL_TYPE", 72, 77], ["HIV", "SPECIES", 79, 82], ["HIV-1", "SPECIES", 192, 197], ["HIV", "SPECIES", 328, 331], ["HIV", "SPECIES", 33, 36], ["HIV", "SPECIES", 79, 82], ["HIV-1", "SPECIES", 192, 197], ["HIV-Pmin", "SPECIES", 328, 336], ["HIV-Pmax", "TEST", 33, 41], ["PBMCs", "TEST", 72, 77], ["HIV-Pmax", "TEST", 79, 87], ["type virus", "PROBLEM", 111, 121], ["modified codon", "TREATMENT", 203, 217], ["pair bias", "PROBLEM", 218, 227], ["deoptimized viable virus", "PROBLEM", 237, 261], ["underrepresented pair codons", "PROBLEM", 288, 316], ["virus", "OBSERVATION", 256, 261], ["pair codons", "OBSERVATION", 305, 316]]], ["These new variants, which have a different number of synonymous substitutions and different codon-pair scores (Table 1) , yielded viruses with diverse ex vivo replication capabilities ( Figure 2 ).", [["synonymous substitutions", "TREATMENT", 53, 77], ["viruses", "PROBLEM", 130, 137], ["diverse ex vivo replication capabilities", "TREATMENT", 143, 183], ["new", "OBSERVATION_MODIFIER", 6, 9], ["variants", "OBSERVATION", 10, 18], ["synonymous substitutions", "OBSERVATION", 53, 77], ["different codon", "OBSERVATION", 82, 97], ["viruses", "OBSERVATION", 130, 137]]], ["HIV-PminB, HIV-PminC, and HIV-PminBC produced viable virus in MT-4 cells and PBMCs with a replication capacity that was indistinguishable from the wild-type virus (p = 0.2317, 0.8742, and 0.1984, respectively, for MT-4 cells and p = 0.8539, 0.2789 and 0.1014, respectively, for PBMCs).", [["MT-4 cells", "ANATOMY", 62, 72], ["PBMCs", "ANATOMY", 77, 82], ["MT-4 cells", "ANATOMY", 214, 224], ["PBMCs", "ANATOMY", 278, 283], ["HIV-PminB", "ORGANISM", 0, 9], ["HIV-PminC", "ORGANISM", 11, 20], ["HIV-PminBC", "ORGANISM", 26, 36], ["MT-4 cells", "CELL", 62, 72], ["PBMCs", "CELL", 77, 82], ["wild-type virus", "ORGANISM", 147, 162], ["MT-4 cells", "CELL", 214, 224], ["PBMCs", "CELL", 278, 283], ["MT-4 cells", "CELL_LINE", 62, 72], ["PBMCs", "CELL_TYPE", 77, 82], ["MT", "PROTEIN", 214, 216], ["PBMCs", "CELL_TYPE", 278, 283], ["HIV", "SPECIES", 0, 3], ["HIV", "SPECIES", 11, 14], ["HIV", "SPECIES", 26, 29], ["HIV", "SPECIES", 0, 3], ["HIV-PminC", "SPECIES", 11, 20], ["HIV-PminBC", "SPECIES", 26, 36], ["HIV", "TEST", 0, 3], ["HIV", "TEST", 11, 14], ["PminC", "TEST", 15, 20], ["HIV", "TEST", 26, 29], ["viable virus", "PROBLEM", 46, 58], ["PBMCs", "TEST", 77, 82], ["a replication capacity", "TEST", 88, 110], ["MT", "TEST", 214, 216], ["p", "TEST", 229, 230], ["PBMCs", "TEST", 278, 283], ["virus", "OBSERVATION", 53, 58]]], ["Growth competition experiments in MT-4 cells between the former variants and the wild-type virus confirmed that these deoptimized protease viruses had a replication capacity similar to that of the wild-type virus (data not shown).", [["MT-4 cells", "ANATOMY", 34, 44], ["MT-4 cells", "CELL", 34, 44], ["wild-type virus", "ORGANISM", 81, 96], ["wild-type virus", "ORGANISM", 197, 212], ["MT-4 cells", "CELL_LINE", 34, 44], ["type virus", "PROBLEM", 86, 96], ["these deoptimized protease viruses", "PROBLEM", 112, 146], ["a replication capacity", "PROBLEM", 151, 173], ["type virus", "PROBLEM", 202, 212]]], ["In contrast, HIV-PminA, with only 15 synonymous substitutions (Table 1 ), produced a virus that had its replication capacity highly reduced in PBMCs (p < 0.001) and MT-4 cells (p < 0.05) ( Figure 2 ).", [["PBMCs", "ANATOMY", 143, 148], ["MT-4 cells", "ANATOMY", 165, 175], ["HIV-PminA", "ORGANISM", 13, 22], ["PBMCs", "CELL", 143, 148], ["MT-4 cells", "CELL", 165, 175], ["PBMCs", "CELL_TYPE", 143, 148], ["MT-4 cells", "CELL_LINE", 165, 175], ["HIV", "SPECIES", 13, 16], ["HIV-PminA", "SPECIES", 13, 22], ["HIV-PminA", "TEST", 13, 22], ["15 synonymous substitutions", "PROBLEM", 34, 61], ["a virus", "PROBLEM", 83, 90], ["its replication capacity", "PROBLEM", 100, 124], ["PBMCs", "TEST", 143, 148], ["MT", "TEST", 165, 167], ["virus", "OBSERVATION", 85, 90], ["reduced", "OBSERVATION_MODIFIER", 132, 139]]], ["Of note, all constructs except HIV-PminA had a similar infectivity/ p24 antigen ratio compared to HIV-Pwt (see time 0 on Figure 2A and B).", [["HIV-PminA", "ORGANISM", 31, 40], ["p24 antigen", "GENE_OR_GENE_PRODUCT", 68, 79], ["HIV-Pwt", "ORGANISM", 98, 105], ["p24 antigen", "PROTEIN", 68, 79], ["HIV", "SPECIES", 31, 34], ["HIV", "SPECIES", 98, 101], ["HIV-PminA", "SPECIES", 31, 40], ["HIV-Pwt", "SPECIES", 98, 105], ["HIV", "PROBLEM", 31, 34], ["a similar infectivity/ p24 antigen ratio", "PROBLEM", 45, 85], ["HIV", "TEST", 98, 101], ["Pwt", "TEST", 102, 105]]], ["This result was also an indicator of the HIV-PminA attenuation.", [["HIV", "ORGANISM", 41, 44], ["PminA", "GENE_OR_GENE_PRODUCT", 45, 50], ["HIV", "SPECIES", 41, 44], ["HIV", "OBSERVATION", 41, 44], ["PminA attenuation", "OBSERVATION", 45, 62]]], ["No viable virus was obtained from HIV-PminAB and HIV-PminAC constructs.Construction of synthetically recoded HIV-1 with modified codon-pair biasTo investigate the possible effect of codon pair bias on translation, we used a GFP reporter HIV-1 single cycle infectious clone (pNL4-3-deltaE-EGFP).", [["HIV-PminAB", "ORGANISM", 34, 44], ["HIV", "ORGANISM", 49, 52], ["HIV-1", "ORGANISM", 109, 114], ["GFP", "GENE_OR_GENE_PRODUCT", 224, 227], ["HIV-1", "ORGANISM", 237, 242], ["pNL4-3", "GENE_OR_GENE_PRODUCT", 274, 280], ["EGFP", "GENE_OR_GENE_PRODUCT", 288, 292], ["HIV-PminAB and HIV-PminAC constructs", "DNA", 34, 70], ["HIV-1", "DNA", 109, 114], ["GFP reporter HIV-1 single cycle infectious clone", "DNA", 224, 272], ["pNL4", "DNA", 274, 278], ["deltaE", "DNA", 281, 287], ["EGFP", "DNA", 288, 292], ["HIV", "SPECIES", 34, 37], ["HIV", "SPECIES", 49, 52], ["HIV-1", "SPECIES", 109, 114], ["HIV-1", "SPECIES", 237, 242], ["HIV", "SPECIES", 34, 37], ["HIV", "SPECIES", 49, 52], ["HIV-1", "SPECIES", 109, 114], ["HIV-1", "SPECIES", 237, 242], ["viable virus", "PROBLEM", 3, 15], ["HIV", "TEST", 34, 37], ["HIV", "PROBLEM", 49, 52], ["modified codon-pair bias", "TREATMENT", 120, 144], ["codon pair bias", "PROBLEM", 182, 197], ["a GFP reporter HIV", "TEST", 222, 240], ["single cycle infectious clone", "PROBLEM", 243, 272], ["pNL4", "TEST", 274, 278], ["viable", "OBSERVATION_MODIFIER", 3, 9], ["virus", "OBSERVATION", 10, 15]]], ["Because GFP expression depends on the vector transfection efficiency only and not on the viral replication capacity, normalization of GFP production after transfection can be used to quantify viral growth, viral transcription, and viral translation efficiency.", [["GFP", "GENE_OR_GENE_PRODUCT", 8, 11], ["GFP", "GENE_OR_GENE_PRODUCT", 134, 137], ["GFP", "PROTEIN", 8, 11], ["GFP", "PROTEIN", 134, 137], ["GFP expression", "PROBLEM", 8, 22], ["the vector transfection efficiency", "PROBLEM", 34, 68], ["the viral replication capacity", "PROBLEM", 85, 115], ["GFP production", "PROBLEM", 134, 148], ["transfection", "TREATMENT", 155, 167], ["viral growth", "PROBLEM", 192, 204], ["viral transcription", "PROBLEM", 206, 225], ["viral translation efficiency", "PROBLEM", 231, 259], ["viral translation efficiency", "OBSERVATION", 231, 259]]], ["HIV-1 protease recoded variants were used in these experiments.", [["HIV-1", "ORGANISM", 0, 5], ["HIV-1 protease recoded variants", "DNA", 0, 31], ["HIV-1", "SPECIES", 0, 5], ["HIV-1", "SPECIES", 0, 5], ["HIV", "PROBLEM", 0, 3], ["1 protease recoded variants", "TREATMENT", 4, 31]]], ["After cell vector transfection and GFP normalization, quantification of the production of viral protein p24 confirmed the lower replication capacity of the HIV-PminA deoptimized variant compared to wild-type virus ( Figure 3 ).", [["cell", "ANATOMY", 6, 10], ["cell", "CELL", 6, 10], ["GFP", "GENE_OR_GENE_PRODUCT", 35, 38], ["p24", "GENE_OR_GENE_PRODUCT", 104, 107], ["HIV-PminA", "ORGANISM", 156, 165], ["wild-type virus", "ORGANISM", 198, 213], ["viral protein p24", "PROTEIN", 90, 107], ["PminA", "PROTEIN", 160, 165], ["HIV-PminA", "SPECIES", 156, 165], ["cell vector transfection", "TREATMENT", 6, 30], ["GFP normalization", "TEST", 35, 52], ["viral protein p24", "TEST", 90, 107], ["the lower replication capacity", "PROBLEM", 118, 148], ["the HIV", "TEST", 152, 159], ["PminA deoptimized variant", "PROBLEM", 160, 185], ["lower replication", "OBSERVATION_MODIFIER", 122, 139], ["capacity", "OBSERVATION_MODIFIER", 140, 148]]], ["The reduction in p24 was not accompanied by a reduction in the production of gag RNA ( Table 2 ), suggesting that deoptimized codon pairs reduced translation.Construction of synthetically recoded HIV-1 with modified codon-pair biasTo explore how codon-pair deoptimization could affect other HIV-1 genomic regions, we deoptimized the gag coding region.", [["p24", "GENE_OR_GENE_PRODUCT", 17, 20], ["gag RNA ( Table 2", "GENE_OR_GENE_PRODUCT", 77, 94], ["HIV-1", "ORGANISM", 196, 201], ["p24", "PROTEIN", 17, 20], ["gag RNA", "RNA", 77, 84], ["deoptimized codon pairs", "DNA", 114, 137], ["HIV-1 genomic regions", "DNA", 291, 312], ["gag coding region", "DNA", 333, 350], ["HIV-1", "SPECIES", 196, 201], ["HIV-1", "SPECIES", 291, 296], ["HIV-1", "SPECIES", 196, 201], ["HIV-1", "SPECIES", 291, 296], ["The reduction in p24", "PROBLEM", 0, 20], ["a reduction", "PROBLEM", 44, 55], ["the production of gag RNA", "PROBLEM", 59, 84], ["deoptimized codon pairs reduced translation", "PROBLEM", 114, 157], ["modified codon-pair bias", "TREATMENT", 207, 231], ["the gag coding region", "PROBLEM", 329, 350], ["reduction", "OBSERVATION_MODIFIER", 4, 13], ["p24", "OBSERVATION", 17, 20], ["reduction", "OBSERVATION_MODIFIER", 46, 55], ["gag RNA", "OBSERVATION", 77, 84]]], ["Gag encodes the viral capsid proteins and therefore has a very different role in HIV-1 biology from that of virus protease.", [["Gag", "GENE_OR_GENE_PRODUCT", 0, 3], ["HIV-1", "ORGANISM", 81, 86], ["Gag", "PROTEIN", 0, 3], ["viral capsid proteins", "PROTEIN", 16, 37], ["virus protease", "PROTEIN", 108, 122], ["HIV-1", "SPECIES", 81, 86], ["HIV-1", "SPECIES", 81, 86], ["the viral capsid proteins", "PROBLEM", 12, 37], ["virus protease", "TREATMENT", 108, 122], ["viral capsid proteins", "OBSERVATION", 16, 37]]], ["Three hundred and eight synonymous substitutions were introduced in the 1 503 nucleotides of gag.", [["nucleotides", "CHEMICAL", 78, 89], ["gag", "GENE_OR_GENE_PRODUCT", 93, 96], ["1 503 nucleotides of gag", "DNA", 72, 96], ["eight synonymous substitutions", "TREATMENT", 18, 48], ["synonymous substitutions", "OBSERVATION", 24, 48]]], ["No substitutions were introduced in the gag-pol ribosomal slip site or in the p6 portion of gag, in order to avoid lethality and/or the introduction of nonsynonymous substitutions.", [["gag-pol", "GENE_OR_GENE_PRODUCT", 40, 47], ["gag", "GENE_OR_GENE_PRODUCT", 92, 95], ["gag-pol ribosomal slip site", "DNA", 40, 67], ["p6 portion", "DNA", 78, 88], ["substitutions", "PROBLEM", 3, 16], ["pol ribosomal slip site", "PROBLEM", 44, 67], ["lethality", "PROBLEM", 115, 124], ["nonsynonymous substitutions", "PROBLEM", 152, 179], ["substitutions", "OBSERVATION", 3, 16], ["ribosomal slip", "OBSERVATION", 48, 62], ["gag", "OBSERVATION", 92, 95], ["nonsynonymous substitutions", "OBSERVATION", 152, 179]]], ["Similar to the results obtained with the protease variants, HIV-Gmin ( Figure 1 ) yielded no viable virus.", [["HIV-Gmin", "ORGANISM", 60, 68], ["protease variants", "PROTEIN", 41, 58], ["HIV", "SPECIES", 60, 63], ["HIV-Gmin", "SPECIES", 60, 68], ["the protease variants", "TEST", 37, 58], ["HIV", "TEST", 60, 63], ["viable virus", "PROBLEM", 93, 105], ["no", "UNCERTAINTY", 90, 92], ["viable virus", "OBSERVATION", 93, 105]]], ["Again, (Table 3) , produced viable viruses.", [["viruses", "OBSERVATION", 35, 42]]], ["Similar to deoptimized protease sequences, these four constructs had a lower percentage of As and an increased percentage of Gs (data not shown).", [["As", "CHEMICAL", 91, 93], ["Gs", "GENE_OR_GENE_PRODUCT", 125, 127], ["deoptimized protease sequences", "DNA", 11, 41], ["Gs", "PROTEIN", 125, 127], ["deoptimized protease sequences", "TREATMENT", 11, 41], ["an increased percentage of Gs", "PROBLEM", 98, 127], ["increased", "OBSERVATION_MODIFIER", 101, 110]]], ["Likewise, the HIV-GminA, HIV-GminB, HIV-GminC, and HIV-GminD constructs had a lower infectivity/p24 antigen ratio compared to HIV-Gwt (see time 0 on Figure 4A and B), suggesting that they were attenuated.", [["HIV-GminA", "ORGANISM", 14, 23], ["HIV-GminB", "ORGANISM", 25, 34], ["HIV-GminC", "ORGANISM", 36, 45], ["HIV-GminD", "ORGANISM", 51, 60], ["p24 antigen", "GENE_OR_GENE_PRODUCT", 96, 107], ["HIV-Gwt", "ORGANISM", 126, 133], ["HIV-GminA, HIV-GminB, HIV-GminC, and HIV-GminD constructs", "DNA", 14, 71], ["p24 antigen", "PROTEIN", 96, 107], ["HIV", "SPECIES", 14, 17], ["HIV", "SPECIES", 25, 28], ["HIV", "SPECIES", 36, 39], ["HIV", "SPECIES", 51, 54], ["HIV", "SPECIES", 126, 129], ["HIV-GminA", "SPECIES", 14, 23], ["HIV", "SPECIES", 25, 28], ["HIV-GminC", "SPECIES", 36, 45], ["HIV-GminD", "SPECIES", 51, 60], ["HIV-Gwt", "SPECIES", 126, 133], ["the HIV", "TEST", 10, 17], ["GminA", "TEST", 18, 23], ["HIV", "TEST", 25, 28], ["GminB", "TEST", 29, 34], ["HIV", "TEST", 36, 39], ["GminC", "TEST", 40, 45], ["HIV", "PROBLEM", 51, 54], ["a lower infectivity/p24 antigen ratio", "PROBLEM", 76, 113], ["HIV", "TEST", 126, 129], ["attenuated", "OBSERVATION", 193, 203]]], ["Indeed, these four viable deoptimized viruses showed a highly significant attenuated phenotype in PBMCs (p < 0.001).Construction of synthetically recoded HIV-1 with modified codon-pair biasHIV-GminA, HIV-GminB, and HIV-GminC were also highly attenuated in MT-4 cells (p < 0.001) ( Figure 4 ).Construction of synthetically recoded HIV-1 with modified codon-pair biasWe next tested the susceptibility of recoded HIV-1 variants to antiretroviral compounds.", [["PBMCs", "ANATOMY", 98, 103], ["MT-4 cells", "ANATOMY", 256, 266], ["PBMCs", "CELL", 98, 103], ["HIV-1", "ORGANISM", 154, 159], ["GminA", "GENE_OR_GENE_PRODUCT", 193, 198], ["HIV-GminB", "ORGANISM", 200, 209], ["HIV-GminC", "ORGANISM", 215, 224], ["MT-4 cells", "CELL", 256, 266], ["HIV-1", "ORGANISM", 330, 335], ["HIV-1", "ORGANISM", 410, 415], ["PBMCs", "CELL_TYPE", 98, 103], ["HIV-GminA, HIV-GminB, and HIV-GminC", "DNA", 189, 224], ["MT-4 cells", "CELL_LINE", 256, 266], ["modified codon-pair biasWe", "DNA", 341, 367], ["HIV-1", "SPECIES", 154, 159], ["HIV", "SPECIES", 200, 203], ["HIV", "SPECIES", 215, 218], ["HIV-1", "SPECIES", 330, 335], ["HIV-1", "SPECIES", 410, 415], ["HIV-1", "SPECIES", 154, 159], ["HIV", "SPECIES", 200, 203], ["HIV-GminC", "SPECIES", 215, 224], ["HIV-1", "SPECIES", 330, 335], ["HIV-1", "SPECIES", 410, 415], ["a highly significant attenuated phenotype in PBMCs", "PROBLEM", 53, 103], ["modified codon", "TEST", 165, 179], ["HIV", "TEST", 189, 192], ["GminA", "TEST", 193, 198], ["HIV", "TEST", 200, 203], ["HIV-GminC", "TEST", 215, 224], ["modified codon", "TREATMENT", 341, 355], ["antiretroviral compounds", "TREATMENT", 428, 452], ["highly", "OBSERVATION_MODIFIER", 55, 61], ["significant", "OBSERVATION_MODIFIER", 62, 73], ["attenuated", "OBSERVATION_MODIFIER", 74, 84], ["phenotype", "OBSERVATION", 85, 94], ["antiretroviral compounds", "OBSERVATION", 428, 452]]], ["The association between hypersusceptibility to protease inhibitors and low replication capacity of viruses isolated from chronically infected patients promoted us to test the susceptibility of recoded HIV-1 variants to antiretroviral compounds [17] .", [["chronically infected", "DISEASE", 121, 141], ["patients", "ORGANISM", 142, 150], ["HIV-1", "ORGANISM", 201, 206], ["patients", "SPECIES", 142, 150], ["HIV-1", "SPECIES", 201, 206], ["HIV-1", "SPECIES", 201, 206], ["hypersusceptibility to protease inhibitors", "TREATMENT", 24, 66], ["low replication capacity of viruses", "PROBLEM", 71, 106], ["antiretroviral compounds", "TEST", 219, 243], ["low replication", "OBSERVATION_MODIFIER", 71, 86]]], ["The IC50 of all viable gag and protease recoded variants to two NRTIs, AZT and TNF, and four protease inhibitors, NFV, DRV, ATV and APV, was calculated.", [["NRTIs", "CHEMICAL", 64, 69], ["AZT", "CHEMICAL", 71, 74], ["NFV", "CHEMICAL", 114, 117], ["ATV", "CHEMICAL", 124, 127], ["APV", "CHEMICAL", 132, 135], ["NRTIs", "CHEMICAL", 64, 69], ["AZT", "CHEMICAL", 71, 74], ["NFV", "CHEMICAL", 114, 117], ["APV", "CHEMICAL", 132, 135], ["gag", "GENE_OR_GENE_PRODUCT", 23, 26], ["NRTIs", "SIMPLE_CHEMICAL", 64, 69], ["AZT", "SIMPLE_CHEMICAL", 71, 74], ["TNF", "GENE_OR_GENE_PRODUCT", 79, 82], ["NFV", "SIMPLE_CHEMICAL", 114, 117], ["DRV", "SIMPLE_CHEMICAL", 119, 122], ["ATV", "SIMPLE_CHEMICAL", 124, 127], ["APV", "SIMPLE_CHEMICAL", 132, 135], ["protease", "PROTEIN", 31, 39], ["TNF", "PROTEIN", 79, 82], ["two NRTIs", "TREATMENT", 60, 69], ["AZT", "TREATMENT", 71, 74], ["TNF", "TREATMENT", 79, 82], ["four protease inhibitors", "TREATMENT", 88, 112], ["NFV", "TREATMENT", 114, 117], ["DRV", "TREATMENT", 119, 122], ["ATV", "TREATMENT", 124, 127], ["APV", "TREATMENT", 132, 135], ["viable", "OBSERVATION_MODIFIER", 16, 22], ["gag", "OBSERVATION", 23, 26], ["DRV", "ANATOMY", 119, 122]]], ["No differences in drug susceptibility were found between wild-type virus and low or high fitness gag or protease recoded variants (Additional file 3: Table S2 ).Construction of synthetically recoded HIV-1 with modified codon-pair biasOverall, our results demonstrate that the codon pair recoding of HIV-1 gag or protease coding regions significantly modified HIV-1 replication capacity in MT-4 cells and PBMCs. .", [["MT-4 cells", "ANATOMY", 389, 399], ["PBMCs", "ANATOMY", 404, 409], ["wild-type virus", "ORGANISM", 57, 72], ["HIV-1", "ORGANISM", 199, 204], ["HIV-1", "ORGANISM", 299, 304], ["gag", "GENE_OR_GENE_PRODUCT", 305, 308], ["HIV-1", "ORGANISM", 359, 364], ["MT-4 cells", "CELL", 389, 399], ["PBMCs", "CELL", 404, 409], ["protease", "PROTEIN", 104, 112], ["modified codon-pair biasOverall", "DNA", 210, 241], ["HIV-1 gag or protease coding regions", "DNA", 299, 335], ["MT-4 cells", "CELL_LINE", 389, 399], ["PBMCs", "CELL_TYPE", 404, 409], ["HIV-1", "SPECIES", 199, 204], ["HIV-1", "SPECIES", 299, 304], ["HIV-1", "SPECIES", 359, 364], ["HIV-1", "SPECIES", 199, 204], ["HIV-1", "SPECIES", 299, 304], ["HIV-1", "SPECIES", 359, 364], ["drug susceptibility", "PROBLEM", 18, 37], ["type virus", "PROBLEM", 62, 72], ["low or high fitness gag", "PROBLEM", 77, 100], ["the codon pair", "PROBLEM", 272, 286], ["HIV", "PROBLEM", 299, 302], ["protease coding regions", "PROBLEM", 312, 335], ["HIV", "TEST", 359, 362], ["replication capacity", "TEST", 365, 385], ["PBMCs", "TEST", 404, 409], ["differences", "OBSERVATION_MODIFIER", 3, 14], ["drug susceptibility", "OBSERVATION", 18, 37]]], ["These results demonstrate that deoptimized HIV-1 variants were able to recover fitness in tissue culture.", [["tissue culture", "ANATOMY", 90, 104], ["HIV-1", "ORGANISM", 43, 48], ["tissue", "TISSUE", 90, 96], ["HIV-1", "SPECIES", 43, 48], ["HIV-1", "SPECIES", 43, 48], ["deoptimized HIV-1 variants", "PROBLEM", 31, 57], ["tissue culture", "TEST", 90, 104]]], ["Clonal sequencing of the different deoptimized viral populations at passage 15 showed that several deoptimizing synonymous substitutions reverted to wild-type (Table 4) .", [["Clonal sequencing", "TEST", 0, 17], ["the different deoptimized viral populations", "PROBLEM", 21, 64], ["several deoptimizing synonymous substitutions", "PROBLEM", 91, 136], ["synonymous substitutions", "OBSERVATION", 112, 136]]], ["No significant reversions were observed in the optimized HIV-Pmax.", [["HIV", "SPECIES", 57, 60], ["significant reversions", "PROBLEM", 3, 25], ["significant", "OBSERVATION_MODIFIER", 3, 14], ["reversions", "OBSERVATION", 15, 25]]], ["The average mutation frequency in the deoptimized viral populations at passage 15 was between 1.5-fold and 12.0-fold higher than that of the wild-type population.", [["The average mutation frequency", "PROBLEM", 0, 30], ["the deoptimized viral populations", "PROBLEM", 34, 67], ["average", "OBSERVATION_MODIFIER", 4, 11], ["mutation", "OBSERVATION", 12, 20]]], ["There was a good correlation Figure 3 Single-cycle infectivity assay of HIV-1 protease codon pair-recoded synthetic constructs.", [["HIV-1", "GENE_OR_GENE_PRODUCT", 72, 77], ["HIV-1 protease codon pair-recoded synthetic constructs", "DNA", 72, 126], ["HIV-1", "SPECIES", 72, 77], ["HIV-1", "SPECIES", 72, 77], ["Single-cycle infectivity assay", "TEST", 38, 68], ["HIV", "TEST", 72, 75], ["protease codon pair", "TREATMENT", 78, 97]]], ["HIV-1 protease codon pairrecoded synthetic constructs (Figures 1 and 2) were introduced into the GFP reporter HIV-1 infectious clone pNL4-3-deltaE-EGFP.", [["HIV-1", "ORGANISM", 0, 5], ["GFP", "GENE_OR_GENE_PRODUCT", 97, 100], ["HIV-1", "ORGANISM", 110, 115], ["pNL4-3", "GENE_OR_GENE_PRODUCT", 133, 139], ["deltaE", "GENE_OR_GENE_PRODUCT", 140, 146], ["EGFP", "GENE_OR_GENE_PRODUCT", 147, 151], ["HIV-1 protease codon pairrecoded synthetic constructs", "DNA", 0, 53], ["GFP reporter HIV-1 infectious clone pNL4-3", "DNA", 97, 139], ["deltaE", "DNA", 140, 146], ["EGFP", "DNA", 147, 151], ["HIV-1", "SPECIES", 0, 5], ["HIV-1", "SPECIES", 110, 115], ["HIV-1", "SPECIES", 0, 5], ["HIV-1", "SPECIES", 110, 115], ["HIV", "TEST", 0, 3], ["1 protease codon pairrecoded synthetic constructs", "TREATMENT", 4, 53], ["infectious clone pNL4", "TEST", 116, 137]]], ["The replication capacities of the different protease constructs are represented as a percentage relative to the wild-type HIV-1 HXB2 strain (100%).", [["HIV-1", "ORGANISM", 122, 127], ["HXB2", "ORGANISM", 128, 132], ["protease constructs", "DNA", 44, 63], ["HIV-1", "SPECIES", 122, 127], ["HIV-1", "SPECIES", 122, 127], ["The replication capacities", "PROBLEM", 0, 26], ["the different protease constructs", "TREATMENT", 30, 63], ["replication", "OBSERVATION_MODIFIER", 4, 15], ["capacities", "OBSERVATION_MODIFIER", 16, 26]]], ["The relative replication capacity of the virus was determined by measuring the amount of p24 antigen.", [["p24 antigen", "GENE_OR_GENE_PRODUCT", 89, 100], ["p24 antigen", "PROTEIN", 89, 100], ["The relative replication capacity of the virus", "PROBLEM", 0, 46], ["p24 antigen", "TEST", 89, 100], ["replication", "OBSERVATION_MODIFIER", 13, 24], ["capacity", "OBSERVATION_MODIFIER", 25, 33], ["virus", "OBSERVATION", 41, 46], ["amount", "OBSERVATION_MODIFIER", 79, 85], ["p24 antigen", "OBSERVATION", 89, 100]]], ["A reduction in the production of p24 protein in the culture transfected with a HIV-1 clone carrying a deoptimized protease was observed.", [["p24", "GENE_OR_GENE_PRODUCT", 33, 36], ["HIV-1 clone", "ORGANISM", 79, 90], ["p24 protein", "PROTEIN", 33, 44], ["HIV-1 clone", "CELL_LINE", 79, 90], ["deoptimized protease", "PROTEIN", 102, 122], ["HIV-1", "SPECIES", 79, 84], ["HIV-1", "SPECIES", 79, 84], ["A reduction", "TREATMENT", 0, 11], ["p24 protein", "TEST", 33, 44], ["the culture", "TEST", 48, 59], ["a HIV", "TEST", 77, 82], ["a deoptimized protease", "TREATMENT", 100, 122], ["reduction", "OBSERVATION_MODIFIER", 2, 11], ["p24 protein", "OBSERVATION", 33, 44]]], ["The reduction in p24 expression was not accompanied by a reduction in the production of gag RNA (Table 3) .", [["p24", "GENE_OR_GENE_PRODUCT", 17, 20], ["gag", "GENE_OR_GENE_PRODUCT", 88, 91], ["Table 3", "GENE_OR_GENE_PRODUCT", 97, 104], ["p24", "PROTEIN", 17, 20], ["gag RNA", "RNA", 88, 95], ["The reduction in p24 expression", "PROBLEM", 0, 31], ["a reduction in the production of gag RNA", "PROBLEM", 55, 95], ["reduction", "OBSERVATION_MODIFIER", 4, 13], ["p24 expression", "OBSERVATION", 17, 31], ["reduction", "OBSERVATION_MODIFIER", 57, 66], ["gag RNA", "OBSERVATION", 88, 95]]], ["In addition to the reversion of deoptimized synonymous substitutions, many additional synonymous and nonsynonymous mutations were observed (Table 4 ) (Additional file 4: Table S3 and Additional file 5: Table S4 ).", [["deoptimized synonymous substitutions", "PROBLEM", 32, 68], ["many additional synonymous and nonsynonymous mutations", "PROBLEM", 70, 124], ["synonymous substitutions", "OBSERVATION", 44, 68], ["nonsynonymous mutations", "OBSERVATION", 101, 124]]], ["Most of these additional mutations alleviate negative codon pair-bias scores (data not shown), strongly suggesting that phenotypic reversion was due to the reversion of some initially mutated residues together with the fixation of new mutations.", [["phenotypic reversion", "PROBLEM", 120, 140], ["some initially mutated residues", "PROBLEM", 169, 200], ["the fixation", "TREATMENT", 215, 227], ["new mutations", "PROBLEM", 231, 244], ["new", "OBSERVATION_MODIFIER", 231, 234], ["mutations", "OBSERVATION", 235, 244]]], ["Especially interesting was the high number of nonsynonymous substitutions found in some deoptimized gag populations.", [["deoptimized gag populations", "CELL_LINE", 88, 115], ["nonsynonymous substitutions", "PROBLEM", 46, 73], ["some deoptimized gag populations", "PROBLEM", 83, 115], ["high", "OBSERVATION_MODIFIER", 31, 35], ["nonsynonymous substitutions", "OBSERVATION", 46, 73], ["gag populations", "OBSERVATION", 100, 115]]], ["For instance, the HIV-GminA construct incorporated as majority variants the nonsynonymous mutations R4G, P48T and K114R in both passage replicates, indicating Los Alamos database (http://www.hiv.lanl.gov/).", [["HIV", "ORGANISM", 18, 21], ["GminA", "GENE_OR_GENE_PRODUCT", 22, 27], ["HIV-GminA construct", "DNA", 18, 37], ["HIV", "SPECIES", 18, 21], ["HIV-GminA", "SPECIES", 18, 27], ["the HIV-GminA construct", "PROBLEM", 14, 37], ["nonsynonymous mutations", "OBSERVATION", 76, 99]]], ["Most of the nonsynonymous substitutions occurred in codons carrying deoptimized synonymous mutations, showing that the introduction of synonymous substitutions may allow the virus to explore an alternative nonsynonymous sequence space to improve viral fitness.DiscussionPrior work has documented the effectiveness of making changes to the codon-pair bias of viral genomes in order to generate attenuated poliovirus and influenza virus [3, 11] .", [["influenza virus", "ORGANISM", 419, 434], ["viral genomes", "DNA", 358, 371], ["influenza virus", "SPECIES", 419, 434], ["the nonsynonymous substitutions", "PROBLEM", 8, 39], ["codons carrying deoptimized synonymous mutations", "PROBLEM", 52, 100], ["synonymous substitutions", "TREATMENT", 135, 159], ["the virus", "PROBLEM", 170, 179], ["an alternative nonsynonymous sequence space", "TREATMENT", 191, 234], ["viral fitness", "PROBLEM", 246, 259], ["the codon", "TREATMENT", 335, 344], ["viral genomes", "PROBLEM", 358, 371], ["attenuated poliovirus", "PROBLEM", 393, 414], ["influenza virus", "PROBLEM", 419, 434], ["nonsynonymous substitutions", "OBSERVATION", 12, 39], ["synonymous mutations", "OBSERVATION", 80, 100], ["viral fitness", "OBSERVATION", 246, 259], ["viral genomes", "OBSERVATION", 358, 371], ["poliovirus", "OBSERVATION", 404, 414]]], ["We report here the application of this strategy for modifying the replicative capacity of HIV-1.", [["HIV-1", "ORGANISM", 90, 95], ["HIV-1", "SPECIES", 90, 95], ["HIV-1", "SPECIES", 90, 95], ["this strategy", "TREATMENT", 34, 47]]], ["The fact that very different viruses, such as poliovirus and influenza virus, are highly sensitive to codon-pair deoptimization suggests that this strategy may operate quite generally.", [["influenza virus", "DISEASE", 61, 76], ["poliovirus", "ORGANISM", 46, 56], ["influenza virus", "ORGANISM", 61, 76], ["influenza virus", "SPECIES", 61, 76], ["influenza virus", "SPECIES", 61, 76], ["very different viruses", "PROBLEM", 14, 36], ["poliovirus", "PROBLEM", 46, 56], ["influenza virus", "PROBLEM", 61, 76], ["codon-pair deoptimization", "TREATMENT", 102, 127], ["very", "OBSERVATION_MODIFIER", 14, 18], ["different", "OBSERVATION_MODIFIER", 19, 28], ["viruses", "OBSERVATION", 29, 36], ["influenza virus", "OBSERVATION", 61, 76]]], ["However, no data were available regarding whether this approach would work with lentiviruses, which, in contrast to poliovirus and influenza virus, integrate into the host cell genome.", [["cell", "ANATOMY", 172, 176], ["lentiviruses", "ORGANISM", 80, 92], ["poliovirus", "ORGANISM", 116, 126], ["influenza virus", "ORGANISM", 131, 146], ["host cell", "CELL", 167, 176], ["host cell genome", "DNA", 167, 183], ["influenza virus", "SPECIES", 131, 146], ["influenza virus", "SPECIES", 131, 146], ["lentiviruses", "PROBLEM", 80, 92], ["poliovirus", "PROBLEM", 116, 126], ["influenza virus", "PROBLEM", 131, 146], ["host cell genome", "OBSERVATION", 167, 183]]], ["In this study, we tested the extent to which codon-pair deoptimization and reoptimization of the HIV-1 genome could create viruses with altered replication capacity in cell culture.DiscussionWe found that by codon pair-deoptimizing different moieties of the HIV-1 gag and pol genes it was possible to produce viruses with significantly lower viral replication capacity in MT-4 cells and PBMCs.", [["cell culture", "ANATOMY", 168, 180], ["MT-4 cells", "ANATOMY", 372, 382], ["PBMCs", "ANATOMY", 387, 392], ["HIV-1", "ORGANISM", 97, 102], ["cell culture", "CELL", 168, 180], ["HIV-1", "ORGANISM", 258, 263], ["gag", "GENE_OR_GENE_PRODUCT", 264, 267], ["pol", "GENE_OR_GENE_PRODUCT", 272, 275], ["MT-4 cells", "CELL", 372, 382], ["PBMCs", "CELL", 387, 392], ["HIV-1 genome", "DNA", 97, 109], ["codon pair", "DNA", 208, 218], ["HIV-1 gag and pol genes", "DNA", 258, 281], ["MT-4 cells", "CELL_LINE", 372, 382], ["PBMCs", "CELL_TYPE", 387, 392], ["HIV-1", "SPECIES", 97, 102], ["HIV-1", "SPECIES", 258, 263], ["HIV-1", "SPECIES", 97, 102], ["HIV-1", "SPECIES", 258, 263], ["this study", "TEST", 3, 13], ["codon-pair deoptimization", "TREATMENT", 45, 70], ["reoptimization", "TREATMENT", 75, 89], ["the HIV", "PROBLEM", 93, 100], ["altered replication capacity", "PROBLEM", 136, 164], ["cell culture", "TEST", 168, 180], ["the HIV", "TEST", 254, 261], ["viruses", "PROBLEM", 309, 316], ["significantly lower viral replication capacity", "PROBLEM", 322, 368], ["PBMCs", "TEST", 387, 392], ["viruses", "OBSERVATION", 123, 130], ["replication capacity", "OBSERVATION", 144, 164], ["viral replication", "OBSERVATION", 342, 359]]], ["These findings confirm the validity of using the SAVE strategy to attenuate lentiviruses ex vivo, in particular HIV-1.", [["lentiviruses", "ORGANISM", 76, 88], ["HIV-1", "ORGANISM", 112, 117], ["HIV-1", "SPECIES", 112, 117], ["HIV-1", "SPECIES", 112, 117], ["the SAVE strategy", "TREATMENT", 45, 62], ["lentiviruses", "OBSERVATION", 76, 88]]], ["Our results provide also evidence that attenuated viruses may display decreased rates of protein translation of the targeted genes.", [["targeted genes", "DNA", 116, 130], ["attenuated viruses", "PROBLEM", 39, 57], ["decreased rates of protein translation", "PROBLEM", 70, 108], ["attenuated", "OBSERVATION_MODIFIER", 39, 49], ["viruses", "OBSERVATION", 50, 57], ["decreased", "OBSERVATION_MODIFIER", 70, 79], ["protein translation", "OBSERVATION", 89, 108]]], ["After restricting viral replication to a single cycle by using a single-cycle HIV-1 vector, a significant reduction in protein production was observed in the vector carrying an attenuated virus variant.", [["HIV-1", "ORGANISM", 78, 83], ["HIV-1", "SPECIES", 78, 83], ["HIV-1", "SPECIES", 78, 83], ["restricting viral replication", "TREATMENT", 6, 35], ["a single-cycle HIV-1 vector", "TREATMENT", 63, 90], ["a significant reduction in protein production", "PROBLEM", 92, 137], ["an attenuated virus variant", "PROBLEM", 174, 201], ["viral replication", "OBSERVATION", 18, 35], ["significant", "OBSERVATION_MODIFIER", 94, 105], ["reduction", "OBSERVATION_MODIFIER", 106, 115], ["protein production", "OBSERVATION", 119, 137], ["attenuated virus variant", "OBSERVATION", 177, 201]]], ["This reduction in protein synthesis was not accompanied by a reduction in the targeted RNA copy number, which suggests that translation, and not transcription, is implicated in the generation of the attenuated phenotype.", [["This reduction in protein synthesis", "PROBLEM", 0, 35], ["the attenuated phenotype", "PROBLEM", 195, 219], ["reduction", "OBSERVATION_MODIFIER", 5, 14], ["protein synthesis", "OBSERVATION", 18, 35], ["reduction", "OBSERVATION_MODIFIER", 61, 70]]], ["Moreover, the lower RNA/p24 ratio found in these experiments for the deoptimized virus also suggests that there may be a defect in virus assembly.", [["p24", "GENE_OR_GENE_PRODUCT", 24, 27], ["p24", "PROTEIN", 24, 27], ["the lower RNA/p24 ratio", "TEST", 10, 33], ["the deoptimized virus", "PROBLEM", 65, 86], ["a defect in virus", "PROBLEM", 119, 136], ["lower", "ANATOMY_MODIFIER", 14, 19], ["p24 ratio", "OBSERVATION", 24, 33], ["may be", "UNCERTAINTY", 112, 118], ["defect", "OBSERVATION", 121, 127], ["virus", "OBSERVATION", 131, 136]]], ["It has been hypothesized that the presence of a rare codon, marked by a synonymous polymorphism, affects the timing of protein folding and function [18] .", [["a rare codon", "PROBLEM", 46, 58], ["a synonymous polymorphism", "PROBLEM", 70, 95], ["rare", "OBSERVATION_MODIFIER", 48, 52], ["codon", "OBSERVATION", 53, 58], ["marked", "OBSERVATION_MODIFIER", 60, 66], ["synonymous polymorphism", "OBSERVATION", 72, 95]]], ["This study therefore demonstrates that synonymous codon pair reengineering is an effective tool to phenotypically affect the replicative properties of HIV-1.", [["HIV-1", "ORGANISM", 151, 156], ["HIV-1", "SPECIES", 151, 156], ["HIV-1", "SPECIES", 151, 156], ["This study", "TEST", 0, 10], ["synonymous codon pair", "PROBLEM", 39, 60], ["synonymous codon", "OBSERVATION", 39, 55]]], ["Codon-optimized HIV-1 genes significantly increased protein expression [6] .", [["HIV-1", "GENE_OR_GENE_PRODUCT", 16, 21], ["Codon-optimized HIV-1 genes", "DNA", 0, 27], ["HIV-1", "SPECIES", 16, 21], ["HIV-1", "SPECIES", 16, 21], ["Codon", "TEST", 0, 5], ["significantly increased protein expression", "PROBLEM", 28, 70], ["protein expression", "OBSERVATION", 52, 70]]], ["However, it was unknown whether HIV-1 codon reoptimization increases viral fitness or virulence.", [["HIV-1", "ORGANISM", 32, 37], ["HIV-1", "SPECIES", 32, 37], ["HIV-1", "SPECIES", 32, 37], ["HIV", "PROBLEM", 32, 35], ["viral fitness", "PROBLEM", 69, 82], ["virulence", "PROBLEM", 86, 95]]], ["A high level of preferred human codon use runs the risk of disrupting some unknown property of the HIV-1 RNA that is deleterious for other reasons, e.g. disrupting the secondary structure of the HIV-1 RNA genome [19] or increasing the number of CpG islands [20] .", [["CpG", "CHEMICAL", 245, 248], ["human", "ORGANISM", 26, 31], ["HIV-1", "ORGANISM", 99, 104], ["HIV-1", "ORGANISM", 195, 200], ["HIV-1 RNA", "RNA", 99, 108], ["HIV-1 RNA genome", "DNA", 195, 211], ["CpG islands", "DNA", 245, 256], ["human", "SPECIES", 26, 31], ["HIV-1", "SPECIES", 99, 104], ["HIV-1", "SPECIES", 195, 200], ["human", "SPECIES", 26, 31], ["HIV-1", "SPECIES", 99, 104], ["HIV-1", "SPECIES", 195, 200], ["preferred human codon", "TREATMENT", 16, 37], ["the HIV-1 RNA", "PROBLEM", 95, 108], ["the HIV", "PROBLEM", 191, 198], ["CpG islands", "PROBLEM", 245, 256]]], ["Importantly, in our study, a protease optimized virus carrying 38 synonymous mutations was not attenuated and displayed a replication capacity similar to that of the wild-type virus in MT-4 cells and PBMCs.", [["MT-4 cells", "ANATOMY", 185, 195], ["PBMCs", "ANATOMY", 200, 205], ["wild-type virus", "ORGANISM", 166, 181], ["MT-4 cells", "CELL", 185, 195], ["PBMCs", "CELL", 200, 205], ["MT-4 cells", "CELL_LINE", 185, 195], ["PBMCs", "CELL_TYPE", 200, 205], ["our study", "TEST", 16, 25], ["a protease optimized virus", "TREATMENT", 27, 53], ["a replication capacity", "PROBLEM", 120, 142], ["the wild-type virus", "PROBLEM", 162, 181], ["PBMCs", "TEST", 200, 205], ["replication capacity", "OBSERVATION", 122, 142]]], ["This result suggests that certain neutral genetic drift is operating in protease synonymous nucleotide residues.", [["nucleotide", "CHEMICAL", 92, 102], ["nucleotide", "CHEMICAL", 92, 102], ["protease", "PROTEIN", 72, 80], ["certain neutral genetic drift", "PROBLEM", 26, 55], ["protease synonymous nucleotide residues", "TREATMENT", 72, 111], ["synonymous nucleotide residues", "OBSERVATION", 81, 111]]], ["Thus, in addition to explore virus attenuation, synonymous codon pair recoding can be used to explore other aspects of the HIV-1 biology.", [["HIV-1", "ORGANISM", 123, 128], ["HIV", "SPECIES", 123, 126], ["HIV-1", "SPECIES", 123, 128], ["virus attenuation", "PROBLEM", 29, 46], ["synonymous codon pair recoding", "TREATMENT", 48, 78], ["synonymous codon", "OBSERVATION", 48, 64]]], ["Indeed, synonymous codon pair reoptimization has been used to overcome adeno-associated virus (AAV) Rep gene's inhibitory effects on adenovirus replication [21] , to identify unknown functional RNA elements in poliovirus coding sequences [22] and to study poliovirus evolvability and pathogenesis [23] .DiscussionPreviously, it was found that a codon pair base deoptimized poliovirus variant containing 224 synonymous substitutions did not revert its phenotype after 19 passages in HeLaR19 cells [3] .", [["HeLaR19 cells", "ANATOMY", 482, 495], ["adeno-associated virus", "ORGANISM", 71, 93], ["AAV", "ORGANISM", 95, 98], ["Rep", "GENE_OR_GENE_PRODUCT", 100, 103], ["adenovirus", "ORGANISM", 133, 143], ["HeLaR19 cells", "CELL", 482, 495], ["adeno-associated virus (AAV) Rep gene", "DNA", 71, 108], ["functional RNA elements", "DNA", 183, 206], ["poliovirus coding sequences", "DNA", 210, 237], ["HeLaR19 cells", "CELL_LINE", 482, 495], ["AAV", "SPECIES", 95, 98], ["synonymous codon pair reoptimization", "TREATMENT", 8, 44], ["adeno-associated virus", "PROBLEM", 71, 93], ["AAV) Rep gene's inhibitory effects", "TREATMENT", 95, 129], ["adenovirus replication", "TREATMENT", 133, 155], ["functional RNA elements", "PROBLEM", 183, 206], ["poliovirus coding sequences", "TEST", 210, 237], ["poliovirus evolvability", "PROBLEM", 256, 279], ["pathogenesis", "PROBLEM", 284, 296], ["a codon pair base", "PROBLEM", 343, 360], ["poliovirus variant", "PROBLEM", 373, 391], ["synonymous substitutions", "PROBLEM", 407, 431], ["its phenotype", "PROBLEM", 447, 460], ["synonymous codon", "OBSERVATION", 8, 24], ["RNA elements", "OBSERVATION", 194, 206]]], ["In contrast, we show here that highly attenuated HIV-1 variants carrying more or near one hundred synonymous substitutions reverted their phenotype after 15 passages in MT4-4 cells.", [["MT4-4 cells", "ANATOMY", 169, 180], ["HIV-1", "ORGANISM", 49, 54], ["MT4-4 cells", "CELL", 169, 180], ["HIV-1 variants", "DNA", 49, 63], ["MT4-4 cells", "CELL_LINE", 169, 180], ["HIV-1", "SPECIES", 49, 54], ["HIV-1", "SPECIES", 49, 54], ["highly attenuated HIV-1 variants", "PROBLEM", 31, 63], ["attenuated", "OBSERVATION_MODIFIER", 38, 48], ["HIV", "OBSERVATION", 49, 52], ["synonymous substitutions", "OBSERVATION", 98, 122]]], ["Most notably, sequence clonal analysis of phenotypically reverted viral populations shows that phenotype reversion is due not only to the reversion of initially introduced synonymous mutations but also to the presence of new synonymous and nonsynonymous mutations.", [["sequence clonal analysis", "TEST", 14, 38], ["phenotypically reverted viral populations", "PROBLEM", 42, 83], ["phenotype reversion", "PROBLEM", 95, 114], ["synonymous mutations", "PROBLEM", 172, 192], ["new synonymous and nonsynonymous mutations", "PROBLEM", 221, 263], ["phenotype reversion", "OBSERVATION", 95, 114], ["new", "OBSERVATION_MODIFIER", 221, 224], ["synonymous", "OBSERVATION", 225, 235], ["nonsynonymous mutations", "OBSERVATION", 240, 263]]], ["Of note, no genetic or phenotypic reversion is observed in a codon pair base optimized viral population after the same number of passages in MT-4 cells.", [["MT-4 cells", "ANATOMY", 141, 151], ["MT-4 cells", "CELL", 141, 151], ["MT-4 cells", "CELL_LINE", 141, 151], ["genetic or phenotypic reversion", "PROBLEM", 12, 43], ["a codon pair base", "PROBLEM", 59, 76], ["viral population", "PROBLEM", 87, 103], ["viral population", "OBSERVATION", 87, 103]]], ["Differences in the life cycle between poliovirus and HIV-1 may account for the above discrepancies.", [["poliovirus", "ORGANISM", 38, 48], ["HIV-1", "ORGANISM", 53, 58], ["HIV-1", "SPECIES", 53, 58], ["HIV-1", "SPECIES", 53, 58], ["poliovirus", "PROBLEM", 38, 48], ["HIV", "PROBLEM", 53, 56], ["the above discrepancies", "PROBLEM", 75, 98]]], ["Alternatively, differences in virus protein or genome mutational robustness and evolvability can not be discarded.", [["virus protein", "PROTEIN", 30, 43], ["differences in virus protein", "PROBLEM", 15, 43], ["genome mutational robustness", "PROBLEM", 47, 75]]], ["The different codon usage between poliovirus and HIV-1 may determine differences in their mutational robustness and evolutionary capacity [23, 24] .", [["HIV-1", "ORGANISM", 49, 54], ["HIV-1", "SPECIES", 49, 54], ["HIV-1", "SPECIES", 49, 54], ["The different codon usage", "TREATMENT", 0, 25], ["poliovirus", "PROBLEM", 34, 44], ["HIV", "PROBLEM", 49, 52], ["evolutionary capacity", "TEST", 116, 137], ["different codon", "OBSERVATION", 4, 19]]], ["A higher number of substitutions may better prevent reversion to the wild-type genotype.", [["A higher number of substitutions", "PROBLEM", 0, 32], ["the wild-type genotype", "PROBLEM", 65, 87], ["higher", "OBSERVATION_MODIFIER", 2, 8]]], ["Instead, other HIV-1 genomic regions can be explored to determine whether other structural or accessory genes can be targeted with SAVE to generate recoded virus with a higher genetic barrier for phenotype reversion.DiscussionThis study has some limitations that are worth noting.", [["HIV-1", "ORGANISM", 15, 20], ["SAVE", "GENE_OR_GENE_PRODUCT", 131, 135], ["HIV-1 genomic regions", "DNA", 15, 36], ["SAVE", "PROTEIN", 131, 135], ["HIV-1", "SPECIES", 15, 20], ["HIV-1", "SPECIES", 15, 20], ["other HIV-1 genomic regions", "PROBLEM", 9, 36], ["other structural or accessory genes", "PROBLEM", 74, 109], ["recoded virus", "PROBLEM", 148, 161], ["a higher genetic barrier", "TREATMENT", 167, 191], ["phenotype reversion", "PROBLEM", 196, 215], ["This study", "TEST", 226, 236]]], ["First, despite the fact that reduction in protein synthesis was not accompanied by a reduction in the targeted HIV-1 RNA copy number, RNA sequences may be also targeted by factors other than those of the translation machinery (e.g. aberrant splicing, RNA decay process or miRNA targeting).", [["HIV-1", "ORGANISM", 111, 116], ["HIV-1", "SPECIES", 111, 116], ["HIV-1", "SPECIES", 111, 116], ["reduction in protein synthesis", "PROBLEM", 29, 59], ["RNA sequences", "TEST", 134, 147], ["the translation machinery", "TREATMENT", 200, 225], ["aberrant splicing", "PROBLEM", 232, 249], ["RNA decay process", "PROBLEM", 251, 268], ["reduction", "OBSERVATION_MODIFIER", 29, 38], ["reduction", "OBSERVATION_MODIFIER", 85, 94]]], ["Second, although we obtained a robust attenuation in PBMCs from healthy donors, our variants should be tested in an animal model, ideally the SIV macaque model, in order to demonstrate in vivo attenuation.", [["PBMCs", "ANATOMY", 53, 58], ["PBMCs", "CELL", 53, 58], ["donors", "ORGANISM", 72, 78], ["SIV", "ORGANISM", 142, 145], ["macaque", "ORGANISM", 146, 153], ["PBMCs", "CELL_TYPE", 53, 58], ["SIV macaque", "SPECIES", 142, 153], ["robust", "OBSERVATION_MODIFIER", 31, 37], ["attenuation", "OBSERVATION_MODIFIER", 38, 49], ["SIV macaque", "OBSERVATION", 142, 153], ["vivo attenuation", "OBSERVATION", 188, 204]]], ["Animal experiments should include optimized viruses to test whether these optimized variants are also not attenuated in vivo.", [["optimized viruses", "PROBLEM", 34, 51]]], ["Proof that lower replication capacities ex vivo can be translated into in vivo attenuation come from studies of the evolution of resistance to antiretroviral drugs, which is characterized by significant costs in ex vivo replication capacity [25] .", [["lower replication capacities ex vivo", "TREATMENT", 11, 47], ["antiretroviral drugs", "TREATMENT", 143, 163], ["significant costs in ex vivo replication capacity", "PROBLEM", 191, 240], ["significant", "OBSERVATION_MODIFIER", 191, 202], ["costs", "OBSERVATION", 203, 208]]], ["Future work should include the immunization of animal models with different codon pair-deoptimized attenuated HIV-1 strains to investigate whether recoded viruses are also attenuated in vivo and to determine their long-term stability.ConclusionsOur results demonstrate that codon pair-deoptimization of different moieties of the HIV-1 gag and pol genes produce viruses with significantly lower viral replication capacity in MT-4 cells and PBMCs.", [["MT-4 cells", "ANATOMY", 424, 434], ["PBMCs", "ANATOMY", 439, 444], ["HIV-1 strains", "ORGANISM", 110, 123], ["HIV-1", "ORGANISM", 329, 334], ["gag", "GENE_OR_GENE_PRODUCT", 335, 338], ["pol", "GENE_OR_GENE_PRODUCT", 343, 346], ["MT-4 cells", "CELL", 424, 434], ["PBMCs", "CELL", 439, 444], ["codon pair", "DNA", 76, 86], ["HIV-1 gag and pol genes", "DNA", 329, 352], ["MT-4 cells", "CELL_LINE", 424, 434], ["PBMCs", "CELL_TYPE", 439, 444], ["HIV-1", "SPECIES", 110, 115], ["HIV-1", "SPECIES", 329, 334], ["HIV-1", "SPECIES", 110, 115], ["HIV-1", "SPECIES", 329, 334], ["the immunization", "TREATMENT", 27, 43], ["animal models", "TREATMENT", 47, 60], ["different codon pair", "TREATMENT", 66, 86], ["attenuated HIV", "PROBLEM", 99, 113], ["recoded viruses", "PROBLEM", 147, 162], ["codon pair", "TEST", 274, 284], ["the HIV", "TEST", 325, 332], ["pol genes produce viruses", "PROBLEM", 343, 368], ["significantly lower viral replication capacity", "PROBLEM", 374, 420], ["PBMCs", "TEST", 439, 444], ["viruses", "OBSERVATION", 155, 162], ["long-term stability", "OBSERVATION_MODIFIER", 214, 233], ["viral replication", "OBSERVATION", 394, 411]]], ["This study therefore demonstrates that synonymous codon pair reengineering is an effective tool to phenotypically affect the replicative properties of lentiviruses, in particular HIV-1.Cell linesMT-4 cells were obtained from the National Institutes of Health (NIH) AIDS Research and Reference Reagent Program.", [["Cell linesMT-4 cells", "ANATOMY", 185, 205], ["AIDS", "DISEASE", 265, 269], ["lentiviruses", "ORGANISM", 151, 163], ["HIV-1", "ORGANISM", 179, 184], ["Cell linesMT-4 cells", "CELL", 185, 205], ["MT-4 cells", "CELL_LINE", 195, 205], ["HIV-1", "SPECIES", 179, 184], ["HIV-1", "SPECIES", 179, 184], ["This study", "TEST", 0, 10], ["synonymous codon pair", "PROBLEM", 39, 60], ["Cell linesMT", "TEST", 185, 197], ["synonymous codon", "OBSERVATION", 39, 55], ["lentiviruses", "OBSERVATION", 151, 163]]], ["HEK 293 T cells were obtained from the American Type Culture Collection (ATCC).", [["HEK 293 T cells", "ANATOMY", 0, 15], ["HEK 293 T cells", "CELL", 0, 15], ["HEK 293 T cells", "CELL_LINE", 0, 15], ["T cells", "TEST", 8, 15]]], ["MT-4 cells were grown in Roswell Park Memorial Institute (RPMI) 1640 L-glutamine medium supplemented with 10% heat-inactivated fetal bovine serum (FBS) (Gibco).", [["MT-4 cells", "ANATOMY", 0, 10], ["fetal bovine serum", "ANATOMY", 127, 145], ["FBS", "ANATOMY", 147, 150], ["L-glutamine", "CHEMICAL", 69, 80], ["L-glutamine", "CHEMICAL", 69, 80], ["MT-4 cells", "CELL", 0, 10], ["bovine", "ORGANISM", 133, 139], ["serum", "ORGANISM_SUBSTANCE", 140, 145], ["FBS", "ORGANISM_SUBSTANCE", 147, 150], ["MT-4 cells", "CELL_LINE", 0, 10], ["bovine", "SPECIES", 133, 139], ["bovine", "SPECIES", 133, 139], ["L-glutamine medium", "TREATMENT", 69, 87], ["fetal bovine serum", "TEST", 127, 145]]], ["The 293 T cells were grown in Dulbecco's Modified Eagle Medium (DMEM) (Gibco) supplemented with 10% heat-inactivated FBS.", [["293 T cells", "ANATOMY", 4, 15], ["FBS", "ANATOMY", 117, 120], ["293 T cells", "CELL", 4, 15], ["FBS", "ORGANISM_SUBSTANCE", 117, 120], ["293 T cells", "CELL_LINE", 4, 15], ["Dulbecco's Modified Eagle Medium (DMEM", "TREATMENT", 30, 68]]], ["For isolation of PBMC blood was taken from healthy donors.", [["PBMC blood", "ANATOMY", 17, 27], ["PBMC", "ORGANISM_SUBSTANCE", 17, 21], ["blood", "ORGANISM_SUBSTANCE", 22, 27], ["donors", "ORGANISM", 51, 57], ["PBMC", "CELL_TYPE", 17, 21], ["PBMC blood", "TEST", 17, 27]]], ["PBMCs were provided by the Banc de Sang i de Teixits (BST, Barcelona, Spain) after approval from the Germans Trias i Pujol hospital ethics committee.", [["PBMCs", "ANATOMY", 0, 5], ["PBMCs", "CELL", 0, 5], ["PBMCs", "CELL_TYPE", 0, 5], ["PBMCs", "TREATMENT", 0, 5]]], ["PBMCs purified by ficoll density gradient were stimulated with phytohemagglutinin (PHA) and interleukin-2 (IL2) (see below) and maintained in RPMI medium supplemented with 20% FBS.Generation of synthetic HIV-1All of the synthetic HIV-1 variants used in this study are based on the HXB2 strain (http://www.hiv.lanl.gov).Generation of synthetic HIV-1Synthetic HIV-1 protease was generated by combining three overlapping synthetic DNA oligonucleotides (Integrated DNA Technologies) by PCR; we used the overlap extension protocol described in our previous paper [26] .", [["PBMCs", "ANATOMY", 0, 5], ["FBS", "ANATOMY", 176, 179], ["PBMCs", "CELL", 0, 5], ["ficoll", "SIMPLE_CHEMICAL", 18, 24], ["phytohemagglutinin", "SIMPLE_CHEMICAL", 63, 81], ["PHA", "SIMPLE_CHEMICAL", 83, 86], ["interleukin-2", "GENE_OR_GENE_PRODUCT", 92, 105], ["IL2", "GENE_OR_GENE_PRODUCT", 107, 110], ["FBS", "ORGANISM_SUBSTANCE", 176, 179], ["HIV-1", "ORGANISM", 204, 209], ["HIV-1", "ORGANISM", 230, 235], ["HIV-1Synthetic HIV-1", "ORGANISM", 343, 363], ["DNA", "CELLULAR_COMPONENT", 428, 431], ["DNA", "CELLULAR_COMPONENT", 461, 464], ["PBMCs", "CELL_TYPE", 0, 5], ["phytohemagglutinin", "PROTEIN", 63, 81], ["PHA", "PROTEIN", 83, 86], ["interleukin-2", "PROTEIN", 92, 105], ["IL2", "PROTEIN", 107, 110], ["synthetic HIV-1 variants", "DNA", 220, 244], ["HIV", "SPECIES", 204, 207], ["HIV-1", "SPECIES", 230, 235], ["HIV-1Synthetic HIV-1", "SPECIES", 343, 363], ["HIV-1", "SPECIES", 204, 209], ["HIV-1", "SPECIES", 230, 235], ["HIV-1Synthetic HIV-1", "SPECIES", 343, 363], ["PBMCs", "TEST", 0, 5], ["ficoll density gradient", "PROBLEM", 18, 41], ["phytohemagglutinin (PHA", "TREATMENT", 63, 86], ["interleukin-2 (IL2)", "TREATMENT", 92, 111], ["20% FBS", "TREATMENT", 172, 179], ["synthetic HIV", "PROBLEM", 194, 207], ["the synthetic HIV", "TEST", 216, 233], ["this study", "TEST", 253, 263], ["the HXB2 strain", "PROBLEM", 277, 292], ["synthetic HIV", "TEST", 333, 346], ["three overlapping synthetic DNA oligonucleotides", "TREATMENT", 400, 448], ["PCR", "TEST", 482, 485], ["the overlap extension protocol", "TREATMENT", 495, 525], ["ficoll density", "OBSERVATION", 18, 32]]], ["PCRs were purified with the QIAquick PCR Purification Kit (QIAGEN) and sequenced to confirm the desired sequence.", [["PCRs", "TEST", 0, 4], ["the QIAquick PCR", "TEST", 24, 40]]], ["Sequencing was performed with the Big Dye v3.1 kit and the 3100 DNA sequencing system (Applied Biosystems).", [["DNA", "CELLULAR_COMPONENT", 64, 67], ["Sequencing", "TEST", 0, 10], ["the Big Dye", "TEST", 30, 41], ["the 3100 DNA sequencing system", "TREATMENT", 55, 85]]], ["Similarly, synthetic HIV-1 gag was generated by combining eight overlapping synthetic DNA oligonucleotides.", [["HIV-1", "ORGANISM", 21, 26], ["gag", "ORGANISM", 27, 30], ["DNA", "CELLULAR_COMPONENT", 86, 89], ["synthetic HIV-1 gag", "DNA", 11, 30], ["HIV-1", "SPECIES", 21, 26], ["HIV-1", "SPECIES", 21, 26], ["combining eight overlapping synthetic DNA oligonucleotides", "TREATMENT", 48, 106], ["synthetic DNA oligonucleotides", "OBSERVATION", 76, 106]]], ["Sequencing oligonuclotides for protease and gag were described previously [27] .Generation of synthetic HIV-1Codon pair score is defined as the natural log of the ratio of the observed over the expected number of occurrences of each codon pair over all human coding regions [3] .", [["oligonuclotides", "GENE_OR_GENE_PRODUCT", 11, 26], ["gag", "GENE_OR_GENE_PRODUCT", 44, 47], ["HIV", "ORGANISM", 104, 107], ["human", "ORGANISM", 253, 258], ["protease", "PROTEIN", 31, 39], ["human coding regions", "DNA", 253, 273], ["HIV", "SPECIES", 104, 107], ["human", "SPECIES", 253, 258], ["human", "SPECIES", 253, 258], ["Sequencing oligonuclotides", "TEST", 0, 26], ["protease and gag", "TREATMENT", 31, 47], ["synthetic HIV", "PROBLEM", 94, 107], ["1Codon pair score", "PROBLEM", 108, 125]]], ["The expected frequency is calculated based on the relative proportion of the number of times an amino acid is encoded by a specific codon.", [["amino acid", "CHEMICAL", 96, 106], ["amino acid", "CHEMICAL", 96, 106], ["amino acid", "AMINO_ACID", 96, 106], ["an amino acid", "TREATMENT", 93, 106]]], ["A positive codon pair score value signifies that the given codon pair is statistically over-represented, and a negative codon pair score indicates the pair is statistically under-represented in the human genome.", [["human", "ORGANISM", 198, 203], ["human genome", "DNA", 198, 210], ["human", "SPECIES", 198, 203], ["human", "SPECIES", 198, 203], ["A positive codon pair score value", "PROBLEM", 0, 33], ["codon pair", "PROBLEM", 59, 69], ["a negative codon pair score", "PROBLEM", 109, 136], ["positive codon", "OBSERVATION", 2, 16], ["human genome", "OBSERVATION", 198, 210]]], ["Using these calculated codon pair scores, the codon pair bias for an entire open reading frame can then be calculated as the arithmetic mean of the individual codon pair scores (Tables 1 and 3) .Generation of synthetic HIV-1Recombinant infectious viruses were generated as we described previously [27, 28] .", [["HIV-1Recombinant infectious viruses", "ORGANISM", 219, 254], ["open reading frame", "DNA", 76, 94], ["HIV", "SPECIES", 219, 222], ["HIV-1Recombinant infectious viruses", "SPECIES", 219, 254], ["the codon pair bias", "TREATMENT", 42, 61], ["1Recombinant infectious viruses", "PROBLEM", 223, 254], ["infectious viruses", "OBSERVATION", 236, 254]]], ["Briefly, 100 ng of fulllength protease or 500 ng of gag purified PCR products were cotransfected into MT-4 cells with 1 \u03bcg of protease-deleted [29] or gag-protease-deleted [30] HXB2 clone that had been previously linearized with BstE II (New England Biolabs).", [["MT-4 cells", "ANATOMY", 102, 112], ["gag", "ORGANISM", 52, 55], ["MT-4 cells", "CELL", 102, 112], ["gag", "ORGANISM", 151, 154], ["Biolabs", "GENE_OR_GENE_PRODUCT", 250, 257], ["fulllength protease", "PROTEIN", 19, 38], ["gag purified PCR products", "PROTEIN", 52, 77], ["MT-4 cells", "CELL_LINE", 102, 112], ["protease-deleted [29] or gag-protease-deleted [30] HXB2 clone", "DNA", 126, 187], ["BstE II", "PROTEIN", 229, 236], ["fulllength protease", "TREATMENT", 19, 38], ["gag purified PCR products", "TREATMENT", 52, 77], ["protease", "TEST", 126, 134], ["gag", "TEST", 151, 154], ["HXB2 clone", "PROBLEM", 177, 187]]], ["Cell culture supernatants were harvested on days 3, 5, and 7 after transfection when the concentration of HIV-1 p24 antigen (Genscreen HIV-1 Ag assay, Bio-Rad) surpassed 500 ng/ml.", [["Cell", "ANATOMY", 0, 4], ["supernatants", "ANATOMY", 13, 25], ["Ag", "CHEMICAL", 141, 143], ["Cell", "CELL", 0, 4], ["HIV-1", "ORGANISM", 106, 111], ["p24", "ORGANISM", 112, 115], ["Genscreen HIV-1 Ag", "ORGANISM", 125, 143], ["Bio-Rad", "GENE_OR_GENE_PRODUCT", 151, 158], ["p24 antigen", "PROTEIN", 112, 123], ["Bio-Rad", "PROTEIN", 151, 158], ["HIV-1", "SPECIES", 106, 111], ["HIV-1", "SPECIES", 135, 140], ["HIV-1", "SPECIES", 106, 111], ["Genscreen HIV-1", "SPECIES", 125, 140], ["Cell culture supernatants", "TEST", 0, 25], ["the concentration", "TEST", 85, 102], ["HIV", "TEST", 106, 109], ["p24 antigen", "TEST", 112, 123], ["Genscreen", "TEST", 125, 134], ["HIV", "TEST", 135, 138], ["Ag assay", "TEST", 141, 149], ["Bio", "TEST", 151, 154]]], ["If p24 antigen was not detected after 7 days of culture, five blind passages, feeding the cultures with fresh medium and new MT-4 cells, were performed to recover viable virus.", [["cultures", "ANATOMY", 90, 98], ["MT-4 cells", "ANATOMY", 125, 135], ["p24 antigen", "GENE_OR_GENE_PRODUCT", 3, 14], ["MT-4 cells", "CELL", 125, 135], ["p24 antigen", "PROTEIN", 3, 14], ["MT-4 cells", "CELL_LINE", 125, 135], ["p24 antigen", "TEST", 3, 14], ["culture", "TEST", 48, 55], ["blind passages", "TEST", 62, 76], ["the cultures", "TEST", 86, 98], ["fresh medium", "TEST", 104, 116], ["new MT-4 cells", "PROBLEM", 121, 135], ["viable virus", "PROBLEM", 163, 175], ["virus", "OBSERVATION", 170, 175]]], ["After five blind passages without p24 antigen detection in the cultured supernatant, the construct was considered nonviable in MT-4 cell culture.", [["supernatant", "ANATOMY", 72, 83], ["MT-4 cell", "ANATOMY", 127, 136], ["p24 antigen", "GENE_OR_GENE_PRODUCT", 34, 45], ["MT-4 cell culture", "CELL", 127, 144], ["p24 antigen", "PROTEIN", 34, 45], ["MT-4 cell culture", "CELL_LINE", 127, 144], ["p24 antigen detection", "TEST", 34, 55], ["cell culture", "TEST", 132, 144]]], ["Virus titration was performed in MT-4 cells, and values were expressed as tissue culture dose for 50% infectivity (TCID 50 ), as previously described [31] .Generation of synthetic HIV-1To control the folding free energy of the RNA of the recoded constructs, we determined their RNA folding energies with the program mfold [32] , as previously described [3] . mfold prevents the creation of any regions with large secondary structures, such as stable hairpins or stem loops.", [["MT-4 cells", "ANATOMY", 33, 43], ["tissue", "ANATOMY", 74, 80], ["stem loops", "ANATOMY", 462, 472], ["Virus", "ORGANISM", 0, 5], ["MT-4 cells", "CELL", 33, 43], ["tissue", "TISSUE", 74, 80], ["HIV-1To", "ORGANISM", 180, 187], ["MT-4 cells", "CELL_LINE", 33, 43], ["HIV", "SPECIES", 180, 183], ["HIV-1To", "SPECIES", 180, 187], ["Virus titration", "TREATMENT", 0, 15], ["tissue culture dose", "TEST", 74, 93], ["synthetic HIV", "TREATMENT", 170, 183], ["large secondary structures", "PROBLEM", 407, 433], ["large", "OBSERVATION_MODIFIER", 407, 412], ["secondary structures", "OBSERVATION", 413, 433], ["stable", "OBSERVATION_MODIFIER", 443, 449], ["hairpins", "OBSERVATION", 450, 458], ["stem loops", "OBSERVATION", 462, 472]]], ["To ensure that changes in synonymous codons do not systematically reduce codon bias, the effective number of codons (ENC) was also calculated by use of the Codon W program (http://mobyle.pasteur.fr) [33] , as previously described [34] .Replication capacity assaysViral replication kinetics were performed by infecting either 1 \u00d7 10 6 MT-4 cells with 200 TCID 50 (MOI of 0.0002) or 2 \u00d7 10 6 PBMCs (mixed from four healthy donors), stimulated 3 days previously with 5 \u03bcg/ml PHA (Sigma-Aldrich) and 10 U/ml IL2, with 2000 TCID 50 of each viral stock (MOI 0.001).", [["MT-4 cells", "ANATOMY", 334, 344], ["PBMCs", "ANATOMY", 390, 395], ["PHA", "CHEMICAL", 472, 475], ["PHA", "CHEMICAL", 472, 475], ["MT-4 cells", "CELL", 334, 344], ["PBMCs", "CELL", 390, 395], ["donors", "ORGANISM", 421, 427], ["PHA", "SIMPLE_CHEMICAL", 472, 475], ["Sigma-Aldrich", "ORGANISM", 477, 490], ["IL2", "GENE_OR_GENE_PRODUCT", 504, 507], ["ENC", "DNA", 117, 120], ["PBMCs", "CELL_TYPE", 390, 395], ["PHA", "PROTEIN", 472, 475], ["IL2", "PROTEIN", 504, 507], ["changes in synonymous codons", "PROBLEM", 15, 43], ["codon bias", "PROBLEM", 73, 83], ["the Codon W program", "TREATMENT", 152, 171], ["Replication capacity assays", "TEST", 236, 263], ["Viral replication kinetics", "PROBLEM", 263, 289], ["IL2", "TREATMENT", 504, 507], ["synonymous codons", "OBSERVATION", 26, 43]]], ["After 4 h of incubation at 37\u00b0C and 5% CO 2 , cells were washed twice with phosphatebuffered saline (PBS) and resuspended in RPMI medium supplemented with 10% FBS (MT-4 cells) or 20% FBS plus 10 U/ml IL2 (PMBCs).", [["cells", "ANATOMY", 46, 51], ["FBS", "ANATOMY", 159, 162], ["MT-4 cells", "ANATOMY", 164, 174], ["FBS", "ANATOMY", 183, 186], ["CO 2", "CHEMICAL", 39, 43], ["cells", "CELL", 46, 51], ["saline", "SIMPLE_CHEMICAL", 93, 99], ["FBS", "ORGANISM_SUBSTANCE", 159, 162], ["MT-4 cells", "CELL", 164, 174], ["FBS", "ORGANISM_SUBSTANCE", 183, 186], ["IL2", "GENE_OR_GENE_PRODUCT", 200, 203], ["PMBCs", "CANCER", 205, 210], ["IL2", "PROTEIN", 200, 203], ["incubation", "TREATMENT", 13, 23], ["cells", "TEST", 46, 51], ["phosphatebuffered saline (PBS", "TREATMENT", 75, 104]]], ["Every 24 h, 200 \u03bcl of supernatant was removed for p24 antigen quantification.", [["supernatant", "ANATOMY", 22, 33], ["p24 antigen", "GENE_OR_GENE_PRODUCT", 50, 61], ["p24 antigen", "PROTEIN", 50, 61], ["supernatant", "TREATMENT", 22, 33], ["p24 antigen quantification", "TEST", 50, 76]]], ["Viral replication was quantified by measuring HIV-1 capsid p24 antigen production in the culture supernatant for 5 days (MT-4) or 7 days (PBMCs).", [["supernatant", "ANATOMY", 97, 108], ["PBMCs", "ANATOMY", 138, 143], ["Viral", "ORGANISM", 0, 5], ["HIV-1", "ORGANISM", 46, 51], ["p24 antigen", "GENE_OR_GENE_PRODUCT", 59, 70], ["PBMCs", "CELL", 138, 143], ["p24 antigen", "PROTEIN", 59, 70], ["PBMCs", "CELL_TYPE", 138, 143], ["HIV-1", "SPECIES", 46, 51], ["HIV-1", "SPECIES", 46, 51], ["Viral replication", "PROBLEM", 0, 17], ["capsid p24 antigen production", "TREATMENT", 52, 81], ["the culture supernatant", "TREATMENT", 85, 108]]], ["Growth kinetics were analyzed by fitting a linear model to the log-transformed p24 data during the exponential growth phase by maximum likelihood methods as we described previously [35] .Growth competition assaysDual competition experiments were performed by infecting 1 \u00d7 10 6 MT-4 cells with each pair of competing viruses mixed at different ratios with an overall TCID 50 of 1000 (MOI of 0.001).", [["MT-4 cells", "ANATOMY", 278, 288], ["MT-4 cells", "CELL", 278, 288], ["p24", "PROTEIN", 79, 82], ["Dual competition experiments", "TEST", 212, 240], ["competing viruses", "PROBLEM", 307, 324], ["viruses", "OBSERVATION", 317, 324]]], ["HIV-PminB and HIV-PminC were independently competed with the HXB2 wild-type virus.", [["HIV-PminB", "ORGANISM", 0, 9], ["HIV-PminC", "ORGANISM", 14, 23], ["HXB2 wild-type virus", "ORGANISM", 61, 81], ["HIV-PminB and HIV-PminC", "DNA", 0, 23], ["HIV", "SPECIES", 0, 3], ["HIV", "SPECIES", 14, 17], ["HIV", "SPECIES", 0, 3], ["HIV-PminC", "SPECIES", 14, 23], ["HXB2 wild-type virus", "SPECIES", 61, 81], ["HIV", "PROBLEM", 14, 17], ["type virus", "PROBLEM", 71, 81]]], ["After 4 h at 37\u00b0C, cells were washed twice with PBS, resuspended in 5 ml of medium, and cultured in six-well plates.", [["cells", "ANATOMY", 19, 24], ["cells", "CELL", 19, 24], ["cells", "TREATMENT", 19, 24], ["PBS", "TREATMENT", 48, 51]]], ["Culture supernatants were collected twice weekly, and 100 \u03bcl of supernatant was used to infect fresh cells.", [["supernatants", "ANATOMY", 8, 20], ["supernatant", "ANATOMY", 64, 75], ["cells", "ANATOMY", 101, 106], ["cells", "CELL", 101, 106], ["Culture supernatants", "TEST", 0, 20], ["supernatant", "TREATMENT", 64, 75], ["fresh cells", "OBSERVATION", 95, 106]]], ["Viral RNA was extracted and amplified by one-step RT-PCR with oligonucleotides 5\u2032prot 2 and 3\u2032prot 2.", [["Viral", "ORGANISM", 0, 5], ["Viral RNA", "RNA", 0, 9], ["oligonucleotides 5\u2032prot 2 and 3\u2032prot 2", "DNA", 62, 100], ["Viral RNA", "PROBLEM", 0, 9], ["oligonucleotides", "TEST", 62, 78]]], ["Ratios of the two competing variants were estimated on days 0, 7, 14, and 21, based on the relative peak heights of all the different mutations in electropherograms obtained by bidirectional sequencing of the protease coding region.Single-cycle infectivity assayRecoded HIV-1 proteases and wild-type HXB2 protease were cloned into the GFP reporter HIV-1 infectious clone pNL4-3-deltaE-EGFP (NIH AIDS Research and Reference Reagent Program).", [["AIDS", "DISEASE", 395, 399], ["HIV-1", "ORGANISM", 270, 275], ["HXB2", "ORGANISM", 300, 304], ["GFP", "GENE_OR_GENE_PRODUCT", 335, 338], ["HIV-1", "ORGANISM", 348, 353], ["EGFP", "GENE_OR_GENE_PRODUCT", 385, 389], ["protease coding region", "DNA", 209, 231], ["HIV-1 proteases", "PROTEIN", 270, 285], ["wild-type HXB2 protease", "PROTEIN", 290, 313], ["GFP reporter HIV-1 infectious clone pNL4-3-deltaE-EGFP", "DNA", 335, 389], ["HIV-1", "SPECIES", 270, 275], ["HIV-1", "SPECIES", 348, 353], ["HIV-1", "SPECIES", 270, 275], ["HIV-1", "SPECIES", 348, 353], ["the two competing variants", "PROBLEM", 10, 36], ["the protease coding region", "TREATMENT", 205, 231], ["Single-cycle infectivity", "TEST", 232, 256], ["HIV", "TEST", 270, 273], ["wild-type HXB2 protease", "TREATMENT", 290, 313], ["HIV", "TEST", 348, 351], ["infectious clone pNL4", "TEST", 354, 375], ["different mutations", "OBSERVATION", 124, 143]]], ["Protease sequences were PCR amplified with oligonuclotides Apa1988 (5\u2032-ACATAGCCAAA AATTGCAGGGCCCCTAG-3\u2032) and Sbf2838 (5\u2032-CTGA TTTTTTCTGTTTTAACCCTGCAGGATG-3\u2032), digested with Apa I and Sbf I (New England Biolabs), and cloned into pNL4-3-deltaE-EGFP between the Apa I and Sbf I sites.", [["Sbf2838", "CHEMICAL", 109, 116], ["Protease", "GENE_OR_GENE_PRODUCT", 0, 8], ["Apa I", "GENE_OR_GENE_PRODUCT", 173, 178], ["Sbf I", "GENE_OR_GENE_PRODUCT", 183, 188], ["Biolabs", "GENE_OR_GENE_PRODUCT", 202, 209], ["pNL4-3", "GENE_OR_GENE_PRODUCT", 228, 234], ["EGFP", "GENE_OR_GENE_PRODUCT", 242, 246], ["Apa I", "GENE_OR_GENE_PRODUCT", 259, 264], ["Sbf I", "GENE_OR_GENE_PRODUCT", 269, 274], ["Apa I", "DNA", 173, 178], ["Sbf I", "DNA", 183, 188], ["pNL4-3", "DNA", 228, 234], ["deltaE", "DNA", 235, 241], ["EGFP", "DNA", 242, 246], ["Apa I and Sbf I sites", "DNA", 259, 280], ["Protease sequences", "TEST", 0, 18], ["PCR", "TEST", 24, 27], ["oligonuclotides", "TEST", 43, 58], ["Apa", "TEST", 59, 62], ["ACATAGCCAAA", "TEST", 71, 82], ["AATTGCAGGGCCCCTAG", "TEST", 83, 100], ["Sbf2838", "TEST", 109, 116], ["TTTTTTCTGTTTTAACCCTGCAGGATG", "TEST", 126, 153], ["New England Biolabs)", "TREATMENT", 190, 210]]], ["Recombinant pNL4-3-deltaE-EGFP plasmids (4 \u03bcg) were used to transfect 8 \u00d7 10 5 293 T cells in the presence of Lipofectamine 2000 (Invitrogen).", [["293 T cells", "ANATOMY", 79, 90], ["pNL4-3", "GENE_OR_GENE_PRODUCT", 12, 18], ["EGFP", "GENE_OR_GENE_PRODUCT", 26, 30], ["293 T cells", "CELL", 79, 90], ["Recombinant pNL4-3-deltaE-EGFP plasmids", "DNA", 0, 39], ["293 T cells", "CELL_LINE", 79, 90], ["Recombinant pNL4", "TEST", 0, 16], ["deltaE-EGFP plasmids", "TREATMENT", 19, 39], ["Lipofectamine", "TREATMENT", 110, 123]]], ["The relative replication capacity of the virus was determined by measuring the amount of p24 antigen produced 72 h after transfection.", [["p24 antigen", "GENE_OR_GENE_PRODUCT", 89, 100], ["p24 antigen", "PROTEIN", 89, 100], ["The relative replication capacity of the virus", "PROBLEM", 0, 46], ["replication", "OBSERVATION_MODIFIER", 13, 24], ["capacity", "OBSERVATION_MODIFIER", 25, 33], ["virus", "OBSERVATION", 41, 46]]]], "1388ce7cf9e047c0f147035ac083655e04dfebad": [["IntroductionFire prevention is crucial for the safety of life and property in residential and public scenes such as restaurants, hotels and factories.", [["IntroductionFire prevention", "TREATMENT", 0, 27]]], ["Although fire regulations have been made to prevent fire accidents, they are sometimes ignored or disobeyed.", [["accidents", "DISEASE", 57, 66]]], ["The earlier the accidents can be detected, the easier they can be dealt with and the fewer damages can be caused.", [["accidents", "DISEASE", 16, 25]]], ["Therefore, it is necessary to build a smart alarm system for fire prevention.", [["a smart alarm system", "TREATMENT", 36, 56], ["fire prevention", "TREATMENT", 61, 76]]], ["The system needs two essential modules, potential fire sensing and proper disposal strategy.IntroductionThere are various methods for fire sensing such as by detecting smoke, carbon monoxide or flame.", [["carbon monoxide", "CHEMICAL", 175, 190], ["carbon monoxide", "CHEMICAL", 175, 190], ["carbon monoxide", "SIMPLE_CHEMICAL", 175, 190], ["proper disposal strategy", "TREATMENT", 67, 91], ["carbon monoxide", "TEST", 175, 190], ["essential", "OBSERVATION_MODIFIER", 21, 30], ["modules", "OBSERVATION", 31, 38]]], ["There are three necessary ingredients for most fires, i.e. fuel, oxygen and heat.", [["oxygen", "CHEMICAL", 65, 71], ["oxygen", "CHEMICAL", 65, 71], ["oxygen", "SIMPLE_CHEMICAL", 65, 71]]], ["It is feasible to predict potential fire accidents when the temperature rises too quickly or near the ignition point.", [["the temperature rises", "PROBLEM", 56, 77]]], ["Temperature measurement sites in application scenario, e.g. stoves in kitchen, are usually numerous and irregularly distributed.", [["Temperature measurement", "TEST", 0, 23], ["irregularly", "OBSERVATION_MODIFIER", 104, 115], ["distributed", "OBSERVATION_MODIFIER", 116, 127]]], ["Consequently, it is more practical to deploy remote and wide-ranged thermal cameras than single-point thermometers to monitor temperature.IntroductionNevertheless, merely monitoring temperature may lead to the problem of false alarm when someone is working in the scene, for example a chef in the kitchen.", [["temperature", "TEST", 126, 137], ["false alarm", "PROBLEM", 221, 232], ["false alarm", "OBSERVATION", 221, 232]]], ["As a correction, it is necessary to judge the presence of persons.", [["persons", "ORGANISM", 58, 65], ["persons", "SPECIES", 58, 65]]], ["The task can be fulfilled by person detection.", [["person", "SPECIES", 29, 35]]], ["With the development of computer vision and deep learning, person detection has been widely researched and various algorithms have been proposed.", [["person", "SPECIES", 59, 65]]], ["Surveillance cameras have become common in public places, providing clear and realtime videos.", [["Surveillance cameras", "TEST", 0, 20], ["common", "OBSERVATION_MODIFIER", 33, 39]]], ["But there are still challenges for person detection in different sites.", [["person", "SPECIES", 35, 41]]], ["For instance, chefs in kitchen usually wear white suits with masks and tall hats, which are rare in public datasets and difficult to detect for existing models.", [["chefs", "TREATMENT", 14, 19], ["masks", "TREATMENT", 61, 66], ["rare", "OBSERVATION_MODIFIER", 92, 96]]], ["Moreover, the system should be reliable, low-cost and easy to deploy.", [["low", "OBSERVATION_MODIFIER", 41, 44]]], ["Instead, person detection should be implemented on distributed mobile processors on an edge device and only detection results are sent to communication server.", [["person", "SPECIES", 9, 15], ["an edge device", "TREATMENT", 84, 98]]], ["To ensure the speed of person detection, a device-specific deep learning acceleration framework is necessary.IntroductionIn this paper, we propose a smart fire alarm system with bi-spectrum camera and embedded Industry Personal Computer (IPC).", [["person", "SPECIES", 23, 29], ["a device", "TREATMENT", 41, 49], ["bi-spectrum camera", "TREATMENT", 178, 196]]], ["The system is applied in kitchens and the diagram is shown in Fig. 1 .", [["The system", "TREATMENT", 0, 10]]], ["The camera has an optical lens and a thermal lens to capture visible videos and monitor the temperature of cookware respectively.", [["a thermal lens", "TREATMENT", 35, 49], ["optical lens", "OBSERVATION", 18, 30]]], ["The processor performs person detection with YOLOv3-tiny [3] model.", [["YOLOv3", "PROTEIN", 45, 51], ["person", "SPECIES", 23, 29]]], ["The algorithm is modified to deal with special appearance and occlusions of chefs in kitchen, and the inconsistency of aspect ratio between different training datasets.", [["occlusions", "DISEASE", 62, 72], ["occlusions of chefs in kitchen", "PROBLEM", 62, 92], ["different training datasets", "TREATMENT", 140, 167], ["occlusions", "OBSERVATION", 62, 72]]], ["To implement the system on a mobile processor, we propose a high-performance neural network inference computing framework called TuringNN.", [["TuringNN", "CELL_LINE", 129, 137], ["a mobile processor", "TREATMENT", 27, 45]]], ["Person detection and temperature analysis are completed in real time on the IPC.", [["Person detection", "TEST", 0, 16], ["temperature analysis", "TEST", 21, 41]]], ["When the temperature reaches preset thresholds and no person is detected, staff in charge are alarmed with buzzers in the kitchen, phone calls or instant messages from mobile applications.", [["person", "SPECIES", 54, 60]]], ["In severe cases when temperature gets too high or rises too fast, the IPC sends a signal to controller to shut off the stove.", [["too high", "PROBLEM", 38, 46], ["severe", "OBSERVATION_MODIFIER", 3, 9]]], ["The system has been applied for kitchen fire alarm in Freshhema [4] , a combination of fresh food supermarket and restaurant with over 130 chain stores all over China.", [["The system", "TREATMENT", 0, 10]]], ["Section 2 reviews the related work on fire alarm systems and person detection.", [["person", "SPECIES", 61, 67]]], ["Fire safety solutions have been widely researched for years.", [["Fire safety solutions", "TREATMENT", 0, 21]]], ["A fire alarm system has a number of devices working together to detect fire and warn people through visual and audio appliances when smoke, flame, carbon monoxide or other emergencies occur.", [["carbon monoxide", "CHEMICAL", 147, 162], ["carbon monoxide", "CHEMICAL", 147, 162], ["people", "ORGANISM", 85, 91], ["carbon monoxide", "SIMPLE_CHEMICAL", 147, 162], ["people", "SPECIES", 85, 91], ["a number of devices", "TREATMENT", 24, 43], ["carbon monoxide", "TREATMENT", 147, 162]]], ["These alarms may be activated automatically from smoke detectors and heat detectors or be activated via manual fire alarm activation devices like manual call points.", [["heat detectors", "TREATMENT", 69, 83], ["manual fire alarm activation devices", "TREATMENT", 104, 140]]], ["Siemens [5] proposed a solution of fire detection in kitchens with fire detector which consists of smoke, carbon monoxide and flame detectors.", [["carbon monoxide", "CHEMICAL", 106, 121], ["carbon monoxide", "CHEMICAL", 106, 121], ["carbon monoxide", "SIMPLE_CHEMICAL", 106, 121], ["fire detector", "TEST", 67, 80], ["carbon monoxide and flame detectors", "TREATMENT", 106, 141]]], ["Moreover, although Siemens claims that selectable parameter settings make the detectors immune to deceptive phenomena, they are not well adaptive to environment changes.", [["selectable parameter settings", "TREATMENT", 39, 68], ["deceptive phenomena", "PROBLEM", 98, 117]]], ["Cheng et al. [6] proposed a fire safety device for stove-top burner.", [["a fire safety device", "TREATMENT", 26, 46]]], ["It senses the temperature of the cooking utensil and automatically shuts off the flow of electricity or gas to the burner when the temperature of the cooking utensil exceeds threshold.", [["utensil", "SIMPLE_CHEMICAL", 158, 165]]], ["However, the device does not consider the presence of persons, which may cause false alarms.", [["persons", "ORGANISM", 54, 61], ["persons", "SPECIES", 54, 61], ["the device", "TREATMENT", 9, 19], ["false alarms", "PROBLEM", 79, 91], ["false alarms", "OBSERVATION", 79, 91]]], ["There are some other fire alarm solutions such as [19] [20] [21] , which are similar to [5] and [6] .", [["[19] [20] [21]", "SIMPLE_CHEMICAL", 50, 64], ["[5]", "SIMPLE_CHEMICAL", 88, 91], ["[6]", "SIMPLE_CHEMICAL", 96, 99]]], ["Thermal camera (also called infrared camera) is a device that creates an image using infrared radiation.", [["Thermal camera", "TREATMENT", 0, 14], ["a device", "TREATMENT", 48, 56], ["infrared radiation", "TREATMENT", 85, 103]]], ["All objects with temperature higher than absolute zero (\u2212273.15\u00b0C) radiate infrared constantly.", [["temperature", "TEST", 17, 28]]], ["Infrared thermal imager is a device that receives infrared radiation from objects and converts it into visible-light image.", [["Infrared thermal imager", "TREATMENT", 0, 23], ["a device", "TREATMENT", 27, 35], ["infrared radiation", "TREATMENT", 50, 68]]], ["This thermal image corresponds to the temperature distribution field on the surface of the object, which is essentially the infrared radiation distribution map of all parts of the object.", [["surface", "ANATOMY", 76, 83], ["This thermal image", "TEST", 0, 18], ["temperature", "OBSERVATION_MODIFIER", 38, 49], ["distribution", "OBSERVATION_MODIFIER", 50, 62], ["field", "OBSERVATION_MODIFIER", 63, 68], ["surface", "OBSERVATION_MODIFIER", 76, 83], ["object", "OBSERVATION", 91, 97], ["essentially", "OBSERVATION_MODIFIER", 108, 119], ["infrared", "OBSERVATION_MODIFIER", 124, 132], ["radiation distribution", "OBSERVATION", 133, 155], ["all parts", "ANATOMY_MODIFIER", 163, 172], ["object", "ANATOMY", 180, 186]]], ["Different from the 400-700 nm range of the visible light camera, thermal cameras are sensitive to wavelengths from about 1 lm to about 14 lm.", [["thermal cameras", "TREATMENT", 65, 80]]], ["When sensitive enough, infrared camera can capture accurate temperature of every position in an image, and further calculate the temperature change rate in a video.Person Detection and Deep Learning Inference FrameworkIn kitchens, cooking is similar to fire accident when only monitoring heat, flame or smoke.", [["infrared camera", "TEST", 23, 38], ["an image", "TEST", 93, 101], ["the temperature change rate", "TEST", 125, 152]]], ["Therefore, person detection is an essential task in an intelligent fire alarm system to prevent false alarms.", [["person", "SPECIES", 11, 17], ["false alarms", "PROBLEM", 96, 108], ["false alarms", "OBSERVATION", 96, 108]]], ["Compared with general object detection, there are more challenges in person detection, such as various clothing, appearance, poses and different viewpoints of the camera.", [["person", "SPECIES", 69, 75], ["general object detection", "TEST", 14, 38]]], ["With the development of computer vision and deep learning, various object detection algorithms are proposed such as Faster R-CNN [7] , SSD [8] and YOLO [9] .", [["various object detection algorithms", "TEST", 59, 94], ["SSD", "TEST", 135, 138]]], ["Although new algorithms are constantly proposed and better performances have been achieved, they usually require lots of computing resources and long inference time.", [["new", "OBSERVATION_MODIFIER", 9, 12]]], ["In application scenarios, deep learning models should be economical and efficient on mobile platforms with limited computing power.Person Detection and Deep Learning Inference FrameworkNumerous techniques have been proposed to accelerate deep learning models on low-power devices.", [["deep learning models", "PROBLEM", 26, 46], ["low-power devices", "TREATMENT", 262, 279]]], ["In the context of deep learning, the predominant numerical format used for research and for deployment has so far been 32bit floating point.", [["deployment", "TREATMENT", 92, 102], ["deep", "ANATOMY_MODIFIER", 18, 22]]], ["However, the pursuit for reduced bandwidth and computing requirements of deep learning models has driven research into using lower-precision numerical formats.", [["reduced bandwidth", "PROBLEM", 25, 42], ["deep learning models", "TREATMENT", 73, 93]]], ["It has been proved that weights and activations can be represented using 8-bit integers without incurring significant loss in accuracy.", [["significant loss in accuracy", "PROBLEM", 106, 134]]], ["By combining various acceleration techniques, researchers have built deep learning inference frameworks for mobile devices, such as TensorFlow Lite [11] and NCNN [12] .", [["various acceleration techniques", "TREATMENT", 13, 44], ["mobile devices", "TREATMENT", 108, 122], ["TensorFlow Lite", "TEST", 132, 147]]], ["The frameworks make deep learning models faster and smaller while maintain or even improve the performance by combining multiple optimization methods.", [["deep", "ANATOMY_MODIFIER", 20, 24]]], ["Despite the convenience of public frameworks, there are still adaption problems for specific devices and network structures, and there is still space for further optimization.The Proposed SystemThe workflow of our system is demonstrated in Fig. 2 .", [["network structures", "MULTI-TISSUE_STRUCTURE", 105, 123], ["still adaption problems", "PROBLEM", 56, 79], ["specific devices", "TREATMENT", 84, 100], ["further optimization", "TREATMENT", 154, 174], ["Fig", "OBSERVATION_MODIFIER", 240, 243]]], ["It consists of four modules, (a) temperature measurement, (b) person detection, (c) TuringNN and (d) disposal rules.Temperature MeasurementThe temperature is measured with thermal videos.", [["person", "SPECIES", 62, 68], ["a) temperature measurement", "TEST", 30, 56], ["TuringNN and (d) disposal rules", "TREATMENT", 84, 115], ["Temperature Measurement", "TEST", 116, 139], ["The temperature", "TEST", 139, 154], ["four modules", "OBSERVATION_MODIFIER", 15, 27]]], ["First of all, the locations of stoves are manually annotated in thermal videos, as shown in Fig. 3 right.", [["right", "ANATOMY_MODIFIER", 99, 104]]], ["The temperature of target locations is sampled with an adjustable time interval.", [["temperature", "OBSERVATION_MODIFIER", 4, 15]]], ["The heating curve is fit with least square method according to the discrete temperature data points in observation period.", [["The heating curve", "TREATMENT", 0, 17]]], ["The slope of the curve, namely current temperature ascent rate R, is calculated asTemperature Measurementwhere the last n temperature data points are used for calculation and n is set to 20 in our system, t denotes the temperature check time interval and is set according to current temperature as shown in Table 1 , y i represents the values of the n temperature data points.", [["the curve", "TEST", 13, 22], ["calculation", "TEST", 159, 170], ["the temperature", "TEST", 215, 230], ["slope", "OBSERVATION_MODIFIER", 4, 9]]], ["If the difference between the current temperature and the previous temperature is more than 20\u00b0C, the current temperature is ignored as a noise.Person DetectionPerson detection is deployed on optical video because the color and texture of persons are more obvious in optical video compared with thermal video, as shown in Fig. 3 .", [["persons", "ORGANISM", 239, 246], ["persons", "SPECIES", 239, 246], ["the current temperature", "TEST", 26, 49], ["the previous temperature", "TEST", 54, 78], ["optical video", "TEST", 192, 205], ["optical video", "TEST", 267, 280], ["thermal video", "TEST", 295, 308]]], ["In order to achieve accurate and efficient person detection, the small model of YOLOv3tiny is utilized in our system.", [["YOLOv3tiny", "DNA", 80, 90], ["small", "OBSERVATION_MODIFIER", 65, 70]]], ["YOLOv3-tiny is pruned from YOLOv3 [3] with fewer layers and scales.", [["YOLOv3", "GENE_OR_GENE_PRODUCT", 0, 6], ["YOLOv3", "PROTEIN", 0, 6], ["tiny", "OBSERVATION_MODIFIER", 7, 11]]], ["Compared to the large model of YOLOv3, YOLOv3-tiny is 5 times faster with small accuracy loss.", [["YOLOv3", "GENE_OR_GENE_PRODUCT", 31, 37], ["YOLOv3", "GENE_OR_GENE_PRODUCT", 39, 45], ["YOLOv3", "DNA", 31, 37], ["YOLOv3", "DNA", 39, 45], ["small accuracy loss", "PROBLEM", 74, 93], ["large", "OBSERVATION_MODIFIER", 16, 21], ["tiny", "OBSERVATION_MODIFIER", 46, 50], ["5 times", "OBSERVATION_MODIFIER", 54, 61], ["small", "OBSERVATION_MODIFIER", 74, 79], ["accuracy loss", "OBSERVATION", 80, 93]]], ["The network structure of YOLOv3-tiny is shown in Fig. 4 .", [["YOLOv3", "GENE_OR_GENE_PRODUCT", 25, 31], ["YOLOv3", "PROTEIN", 25, 31], ["tiny", "OBSERVATION_MODIFIER", 32, 36], ["Fig", "OBSERVATION_MODIFIER", 49, 52]]], ["The model extracts feature map (FM) of input image with a 13-layer backbone network.", [["input image", "TEST", 39, 50], ["a 13-layer backbone network", "TREATMENT", 56, 83]]], ["YOLOv3-tiny predicts bounding boxes at two different scales (with stride 8 and 16) with the idea of Feature Pyramid Network for Object Detection (FPN) [10] .", [["YOLOv3", "GENE_OR_GENE_PRODUCT", 0, 6], ["YOLOv3", "DNA", 0, 6], ["tiny predicts bounding boxes", "PROBLEM", 7, 35], ["tiny", "OBSERVATION_MODIFIER", 7, 11]]], ["Two detection headers, which are separately built on the top of two feature maps with different scales, are responsible for detecting objects with different sizes.", [["Two detection headers", "TEST", 0, 21], ["headers", "OBSERVATION", 14, 21], ["top", "OBSERVATION_MODIFIER", 57, 60], ["different scales", "OBSERVATION_MODIFIER", 86, 102], ["responsible for", "UNCERTAINTY", 108, 123], ["objects", "OBSERVATION", 134, 141], ["different", "OBSERVATION_MODIFIER", 147, 156], ["sizes", "OBSERVATION_MODIFIER", 157, 162]]], ["As shown in Fig. 4(b) , each grid in the detection header is assigned with K different anchors, and thus predicts K detections that consist of 4 bounding box offsets, 1 objectiveness and C class predictions.", [["predicts K detections", "TEST", 105, 126]]], ["In our case, K is set to 3 and C is 1 to only detect person.", [["person", "SPECIES", 53, 59], ["K", "TEST", 13, 14]]], ["The final result tensor of detection header has a shape of N \u00c2 N \u00c2 (K(4 + 1 + C)) where N \u00c2 N denotes the spatial size of the last convolutional feature map.", [["N", "CHEMICAL", 59, 60], ["N", "CHEMICAL", 63, 64], ["N \u00c2 N", "CHEMICAL", 88, 93], ["N \u00c2 N", "PROTEIN", 88, 93], ["N", "TEST", 59, 60], ["K", "TEST", 68, 69], ["spatial", "OBSERVATION_MODIFIER", 106, 113], ["size", "OBSERVATION_MODIFIER", 114, 118]]], ["To deal with the difference of person appearance between public datasets and kitchen and to guarantee the generalization ability of the model, we train it with both public datasets and application dataset of surveillance videos.", [["person", "SPECIES", 31, 37], ["surveillance videos", "TEST", 208, 227]]], ["As shown in Fig. 5(a) and Fig. 5(b) , public datasets have various aspect ratios while surveillance videos have fixed aspect ratio of 16:9 .", [["public datasets", "TEST", 38, 53], ["various aspect ratios", "TEST", 59, 80], ["surveillance videos", "TEST", 87, 106], ["fixed aspect ratio", "TEST", 112, 130]]], ["When training the model, if we directly resize all images into the same aspect ratio, some ground truths will suffer from severe distortion, as illustrated in Fig. 5(c) .", [["severe distortion", "PROBLEM", 122, 139], ["severe", "OBSERVATION_MODIFIER", 122, 128], ["distortion", "OBSERVATION", 129, 139]]], ["Therefore, we keep the aspect ratio of images unchanged by adding borders to the image in data augmentation, as demonstrated Fig. 5(d) .Person DetectionIgnore Label.", [["the image in data augmentation", "TEST", 77, 107]]], ["The original YOLO distinguishes positive and negative objects with an Intersection-Over-Union (IOU) threshold.", [["YOLO", "DNA", 13, 17], ["negative objects", "OBSERVATION", 45, 61]]], ["However, the ground truth is ambiguous in some cases such as crowd, heavy occlusion and blur.", [["heavy occlusion", "DISEASE", 68, 83], ["heavy occlusion", "PROBLEM", 68, 83], ["ground truth", "OBSERVATION", 13, 25], ["heavy", "OBSERVATION_MODIFIER", 68, 73], ["occlusion", "OBSERVATION", 74, 83], ["blur", "OBSERVATION_MODIFIER", 88, 92]]], ["The object is annotated with ignore label if it is a crowd of persons, a part of a person or when we are not sure if the object is a person or not.", [["persons", "SPECIES", 62, 69], ["person", "SPECIES", 83, 89], ["person", "SPECIES", 133, 139]]], ["In training, if the IOU between a box proposal and any ground truth box with ignore label is larger than threshold, the proposal is ignored in loss calculation.", [["IOU", "DNA", 20, 23], ["ground truth box", "DNA", 55, 71], ["a box proposal", "TREATMENT", 32, 46], ["larger", "OBSERVATION_MODIFIER", 93, 99]]], ["With the operation of the system, the incorrect person detection instances are accumulated along with the false fire alarms.", [["false", "OBSERVATION", 106, 111], ["fire alarms", "OBSERVATION", 112, 123]]], ["The instances can be used as hard examples (images that cause the model make errors) to improve the detection model.", [["the detection model", "TEST", 96, 115]]], ["The new model is finetuned from current model with new instances as well as original training data, which effectively avoid overfitting.", [["original training data", "TEST", 76, 98], ["overfitting", "PROBLEM", 124, 135], ["new", "OBSERVATION_MODIFIER", 4, 7], ["model", "OBSERVATION_MODIFIER", 8, 13]]], ["Finally, the model turns stable and accurate.Neural Network Inference Acceleration with TuringNNTuringNN is a novel deep learning inference framework optimized for mobile heterogeneous computing on Android, iOS, Linux and Windows devices.", [["turns", "OBSERVATION_MODIFIER", 19, 24], ["stable", "OBSERVATION_MODIFIER", 25, 31], ["heterogeneous", "OBSERVATION_MODIFIER", 171, 184]]], ["It has optimization solutions for most neural network models, operating systems and mobile processors.", [["neural network", "ANATOMY", 39, 53], ["neural network", "MULTI-TISSUE_STRUCTURE", 39, 53], ["optimization solutions", "TREATMENT", 7, 29], ["mobile processors", "TREATMENT", 84, 101]]], ["Rearrange data for the underlying hardware to reduce the bottleneck of memory reading.", [["the underlying hardware", "PROBLEM", 19, 42], ["hardware", "OBSERVATION", 34, 42]]], ["For example, the technique of Im2col is demonstrated in Fig. 6 .", [["Im2col", "SIMPLE_CHEMICAL", 30, 36], ["Im2col", "PROTEIN", 30, 36]]], ["When dealing with convolutional layers in a neural network, TuringNN rearranges the 2 \u00c2 2 kernel matrix into a 4 \u00c2 1 array.", [["neural network", "ANATOMY", 44, 58], ["neural network", "MULTI-TISSUE_STRUCTURE", 44, 58], ["TuringNN", "DNA", 60, 68], ["2 \u00c2 2 kernel matrix", "DNA", 84, 103], ["4 \u00c2 1 array", "DNA", 111, 122], ["convolutional layers in a neural network", "PROBLEM", 18, 58]]], ["Meanwhile the N \u00c2 M input feature map (image) is reshaped into a P \u00c2 4 matrix by putting the elements of 2 \u00c2 2 neighborhood into a row, where P = (N -2 + 1)(M -2 + 1).", [["P \u00c2 4 matrix", "DNA", 65, 77], ["a P \u00c2 4 matrix", "TREATMENT", 63, 77], ["P", "TEST", 142, 143]]], ["In this way, the operation of convolution is translated to matrix multiplication.", [["matrix", "ANATOMY", 59, 65], ["matrix", "CELLULAR_COMPONENT", 59, 65], ["the operation of convolution", "TREATMENT", 13, 41]]], ["The CPU can then take advantage of special parallel hardware (SSE or MMX) to speed up convolution substantially.Neural Network Inference Acceleration with TuringNNQuantitative Calculation.", [["Neural", "ANATOMY", 112, 118], ["special parallel hardware", "TREATMENT", 35, 60], ["hardware", "OBSERVATION", 52, 60]]], ["8-bit data is calculated for the underlying hardware to increase data multiplication and throughput.", [["bit data", "TEST", 2, 10], ["the underlying hardware", "PROBLEM", 29, 52], ["hardware", "OBSERVATION", 44, 52]]], ["The quantitative calculation chart is shown in Fig. 7 .", [["The quantitative calculation chart", "TEST", 0, 34]]], ["Firstly, TuringNN runs a model of 32-bit floating point (FP32) with a calibration dataset and records the maximum and minimum of the feature map in each layer.", [["TuringNN", "PROTEIN", 9, 17], ["a calibration dataset", "TEST", 68, 89], ["layer", "OBSERVATION_MODIFIER", 153, 158]]], ["During inference, the weights and input in each layer are converted into 8-bit integers (INT8) with the recorded maximum and minimum, and then the output is turned back to FP32.", [["FP32", "GENE_OR_GENE_PRODUCT", 172, 176], ["8-bit integers", "DNA", 73, 87], ["INT8", "DNA", 89, 93], ["FP32", "PROTEIN", 172, 176], ["the output", "TEST", 143, 153]]], ["The quantization and dequantization formula are noted in Eq.", [["The quantization and dequantization formula", "TREATMENT", 0, 43]]], ["(2), where F and Q are the FP32 and INT8 values, while F max and F min are the maximum and minimum FP32 values of each layers.", [["FP32", "GENE_OR_GENE_PRODUCT", 27, 31], ["INT8", "PROTEIN", 36, 40], ["FP32", "PROTEIN", 99, 103], ["the FP32", "TEST", 23, 31], ["INT8 values", "TEST", 36, 47], ["layers", "OBSERVATION_MODIFIER", 119, 125]]], ["As shown in Fig. 7 left, the dequantization of the previous operation and the quantization of the next operation will cancel each other out.", [["the previous operation", "TREATMENT", 47, 69], ["the next operation", "TREATMENT", 94, 112], ["left", "ANATOMY_MODIFIER", 19, 23], ["operation", "OBSERVATION", 60, 69]]], ["Therefore, TuringNN combines the dequantization and quantization before each operation when there are multiple quantified operations in succession, as illustrated in Fig. 7 right.Neural Network Inference Acceleration with TuringNNMultithreading.", [["the dequantization and quantization before each operation", "TREATMENT", 29, 86], ["multiple quantified operations", "TREATMENT", 102, 132], ["multiple", "OBSERVATION_MODIFIER", 102, 110], ["quantified", "OBSERVATION_MODIFIER", 111, 121], ["operations", "OBSERVATION", 122, 132], ["right", "ANATOMY_MODIFIER", 173, 178]]], ["When the compiler supports OpenMP, we set the concurrent number according to the hardware device, and the concurrent time-consuming cycle will use multi-core to complete the operation.", [["the hardware device", "TREATMENT", 77, 96], ["the operation", "TREATMENT", 170, 183], ["hardware", "OBSERVATION", 81, 89]]], ["On Apple's platform, we use Grand Central Dispatch (GCD) to dispatch the time-consuming cycle, and the system dynamically allocates the concurrent number, so as to obtain better performance than OpenMP.", [["OpenMP", "PROTEIN", 195, 201]]], ["On Android and Linux platform, using thread pool for multithreading management and control can make more efficient use of multi-core and large-small-core hardware resources.Neural Network Inference Acceleration with TuringNNMemory Layout.", [["thread pool", "TREATMENT", 37, 48], ["multithreading management", "TREATMENT", 53, 78], ["multi-core and large-small-core hardware resources", "TREATMENT", 122, 172], ["large", "OBSERVATION_MODIFIER", 137, 142], ["small", "OBSERVATION_MODIFIER", 143, 148]]], ["For example, operators such as convolution and pool run on the memory layout of batch number/channel/height/width (NCHW), while operators such as post and split use the memory layout of NHWC.", [["NHWC", "CANCER", 186, 190]]], ["When the memory layouts of adjacent operators are inconsistent, conversion operators are inserted.Neural Network Inference Acceleration with TuringNNFusing.", [["Neural", "ANATOMY", 98, 104], ["conversion operators", "TREATMENT", 64, 84]]], ["The optical lens and thermal lens focus on the same view of the kitchen.", [["optical lens", "OBSERVATION", 4, 16], ["thermal", "OBSERVATION_MODIFIER", 21, 28], ["lens", "OBSERVATION_MODIFIER", 29, 33], ["focus", "OBSERVATION_MODIFIER", 34, 39]]], ["If no person is detected, current temperature of cookware is measured from thermal videos.", [["person", "SPECIES", 6, 12]]], ["When food is fried, the oil temperature rises fast and then slows down.", [["oil", "ANATOMY", 24, 27], ["oil", "ORGANISM_SUBSTANCE", 24, 27], ["the oil temperature", "TEST", 20, 39]]], ["According to this rule, different temperature thresholds are set for temperature analysis, as listed in Table 1 .", [["different temperature thresholds", "PROBLEM", 24, 56], ["temperature analysis", "TEST", 69, 89]]], ["As the temperature rises, the check interval becomes shorter, the accent rate threshold gets smaller and the disposal action becomes more urgent.", [["the temperature rises", "PROBLEM", 3, 24], ["the accent rate threshold", "TEST", 62, 87], ["smaller", "OBSERVATION_MODIFIER", 93, 100]]], ["When the temperature or the ascent rate reaches a threshold, the corresponding disposal actions are triggered.", [["the temperature", "TEST", 5, 20], ["the ascent rate", "TEST", 24, 39]]], ["Each time the system sends an alarm, the frames of the optical and infrared videos are saved along with person detection results and temperature data.", [["person detection", "TEST", 104, 120], ["temperature data", "TEST", 133, 149]]], ["Incorrect person detection results will be fed back to improve person detection algorithm.Disposal Rule and DevicesThe bi-spectrum camera in our system (Fig. 8) is DH-TPC-BF2221-T manufactured by Dahua Technology [13] .", [["DH-TPC-BF2221-T", "CHEMICAL", 164, 179], ["person", "SPECIES", 10, 16], ["The bi-spectrum camera", "TEST", 115, 137], ["TPC", "TEST", 167, 170]]], ["It has an optical lens and a thermal lens to capture optical videos and monitor temperature.", [["a thermal lens", "TREATMENT", 27, 41], ["optical lens", "OBSERVATION", 10, 22]]], ["The thermal lens has many advantages such as fast response (latency less than 40 ms), wide temperature measurement range (\u221220\u00b0C to 550\u00b0C) and small error (less than 5\u00b0C).", [["The thermal lens", "TREATMENT", 0, 16], ["wide temperature", "TEST", 86, 102], ["small error", "PROBLEM", 142, 153], ["thermal lens", "OBSERVATION", 4, 16], ["small", "OBSERVATION_MODIFIER", 142, 147], ["error", "OBSERVATION", 148, 153]]], ["The type of IPC ( Fig. 9) is UNO-2372G produced by Advantech [14] .", [["UNO-2372G", "CHEMICAL", 29, 38], ["UNO-2372G", "CHEMICAL", 29, 38], ["UNO-2372G", "SIMPLE_CHEMICAL", 29, 38]]], ["It has Intel \u00ae atom Baytrial E3845 quad core processor up to 1.91 GHZ and 4 GB DDR3L memory.Experiments and AnalysesTo guarantee the generalization of the person detection model, we build the training and testing dataset with our application dataset and multiple public datasets including Pascal VOC (only person) [15] , COCO2017 (only person) [16] , KITTI [17] and CityPersons [18] .", [["person", "SPECIES", 155, 161], ["person", "SPECIES", 306, 312], ["person", "SPECIES", 336, 342], ["GHZ", "TEST", 66, 69]]], ["There are 60000 and 80000 images in application dataset and public datasets respectively, and 20% of images in each dataset are randomly chosen as test set and the remainder for training.", [["images", "TEST", 101, 107]]], ["The results of the following experiments are based on the test set.Experiments and AnalysesThe results of different person detection algorithms are listed in Table 2 .", [["the test set", "TEST", 54, 66]]], ["Compared with original YOLOv3-tiny, the model with ignore label improves the precisions of both public and application datasets, showing its general effectiveness.", [["YOLOv3", "DNA", 23, 29], ["tiny", "OBSERVATION_MODIFIER", 30, 34]]], ["As a contrast, wide augmentation significantly improves the performance on application dataset while not affects the performance on public datasets.", [["application dataset", "TREATMENT", 75, 94]]], ["The reason is that wide augmentation adapts the model to the highly concentrated aspect ratio of the application dataset (16:9) with input size of 384 \u00c2 224 instead of the original 288 \u00c2 288.", [["input size", "TEST", 133, 143], ["wide", "OBSERVATION_MODIFIER", 19, 23], ["augmentation", "OBSERVATION", 24, 36], ["size", "OBSERVATION_MODIFIER", 139, 143]]], ["By combining ignore label and wide augmentation (IL \u00c2 WA), the model achieves better scores on application dataset, showing the coordination of the two modifications.", [["wide augmentation (IL \u00c2 WA", "TREATMENT", 30, 56], ["application dataset", "TREATMENT", 95, 114], ["wide", "OBSERVATION_MODIFIER", 30, 34], ["augmentation", "OBSERVATION_MODIFIER", 35, 47]]], ["The last line indicates the model finetuned with 500 hard examples.", [["The last line", "TREATMENT", 0, 13]]], ["It further improves the precision on application dataset, proving the effectiveness of iterative model improvement.", [["application dataset", "TREATMENT", 37, 56]]], ["We speed up the person detection model above with different model acceleration frameworks, and the inference time is listed in Table 3 .", [["person", "SPECIES", 16, 22]]], ["It is clear that all the acceleration frameworks have large speedup over original Darknet.", [["clear", "OBSERVATION", 6, 11], ["large", "OBSERVATION_MODIFIER", 54, 59], ["speedup", "OBSERVATION_MODIFIER", 60, 67]]], ["It is 17.4% faster than NCNN [12], 48.5% faster than Tensorflow Lite [11] and 370% faster than Darknet, indicating the effectiveness of the optimizations in TuringNN.Experiments and AnalysesIn summary, the features of existing fire alarm systems and the proposed system are compared in Table 4 .", [["NCNN", "TEST", 24, 28], ["Tensorflow Lite", "TEST", 53, 68], ["17.4%", "OBSERVATION_MODIFIER", 6, 11]]], ["The proposed fire alarm system has been applied for kitchen safety in Freshhema for over 6 months.", [["The proposed fire alarm system", "TREATMENT", 0, 30], ["fire alarm", "OBSERVATION", 13, 23]]], ["An alarm is defined as effective if the oil temperature has risen into the ranges in Table 1 and nobody is near the stove, i.e. both the temperature measurement and person detection are correct.", [["oil", "ANATOMY", 40, 43], ["oil", "ORGANISM_SUBSTANCE", 40, 43], ["person", "SPECIES", 165, 171], ["the oil temperature", "TEST", 36, 55], ["the temperature measurement", "TEST", 133, 160], ["person detection", "TEST", 165, 181], ["alarm", "OBSERVATION", 3, 8]]], ["The proposed system prevents fire accidents by monitoring the temperature of cookware with thermal cameras.", [["accidents", "DISEASE", 34, 43], ["thermal cameras", "TREATMENT", 91, 106], ["fire accidents", "OBSERVATION", 29, 43]]], ["Moreover, the system achieves quick response and avoids false alarm via person detection.", [["person", "SPECIES", 72, 78]]], ["By using YOLOv3-tiny algorithm and model quantification framework TuringNN, we are able to implement the system on small-scale low-cost edge devices for practical situations.", [["YOLOv3", "PROTEIN", 9, 15], ["small-scale low-cost edge devices", "TREATMENT", 115, 148]]], ["Future research will focus on person detection on thermal videos and improving the precision and recall of the system with the detections of both optical and thermal videos.", [["person", "SPECIES", 30, 36], ["thermal videos", "TEST", 50, 64]]]], "PMC7162337": [["Cell Lines ::: MATERIALS AND METHODSBovine adrenal gland capillary endothelial cells (BCE) were obtained from Clonetics Inc. (San Diego, CA).", [["Cell", "ANATOMY", 0, 4], ["adrenal gland capillary endothelial cells", "ANATOMY", 43, 84], ["BCE", "ANATOMY", 86, 89], ["Cell", "CELL", 0, 4], ["adrenal gland capillary endothelial cells", "CELL", 43, 84], ["BCE", "CELL", 86, 89], ["METHODSBovine adrenal gland capillary endothelial cells", "CELL_LINE", 29, 84], ["METHODSBovine adrenal gland capillary endothelial cells", "TEST", 29, 84], ["adrenal gland", "ANATOMY", 43, 56], ["capillary endothelial cells", "OBSERVATION", 57, 84]]], ["Human umbilical vein endothelial cells (HUVEC), passage 2, kindly were provided by Dr. Vercelotti (University of Minnesota).", [["Human umbilical vein endothelial cells", "ANATOMY", 0, 38], ["HUVEC", "ANATOMY", 40, 45], ["Human umbilical vein endothelial cells", "CELL", 0, 38], ["HUVEC", "CELL", 40, 45], ["Human umbilical vein endothelial cells", "CELL_LINE", 0, 38], ["HUVEC", "CELL_LINE", 40, 45], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["Human umbilical vein endothelial cells", "TREATMENT", 0, 38], ["umbilical vein", "ANATOMY", 6, 20], ["endothelial cells", "OBSERVATION", 21, 38]]], ["MA148, a human epithelial ovarian carcinoma cell line, was established locally at the University of Minnesota from a patient with Stage III epithelial ovarian serous adenocarcinoma.18 The human primary melanoma cell line WM35 was provided by Dr. Iida and Dr. McCarthy (University of Minnesota).", [["epithelial ovarian carcinoma cell line", "ANATOMY", 15, 53], ["epithelial ovarian serous adenocarcinoma", "ANATOMY", 140, 180], ["primary melanoma cell line WM35", "ANATOMY", 194, 225], ["MA148", "CHEMICAL", 0, 5], ["epithelial ovarian carcinoma", "DISEASE", 15, 43], ["ovarian serous adenocarcinoma", "DISEASE", 151, 180], ["primary melanoma", "DISEASE", 194, 210], ["MA148", "SIMPLE_CHEMICAL", 0, 5], ["human", "ORGANISM", 9, 14], ["epithelial ovarian carcinoma cell line", "CELL", 15, 53], ["patient", "ORGANISM", 117, 124], ["epithelial ovarian serous adenocarcinoma", "CANCER", 140, 180], ["human", "ORGANISM", 188, 193], ["melanoma cell line WM35", "CELL", 202, 225], ["MA148", "CELL_LINE", 0, 5], ["human epithelial ovarian carcinoma cell line", "CELL_LINE", 9, 53], ["human primary melanoma cell line WM35", "CELL_LINE", 188, 225], ["human", "SPECIES", 9, 14], ["patient", "SPECIES", 117, 124], ["human", "SPECIES", 188, 193], ["human", "SPECIES", 9, 14], ["human", "SPECIES", 188, 193], ["a human epithelial ovarian carcinoma cell line", "TREATMENT", 7, 53], ["Stage III epithelial ovarian serous adenocarcinoma", "PROBLEM", 130, 180], ["The human primary melanoma cell line", "TREATMENT", 184, 220], ["epithelial", "ANATOMY_MODIFIER", 15, 25], ["ovarian", "ANATOMY", 26, 33], ["carcinoma", "OBSERVATION", 34, 43], ["cell line", "OBSERVATION", 44, 53], ["Stage III", "OBSERVATION_MODIFIER", 130, 139], ["epithelial", "ANATOMY_MODIFIER", 140, 150], ["ovarian", "ANATOMY", 151, 158], ["serous adenocarcinoma", "OBSERVATION", 159, 180], ["primary", "OBSERVATION_MODIFIER", 194, 201], ["melanoma cell line", "OBSERVATION", 202, 220]]], ["The human colon carcinoma cell line LS174T was obtained from the American Type Culture Collection (ATCC) (Rockville, MD).", [["colon carcinoma cell line LS174T", "ANATOMY", 10, 42], ["colon carcinoma", "DISEASE", 10, 25], ["human", "ORGANISM", 4, 9], ["colon carcinoma cell line LS174T", "CELL", 10, 42], ["human colon carcinoma cell line LS174T", "CELL_LINE", 4, 42], ["human", "SPECIES", 4, 9], ["human", "SPECIES", 4, 9], ["American Type Culture Collection (ATCC)", "SPECIES", 65, 104], ["The human colon carcinoma cell line LS174T", "PROBLEM", 0, 42], ["colon", "ANATOMY", 10, 15], ["carcinoma", "OBSERVATION", 16, 25]]], ["The mouse ovarian carcinoma cell line LM3 kindly was provided by Dr. Yokoro (Kyoto University, Japan).", [["ovarian carcinoma cell line LM3", "ANATOMY", 10, 41], ["ovarian carcinoma", "DISEASE", 10, 27], ["mouse", "ORGANISM", 4, 9], ["ovarian carcinoma cell line LM3 kindly", "CELL", 10, 48], ["mouse ovarian carcinoma cell line LM3", "CELL_LINE", 4, 41], ["mouse", "SPECIES", 4, 9], ["mouse", "SPECIES", 4, 9], ["The mouse ovarian carcinoma", "PROBLEM", 0, 27], ["ovarian", "ANATOMY", 10, 17], ["carcinoma cell line", "OBSERVATION", 18, 37]]], ["The human leukemic monocytic leukemia cell line U937 and the highly metastatic mouse melanoma cell line B16F10 were obtained from ATCC.Antibodies ::: MATERIALS AND METHODSAntihuman APN monoclonal antibody (3D8) was obtained from NeoMarkers (Fremont, CA).Cloning and Expression of Human Endostatin ::: MATERIALS AND METHODSCloning and expression conditions of human endostatin have been published previously.17 The yeast expression system of Pichia pastoris was purchased from Invitrogen (San Diego, CA).", [["leukemic monocytic leukemia cell line U937", "ANATOMY", 10, 52], ["metastatic mouse melanoma cell line B16F10", "ANATOMY", 68, 110], ["ATCC", "ANATOMY", 130, 134], ["leukemic monocytic leukemia", "DISEASE", 10, 37], ["melanoma", "DISEASE", 85, 93], ["human", "ORGANISM", 4, 9], ["leukemic monocytic leukemia cell line U937", "CELL", 10, 52], ["mouse", "ORGANISM", 79, 84], ["melanoma cell line B16F10", "CELL", 85, 110], ["ATCC", "CELL", 130, 134], ["APN", "GENE_OR_GENE_PRODUCT", 181, 184], ["Human", "ORGANISM", 280, 285], ["Endostatin", "GENE_OR_GENE_PRODUCT", 286, 296], ["human", "ORGANISM", 359, 364], ["endostatin", "GENE_OR_GENE_PRODUCT", 365, 375], ["Pichia pastoris", "ORGANISM", 441, 456], ["human leukemic monocytic leukemia cell line U937", "CELL_LINE", 4, 52], ["highly metastatic mouse melanoma cell line B16F10", "CELL_LINE", 61, 110], ["ATCC", "CELL_LINE", 130, 134], ["METHODSAntihuman APN monoclonal antibody", "PROTEIN", 164, 204], ["3D8", "PROTEIN", 206, 209], ["Human Endostatin", "PROTEIN", 280, 296], ["human endostatin", "PROTEIN", 359, 375], ["human", "SPECIES", 4, 9], ["mouse", "SPECIES", 79, 84], ["Human", "SPECIES", 280, 285], ["human", "SPECIES", 359, 364], ["yeast", "SPECIES", 414, 419], ["Pichia pastoris", "SPECIES", 441, 456], ["human", "SPECIES", 4, 9], ["mouse", "SPECIES", 79, 84], ["ATCC", "SPECIES", 130, 134], ["human", "SPECIES", 359, 364], ["yeast", "SPECIES", 414, 419], ["Pichia pastoris", "SPECIES", 441, 456], ["The human leukemic monocytic leukemia cell line U937", "PROBLEM", 0, 52], ["the highly metastatic mouse melanoma cell line B16F10", "TREATMENT", 57, 110], ["METHODSAntihuman APN monoclonal antibody", "TEST", 164, 204], ["METHODSCloning", "TREATMENT", 315, 329], ["human endostatin", "TREATMENT", 359, 375], ["Pichia pastoris", "PROBLEM", 441, 456], ["human", "ANATOMY", 4, 9], ["leukemic monocytic leukemia cell line U937", "OBSERVATION", 10, 52], ["highly", "OBSERVATION_MODIFIER", 61, 67], ["metastatic", "OBSERVATION_MODIFIER", 68, 78], ["mouse", "OBSERVATION_MODIFIER", 79, 84], ["melanoma cell line B16F10", "OBSERVATION", 85, 110], ["yeast expression", "OBSERVATION", 414, 430], ["Pichia pastoris", "OBSERVATION", 441, 456]]], ["Restriction enzymes and Taq DNA polymerase were purchased from Boehringer Mannheim (Indianapolis, IN).", [["Taq", "GENE_OR_GENE_PRODUCT", 24, 27], ["DNA", "CELLULAR_COMPONENT", 28, 31], ["Boehringer Mannheim", "ORGANISM", 63, 82], ["Indianapolis, IN", "ORGANISM", 84, 100], ["Restriction enzymes", "PROTEIN", 0, 19], ["Taq DNA polymerase", "PROTEIN", 24, 42], ["Restriction enzymes", "TEST", 0, 19], ["Taq DNA polymerase", "TEST", 24, 42]]], ["To make NGR modification, the following sets of primers were used: up, TTCTCGAATTCAACGGGCGCCACAGCCACCGCGACTTCCAG; down, GGGGCGGCCGCCTACTTGGAGGCAGTCATGAAGCT.Cloning and Expression of Human Endostatin ::: MATERIALS AND METHODSAmplified fragments were purified, digested with EcoRl and Notl, and cloned into pPICZ\u03b1\u2010A vector.", [["Human", "ORGANISM", 182, 187], ["Endostatin", "GENE_OR_GENE_PRODUCT", 188, 198], ["EcoRl", "GENE_OR_GENE_PRODUCT", 273, 278], ["Notl", "GENE_OR_GENE_PRODUCT", 283, 287], ["NGR", "DNA", 8, 11], ["Human Endostatin", "PROTEIN", 182, 198], ["METHODSAmplified fragments", "DNA", 217, 243], ["EcoRl", "PROTEIN", 273, 278], ["Notl", "PROTEIN", 283, 287], ["pPICZ\u03b1\u2010A vector", "DNA", 305, 320], ["Human", "SPECIES", 182, 187], ["NGR modification", "TREATMENT", 8, 24], ["METHODSAmplified fragments", "PROBLEM", 217, 243]]], ["Plasmid DNA was then linearized at the Sacl site and used for homologous recombination into the yeast host strain X\u201033 (Invitrogen) by electroporation.", [["Plasmid DNA", "CELLULAR_COMPONENT", 0, 11], ["Invitrogen)", "ORGANISM", 120, 131], ["Plasmid DNA", "DNA", 0, 11], ["Sacl site", "DNA", 39, 48], ["yeast", "SPECIES", 96, 101], ["yeast", "SPECIES", 96, 101], ["Plasmid DNA", "TREATMENT", 0, 11], ["homologous recombination", "TREATMENT", 62, 86], ["yeast host strain", "OBSERVATION", 96, 113]]], ["Recombinant clones were selected on Zeocin\u2010containing plates and were characterized for the expression of endostatins.Purification of Recombinant Proteins ::: MATERIALS AND METHODSPichia clones were cultured in baffled shaker flasks and induced by methanol as described previously.", [["clones", "ANATOMY", 12, 18], ["METHODSPichia clones", "ANATOMY", 173, 193], ["methanol", "CHEMICAL", 248, 256], ["methanol", "CHEMICAL", 248, 256], ["clones", "CELL", 12, 18], ["endostatins", "GENE_OR_GENE_PRODUCT", 106, 117], ["METHODSPichia clones", "CELL", 173, 193], ["methanol", "SIMPLE_CHEMICAL", 248, 256], ["endostatins", "PROTEIN", 106, 117], ["Recombinant Proteins", "PROTEIN", 134, 154], ["METHODSPichia clones", "CELL_LINE", 173, 193], ["Recombinant clones", "PROBLEM", 0, 18], ["Zeocin\u2010containing plates", "TREATMENT", 36, 60], ["endostatins", "PROBLEM", 106, 117], ["METHODSPichia clones", "PROBLEM", 173, 193], ["clones", "OBSERVATION", 12, 18]]], ["For large\u2010scale preparations, a fermentation procedure was used.", [["large\u2010scale preparations", "TREATMENT", 4, 28], ["a fermentation procedure", "TREATMENT", 30, 54]]], ["Endostatin and NGR\u2010endostatin were purified by heparin affinity chromatography by following the published methods.19 The heparin column was equilibrated with 10 mM Tris\u2010HCl buffer, pH 7.6, and 0.5 mM phenylmethylsulfonyl fluoride (PMSF).", [["Endostatin", "CHEMICAL", 0, 10], ["NGR\u2010endostatin", "CHEMICAL", 15, 29], ["heparin", "CHEMICAL", 47, 54], ["heparin", "CHEMICAL", 121, 128], ["Tris\u2010HCl", "CHEMICAL", 164, 172], ["phenylmethylsulfonyl fluoride", "CHEMICAL", 200, 229], ["Endostatin", "CHEMICAL", 0, 10], ["NGR\u2010endostatin", "CHEMICAL", 15, 29], ["Tris", "CHEMICAL", 164, 168], ["HCl", "CHEMICAL", 169, 172], ["phenylmethylsulfonyl fluoride", "CHEMICAL", 200, 229], ["PMSF", "CHEMICAL", 231, 235], ["Endostatin", "GENE_OR_GENE_PRODUCT", 0, 10], ["NGR\u2010endostatin", "SIMPLE_CHEMICAL", 15, 29], ["heparin", "SIMPLE_CHEMICAL", 47, 54], ["heparin", "SIMPLE_CHEMICAL", 121, 128], ["phenylmethylsulfonyl fluoride", "SIMPLE_CHEMICAL", 200, 229], ["PMSF", "SIMPLE_CHEMICAL", 231, 235], ["NGR\u2010endostatin", "PROTEIN", 15, 29], ["Endostatin", "TREATMENT", 0, 10], ["NGR\u2010endostatin", "TREATMENT", 15, 29], ["heparin affinity chromatography", "TREATMENT", 47, 78], ["The heparin column", "TREATMENT", 117, 135], ["10 mM Tris\u2010HCl buffer", "TREATMENT", 158, 179], ["pH", "TEST", 181, 183], ["0.5 mM phenylmethylsulfonyl fluoride", "TREATMENT", 193, 229]]], ["Samples were applied to the column at a flow rate of 1.0 mL per minute with fast\u2010performance liquid chromatography (Amersham Pharmacia Biotech, Piscataway, NJ).", [["Samples", "TEST", 0, 7], ["a flow rate", "TEST", 38, 49], ["fast\u2010performance liquid chromatography", "TEST", 76, 114]]], ["After thorough washing to remove unbound proteins, bound proteins were eluted with a continuous gradient of 0\u20131 M NaCl in 10 mM Tris\u2010HCl, pH 7.6; and 0.5 mM PMSF.", [["NaCl", "CHEMICAL", 114, 118], ["Tris\u2010HCl", "CHEMICAL", 128, 136], ["NaCl", "CHEMICAL", 114, 118], ["Tris", "CHEMICAL", 128, 132], ["HCl", "CHEMICAL", 133, 136], ["PMSF", "CHEMICAL", 157, 161], ["Tris\u2010HCl", "SIMPLE_CHEMICAL", 128, 136], ["PMSF", "SIMPLE_CHEMICAL", 157, 161], ["unbound proteins", "PROTEIN", 33, 49], ["unbound proteins", "PROBLEM", 33, 49], ["bound proteins", "TEST", 51, 65], ["a continuous gradient", "TEST", 83, 104], ["NaCl", "TREATMENT", 114, 118], ["pH", "TEST", 138, 140]]], ["Both endostatin and NGR\u2010endostatin were eluted at \u2248 0.5 M NaCl.", [["\u2010endostatin", "CHEMICAL", 23, 34], ["NaCl", "CHEMICAL", 58, 62], ["\u2010endostatin", "CHEMICAL", 23, 34], ["NaCl", "CHEMICAL", 58, 62], ["endostatin", "GENE_OR_GENE_PRODUCT", 5, 15], ["NGR\u2010endostatin", "SIMPLE_CHEMICAL", 20, 34], ["endostatin", "PROTEIN", 5, 15], ["Both endostatin", "TREATMENT", 0, 15], ["NGR\u2010endostatin", "TREATMENT", 20, 34], ["endostatin", "OBSERVATION", 5, 15]]], ["Purified endostatins were analyzed on sodium dodecyl sulfate (SDS)\u2010polyacrylamide gel electrophoresis gels (15% acrylamide gel) under reducing conditions.Flow Cytometric Analysis ::: MATERIALS AND METHODSExpression levels of APN on a variety of cell lines were analyzed by flow cytometry.", [["cell lines", "ANATOMY", 245, 255], ["sodium dodecyl sulfate", "CHEMICAL", 38, 60], ["acrylamide gel", "CHEMICAL", 112, 126], ["sodium dodecyl sulfate", "CHEMICAL", 38, 60], ["SDS", "CHEMICAL", 62, 65], ["polyacrylamide", "CHEMICAL", 67, 81], ["acrylamide", "CHEMICAL", 112, 122], ["endostatins", "SIMPLE_CHEMICAL", 9, 20], ["sodium dodecyl sulfate", "SIMPLE_CHEMICAL", 38, 60], ["acrylamide", "SIMPLE_CHEMICAL", 112, 122], ["APN", "GENE_OR_GENE_PRODUCT", 225, 228], ["cell lines", "CELL", 245, 255], ["APN", "PROTEIN", 225, 228], ["cell lines", "CELL_LINE", 245, 255], ["Purified endostatins", "TREATMENT", 0, 20], ["sodium dodecyl sulfate (SDS)", "TREATMENT", 38, 66], ["polyacrylamide gel electrophoresis gels", "TREATMENT", 67, 106], ["15% acrylamide gel", "TREATMENT", 108, 126], ["Flow Cytometric Analysis", "TEST", 154, 178], ["METHODSExpression levels", "TEST", 197, 221], ["APN", "PROBLEM", 225, 228], ["cell lines", "TREATMENT", 245, 255], ["flow cytometry", "TEST", 273, 287], ["cell lines", "OBSERVATION", 245, 255], ["flow cytometry", "OBSERVATION", 273, 287]]], ["Cells were detached by 2 mM ethylenediamine tetraacetic acid (EDTA)/phosphate\u2010buffered saline (PBS) and washed with Hank's balanced salt solution (HBSS).", [["Cells", "ANATOMY", 0, 5], ["ethylenediamine tetraacetic acid", "CHEMICAL", 28, 60], ["EDTA", "CHEMICAL", 62, 66], ["phosphate", "CHEMICAL", 68, 77], ["ethylenediamine tetraacetic acid", "CHEMICAL", 28, 60], ["EDTA", "CHEMICAL", 62, 66], ["phosphate", "CHEMICAL", 68, 77], ["Cells", "CELL", 0, 5], ["ethylenediamine tetraacetic acid", "SIMPLE_CHEMICAL", 28, 60], ["EDTA", "SIMPLE_CHEMICAL", 62, 66], ["phosphate\u2010buffered saline", "SIMPLE_CHEMICAL", 68, 93], ["PBS", "SIMPLE_CHEMICAL", 95, 98], ["2 mM ethylenediamine tetraacetic acid (EDTA", "TREATMENT", 23, 66], ["phosphate\u2010buffered saline (PBS", "TREATMENT", 68, 98], ["Hank's balanced salt solution", "TREATMENT", 116, 145]]], ["The cells were fixed with ice\u2010cold 1% paraformaldehyde.", [["cells", "ANATOMY", 4, 9], ["paraformaldehyde", "CHEMICAL", 38, 54], ["cells", "CELL", 4, 9], ["paraformaldehyde", "SIMPLE_CHEMICAL", 38, 54], ["ice\u2010cold 1% paraformaldehyde", "TREATMENT", 26, 54]]], ["After washing the cells with HBSS, a monoclonal antibody to APN (1:20 dilution) was added to the cells.", [["cells", "ANATOMY", 18, 23], ["cells", "ANATOMY", 97, 102], ["cells", "CELL", 18, 23], ["HBSS", "SIMPLE_CHEMICAL", 29, 33], ["APN", "GENE_OR_GENE_PRODUCT", 60, 63], ["cells", "CELL", 97, 102], ["monoclonal antibody", "PROTEIN", 37, 56], ["APN", "PROTEIN", 60, 63], ["HBSS", "TREATMENT", 29, 33], ["a monoclonal antibody", "TREATMENT", 35, 56], ["APN", "TEST", 60, 63]]], ["Fluorescein isothiocyanate (FITC)\u2010conjugated antimouse immunoglobulin G was used as the second antibody.APN Activity ::: MATERIALS AND METHODSAPN was extracted from cells, as described below (see Results), by lysis buffer (20 mM Tris\u2010HCl, pH 7.6; 150 mM NaCl; 2 mM PMSF;, 10 \u03bcg/mL leupeptin; 0.5 mM o\u2010vanadate; 20 mM N\u2010ethyl\u2010maleimide; and 2% Triton\u2010X), and the enzymatic activity was determined using 0.225 mg (0.9 \u03bcmole) alanine p\u2010nitroanilide as a substrate.4 The cell lysate (10 \u03bcg protein) was incubated in a reaction buffer in the presence or absence of inhibitors at 37 \u00b0C for 2 hours.", [["cells", "ANATOMY", 165, 170], ["cell lysate", "ANATOMY", 467, 478], ["Fluorescein isothiocyanate", "CHEMICAL", 0, 26], ["Tris\u2010HCl", "CHEMICAL", 229, 237], ["NaCl", "CHEMICAL", 254, 258], ["o\u2010vanadate", "CHEMICAL", 299, 309], ["N\u2010ethyl\u2010maleimide", "CHEMICAL", 317, 334], ["Triton\u2010X", "CHEMICAL", 343, 351], ["alanine", "CHEMICAL", 423, 430], ["Fluorescein isothiocyanate", "CHEMICAL", 0, 26], ["FITC", "CHEMICAL", 28, 32], ["Tris\u2010HCl", "CHEMICAL", 229, 237], ["NaCl", "CHEMICAL", 254, 258], ["PMSF", "CHEMICAL", 265, 269], ["leupeptin", "CHEMICAL", 281, 290], ["o\u2010vanadate", "CHEMICAL", 299, 309], ["N\u2010ethyl\u2010maleimide", "CHEMICAL", 317, 334], ["alanine", "CHEMICAL", 423, 430], ["p\u2010nitroanilide", "CHEMICAL", 431, 445], ["Fluorescein isothiocyanate", "SIMPLE_CHEMICAL", 0, 26], ["FITC", "SIMPLE_CHEMICAL", 28, 32], ["antimouse immunoglobulin G", "GENE_OR_GENE_PRODUCT", 45, 71], ["APN", "GENE_OR_GENE_PRODUCT", 104, 107], ["cells", "CELL", 165, 170], ["PMSF", "SIMPLE_CHEMICAL", 265, 269], ["leupeptin", "SIMPLE_CHEMICAL", 281, 290], ["o\u2010vanadate", "SIMPLE_CHEMICAL", 299, 309], ["N\u2010ethyl\u2010maleimide", "SIMPLE_CHEMICAL", 317, 334], ["Triton\u2010X", "SIMPLE_CHEMICAL", 343, 351], ["\u03bcmole) alanine p\u2010nitroanilide", "SIMPLE_CHEMICAL", 416, 445], ["cell lysate", "CELL", 467, 478], ["Fluorescein isothiocyanate (FITC)\u2010conjugated antimouse immunoglobulin G", "PROTEIN", 0, 71], ["APN", "PROTEIN", 104, 107], ["Fluorescein isothiocyanate (FITC)\u2010conjugated antimouse immunoglobulin G", "TREATMENT", 0, 71], ["Tris", "TEST", 229, 233], ["HCl", "TEST", 234, 237], ["pH", "TEST", 239, 241], ["NaCl", "TEST", 254, 258], ["PMSF", "TEST", 265, 269], ["leupeptin", "TREATMENT", 281, 290], ["o\u2010vanadate", "TREATMENT", 299, 309], ["20 mM N\u2010ethyl\u2010maleimide", "TREATMENT", 311, 334], ["2% Triton\u2010X", "TREATMENT", 340, 351], ["alanine p\u2010nitroanilide", "TREATMENT", 423, 445], ["The cell lysate", "TREATMENT", 463, 478], ["a reaction buffer", "TREATMENT", 512, 529], ["inhibitors", "TREATMENT", 560, 570], ["cell lysate", "OBSERVATION", 467, 478]]], ["APN activity was measured by changes in absorbance at 405 nanometers (nm).", [["APN", "GENE_OR_GENE_PRODUCT", 0, 3], ["APN", "PROTEIN", 0, 3], ["activity", "OBSERVATION_MODIFIER", 4, 12]]], ["Bestatin, a known APN inhibitor, was used as a positive control; and leupeptin, a serine protease inhibitor, was used as a negative control.Cell Attachment Assay ::: MATERIALS AND METHODSOne nanomolar per well of either endostatin or NGR\u2010endostatin or 0.2% gelatin was used to coat 96\u2010well enzyme\u2010linked immunoadsorbent assay (ELISA) plates.", [["Cell", "ANATOMY", 140, 144], ["Bestatin", "CHEMICAL", 0, 8], ["leupeptin", "CHEMICAL", 69, 78], ["NGR\u2010endostatin", "CHEMICAL", 234, 248], ["gelatin", "CHEMICAL", 257, 264], ["Bestatin", "CHEMICAL", 0, 8], ["leupeptin", "CHEMICAL", 69, 78], ["serine", "CHEMICAL", 82, 88], ["Bestatin", "SIMPLE_CHEMICAL", 0, 8], ["APN", "GENE_OR_GENE_PRODUCT", 18, 21], ["leupeptin", "SIMPLE_CHEMICAL", 69, 78], ["Cell", "CELL", 140, 144], ["endostatin", "GENE_OR_GENE_PRODUCT", 220, 230], ["NGR\u2010endostatin", "SIMPLE_CHEMICAL", 234, 248], ["gelatin", "SIMPLE_CHEMICAL", 257, 264], ["endostatin", "PROTEIN", 220, 230], ["Bestatin", "TREATMENT", 0, 8], ["a known APN inhibitor", "TREATMENT", 10, 31], ["a positive control", "TREATMENT", 45, 63], ["leupeptin", "TREATMENT", 69, 78], ["a serine protease inhibitor", "TREATMENT", 80, 107], ["METHODSOne nanomolar", "TREATMENT", 180, 200], ["either endostatin", "TREATMENT", 213, 230], ["NGR\u2010endostatin", "TREATMENT", 234, 248], ["0.2% gelatin", "TREATMENT", 252, 264]]], ["The plates were incubated at 4 \u00b0C overnight and then blocked with 2% bovine serum albumin (BSA) in PBS at 37 \u00b0C for 2 hours.", [["serum", "ANATOMY", 76, 81], ["bovine", "ORGANISM", 69, 75], ["serum", "ORGANISM_SUBSTANCE", 76, 81], ["albumin", "SIMPLE_CHEMICAL", 82, 89], ["BSA", "SIMPLE_CHEMICAL", 91, 94], ["bovine", "SPECIES", 69, 75], ["bovine", "SPECIES", 69, 75], ["The plates", "TREATMENT", 0, 10], ["2% bovine serum albumin (BSA", "TREATMENT", 66, 94], ["PBS", "TEST", 99, 102]]], ["HUVEC or WM35 cells were harvested by 2 mM EDTA in PBS and prelabeled for 10 minutes at 37 \u00b0C with 5 \u03bcM 5\u2010(and\u20106)\u2010carboxy fluorescein diacetate, succinimidyl ester (5[6]\u2010CFDA), a vital fluorescence dye (Molecular Probes, Eugene, OR).", [["HUVEC", "ANATOMY", 0, 5], ["WM35 cells", "ANATOMY", 9, 19], ["EDTA", "CHEMICAL", 43, 47], ["fluorescein diacetate", "CHEMICAL", 122, 143], ["succinimidyl ester", "CHEMICAL", 145, 163], ["5[6]\u2010CFDA", "CHEMICAL", 165, 174], ["EDTA", "CHEMICAL", 43, 47], ["carboxy fluorescein diacetate", "CHEMICAL", 114, 143], ["succinimidyl ester", "CHEMICAL", 145, 163], ["5[6]\u2010CFDA", "CHEMICAL", 165, 174], ["HUVEC", "CELL", 0, 5], ["WM35 cells", "CELL", 9, 19], ["EDTA", "SIMPLE_CHEMICAL", 43, 47], ["\u20106)\u2010carboxy fluorescein diacetate", "SIMPLE_CHEMICAL", 110, 143], ["succinimidyl ester", "SIMPLE_CHEMICAL", 145, 163], ["5[6]\u2010CFDA", "SIMPLE_CHEMICAL", 165, 174], ["Eugene", "SIMPLE_CHEMICAL", 221, 227], ["HUVEC", "CELL_LINE", 0, 5], ["WM35 cells", "CELL_LINE", 9, 19], ["WM35 cells", "PROBLEM", 9, 19], ["carboxy fluorescein diacetate", "TREATMENT", 114, 143], ["succinimidyl ester", "TREATMENT", 145, 163], ["a vital fluorescence dye", "TREATMENT", 177, 201]]], ["After washing with HBSS, fluorescence\u2010labeled cells were resuspended in endothelial growth medium (HUVEC cells) or RPMI\u20101640 medium (WM35 cells).", [["cells", "ANATOMY", 46, 51], ["endothelial", "ANATOMY", 72, 83], ["HUVEC cells", "ANATOMY", 99, 110], ["WM35 cells", "ANATOMY", 133, 143], ["HBSS", "SIMPLE_CHEMICAL", 19, 23], ["cells", "CELL", 46, 51], ["endothelial", "CELL", 72, 83], ["HUVEC cells", "CELL", 99, 110], ["WM35 cells", "CELL", 133, 143], ["\u2010labeled cells", "CELL_LINE", 37, 51], ["HUVEC cells", "CELL_LINE", 99, 110], ["WM35 cells", "CELL_LINE", 133, 143], ["HBSS", "TREATMENT", 19, 23], ["fluorescence\u2010labeled cells", "TREATMENT", 25, 51], ["RPMI", "TEST", 115, 119], ["endothelial", "ANATOMY", 72, 83]]], ["Cells were added to the wells at a density of 40,000 cells per well.", [["Cells", "ANATOMY", 0, 5], ["cells", "ANATOMY", 53, 58], ["Cells", "CELL", 0, 5], ["cells", "CELL", 53, 58]]], ["After a 1\u2010hour incubation at 37 \u00b0C, plates were washed twice with HBSS to remove unbound cells.", [["cells", "ANATOMY", 89, 94], ["cells", "CELL", 89, 94], ["a 1\u2010hour incubation", "TREATMENT", 6, 25], ["HBSS", "TREATMENT", 66, 70], ["unbound cells", "PROBLEM", 81, 94], ["unbound cells", "OBSERVATION", 81, 94]]], ["Cells bound to the wells were detected by a fluorescence plate reader (Cyto Fluor II; PerSeptive Biosystems, Framingham, MA) (excitation; 485 nm, emission; 530 nm).Endothelial Cell Proliferation Assay ::: MATERIALS AND METHODSEssentially, the method described by O'Reilly et al. was used.12 Confluent BCE cells were trypsinized and resuspended in M199 (Invitrogen) medium with 5% fetal bovine serum (FBS).", [["Cells", "ANATOMY", 0, 5], ["Endothelial Cell", "ANATOMY", 164, 180], ["BCE cells", "ANATOMY", 301, 310], ["fetal bovine serum", "ANATOMY", 380, 398], ["FBS", "ANATOMY", 400, 403], ["Cells", "CELL", 0, 5], ["Endothelial Cell", "CELL", 164, 180], ["Confluent BCE cells", "CELL", 291, 310], ["bovine", "ORGANISM", 386, 392], ["serum", "ORGANISM_SUBSTANCE", 393, 398], ["FBS", "ORGANISM_SUBSTANCE", 400, 403], ["BCE cells", "CELL_LINE", 301, 310], ["bovine", "SPECIES", 386, 392], ["bovine", "SPECIES", 386, 392], ["Cells bound", "PROBLEM", 0, 11], ["a fluorescence plate", "TEST", 42, 62], ["Confluent BCE cells", "TEST", 291, 310], ["5% fetal bovine serum", "TEST", 377, 398], ["Cell Proliferation", "OBSERVATION", 176, 194], ["Confluent", "OBSERVATION_MODIFIER", 291, 300], ["BCE cells", "OBSERVATION", 301, 310]]], ["Cells were then seeded into gelatinized, 96\u2010well culture plates at a density of 5000 cells per well.", [["Cells", "ANATOMY", 0, 5], ["cells", "ANATOMY", 85, 90], ["Cells", "CELL", 0, 5], ["cells", "CELL", 85, 90], ["culture plates", "TEST", 49, 63]]], ["After 24 hours, endostatin or NGR\u2010endostatin was added at a concentration of 2.5 \u03bcg/mL.", [["NGR\u2010endostatin", "CHEMICAL", 30, 44], ["endostatin", "GENE_OR_GENE_PRODUCT", 16, 26], ["NGR\u2010endostatin", "SIMPLE_CHEMICAL", 30, 44], ["endostatin", "PROTEIN", 16, 26], ["endostatin", "TREATMENT", 16, 26], ["NGR\u2010endostatin", "TREATMENT", 30, 44]]], ["Twenty minutes later, cultures were treated with 5 ng/mL of bFGF (Invitrogen).", [["cultures", "ANATOMY", 22, 30], ["bFGF", "GENE_OR_GENE_PRODUCT", 60, 64], ["Invitrogen", "GENE_OR_GENE_PRODUCT", 66, 76], ["bFGF", "PROTEIN", 60, 64], ["cultures", "TEST", 22, 30], ["bFGF (Invitrogen)", "TREATMENT", 60, 77]]], ["The viability of the control cells and the treated cells was determined by 5\u2032\u2010bromo\u20102\u2032\u2010deoxyuridine incorporation (Roche, Indianapolis, IN) according to the manufacturer's instructions.Endothelial Cell Migration Assay ::: MATERIALS AND METHODSThe migration of endothelial cells was determined by using Boyden chambers (Neuro Probe, Gaithersburg, MD).", [["cells", "ANATOMY", 29, 34], ["cells", "ANATOMY", 51, 56], ["Endothelial Cell", "ANATOMY", 185, 201], ["endothelial cells", "ANATOMY", 260, 277], ["5\u2032\u2010bromo\u20102\u2032\u2010deoxyuridine", "CHEMICAL", 75, 99], ["5\u2032\u2010bromo\u20102\u2032\u2010deoxyuridine", "CHEMICAL", 75, 99], ["cells", "CELL", 29, 34], ["cells", "CELL", 51, 56], ["5\u2032\u2010bromo\u20102\u2032\u2010deoxyuridine", "SIMPLE_CHEMICAL", 75, 99], ["Endothelial Cell", "CELL", 185, 201], ["endothelial cells", "CELL", 260, 277], ["control cells", "CELL_TYPE", 21, 34], ["treated cells", "CELL_LINE", 43, 56], ["endothelial cells", "CELL_TYPE", 260, 277], ["the treated cells", "TREATMENT", 39, 56], ["deoxyuridine incorporation", "TREATMENT", 87, 113], ["Endothelial Cell Migration Assay", "TEST", 185, 217], ["METHODSThe migration of endothelial cells", "TREATMENT", 236, 277], ["Boyden chambers", "TREATMENT", 302, 317], ["viability", "OBSERVATION_MODIFIER", 4, 13], ["Cell Migration", "OBSERVATION", 197, 211], ["endothelial cells", "OBSERVATION", 260, 277]]], ["Polycarbonate filters (pore size, 12 \u03bcm) were coated with 0.2% gelatin for 1 hour at 37 \u00b0C. HUVEC cells were harvested in 2 mM EDTA in PBS and were prelabeled with 5 \u03bcM 5[6]\u2010CFDA for 10 minutes at 37 \u00b0C. Cells were resuspended in 0.5% FBS and M199 medium and then preincubated with endostatin, NGR\u2010endostatin, or SR\u20101 (an NGR\u2010containing peptide) for 60 minutes at 37 \u00b0C. bFGF (25 \u03bcL of 25 ng/mL 0.5% FBS and M199 medium) was added to the lower chambers.", [["pore", "ANATOMY", 23, 27], ["HUVEC cells", "ANATOMY", 92, 103], ["Cells", "ANATOMY", 204, 209], ["FBS", "ANATOMY", 235, 238], ["FBS", "ANATOMY", 400, 403], ["gelatin", "CHEMICAL", 63, 70], ["EDTA", "CHEMICAL", 127, 131], ["CFDA", "CHEMICAL", 174, 178], ["bFGF", "CHEMICAL", 371, 375], ["Polycarbonate", "CHEMICAL", 0, 13], ["EDTA", "CHEMICAL", 127, 131], ["Polycarbonate", "SIMPLE_CHEMICAL", 0, 13], ["HUVEC cells", "CELL", 92, 103], ["EDTA", "SIMPLE_CHEMICAL", 127, 131], ["CFDA", "SIMPLE_CHEMICAL", 174, 178], ["Cells", "CELL", 204, 209], ["FBS", "ORGANISM_SUBSTANCE", 235, 238], ["endostatin", "GENE_OR_GENE_PRODUCT", 282, 292], ["NGR\u2010endostatin", "SIMPLE_CHEMICAL", 294, 308], ["SR\u20101", "SIMPLE_CHEMICAL", 313, 317], ["bFGF", "GENE_OR_GENE_PRODUCT", 371, 375], ["FBS", "ORGANISM_SUBSTANCE", 400, 403], ["HUVEC cells", "CELL_LINE", 92, 103], ["endostatin", "PROTEIN", 282, 292], ["bFGF", "PROTEIN", 371, 375], ["Polycarbonate filters (pore size", "TREATMENT", 0, 32], ["0.2% gelatin", "TREATMENT", 58, 70], ["HUVEC cells", "PROBLEM", 92, 103], ["2 mM EDTA in PBS", "TREATMENT", 122, 138], ["Cells", "TEST", 204, 209], ["endostatin", "TREATMENT", 282, 292], ["NGR\u2010endostatin", "TREATMENT", 294, 308], ["SR\u20101", "TREATMENT", 313, 317], ["an NGR\u2010containing peptide", "TREATMENT", 319, 344], ["bFGF", "TEST", 371, 375], ["size", "OBSERVATION_MODIFIER", 28, 32], ["lower", "ANATOMY_MODIFIER", 438, 443]]], ["HUVEC cells (200,000 cells/mL, control and treated) were added to the upper chambers.", [["HUVEC cells", "ANATOMY", 0, 11], ["cells", "ANATOMY", 21, 26], ["HUVEC cells", "CELL", 0, 11], ["cells", "CELL", 21, 26], ["HUVEC cells", "CELL_LINE", 0, 11], ["200,000 cells", "CELL_LINE", 13, 26], ["HUVEC cells", "TEST", 0, 11], ["upper", "ANATOMY_MODIFIER", 70, 75]]], ["After 4 hours of incubation at 37 \u00b0C, endothelial cells that had migrated to the bottom side of the membrane were observed under a fluorescence microscope (Olympus, Melville, NY) using FITC filters (magnification, \u00d7 100).", [["endothelial cells", "ANATOMY", 38, 55], ["membrane", "ANATOMY", 100, 108], ["FITC", "CHEMICAL", 185, 189], ["endothelial cells", "CELL", 38, 55], ["membrane", "CELLULAR_COMPONENT", 100, 108], ["endothelial cells", "CELL_TYPE", 38, 55], ["incubation", "TREATMENT", 17, 27], ["endothelial cells", "PROBLEM", 38, 55], ["a fluorescence microscope", "TEST", 129, 154], ["FITC filters", "TREATMENT", 185, 197], ["endothelial cells", "OBSERVATION", 38, 55], ["bottom", "ANATOMY_MODIFIER", 81, 87], ["membrane", "ANATOMY", 100, 108], ["FITC filters", "OBSERVATION", 185, 197]]], ["The captured images were quantified in the Adobe Photoshop (Adobe Systems, Inc., San Jose, CA) and MetaMorph (Molecular Devices Corporation, Downingtown, PA) programs.", [["The captured images", "TEST", 0, 19], ["MetaMorph (Molecular Devices Corporation", "TREATMENT", 99, 139], ["Downingtown, PA) programs", "TREATMENT", 141, 166]]], ["Two independent experiments were performed.Tumor Localization ::: MATERIALS AND METHODSLS174T cells were injected subcutaneously in both sides of the flanks of female athymic nude mice (age 8 weeks).", [["Tumor", "ANATOMY", 43, 48], ["METHODSLS174T cells", "ANATOMY", 80, 99], ["subcutaneously", "ANATOMY", 114, 128], ["flanks", "ANATOMY", 150, 156], ["Tumor", "CANCER", 43, 48], ["METHODSLS174T cells", "CELL", 80, 99], ["flanks", "ORGANISM_SUBDIVISION", 150, 156], ["athymic nude mice", "ORGANISM", 167, 184], ["METHODSLS174T cells", "CELL_LINE", 80, 99], ["mice", "SPECIES", 180, 184], ["mice", "SPECIES", 180, 184], ["METHODSLS174T cells", "TREATMENT", 80, 99], ["flanks", "ANATOMY", 150, 156]]], ["Tumor size reached \u2248 500 mm3 in volume on Day 10.", [["Tumor", "ANATOMY", 0, 5], ["Tumor", "CANCER", 0, 5], ["Tumor size", "TEST", 0, 10], ["size", "OBSERVATION_MODIFIER", 6, 10], ["500 mm3", "OBSERVATION_MODIFIER", 21, 28]]], ["Tumor\u2010bearing mice were randomized into two groups: a control group with seven mice and an experimental group with eight mice.", [["mice", "ORGANISM", 14, 18], ["mice", "ORGANISM", 79, 83], ["mice", "ORGANISM", 121, 125], ["mice", "SPECIES", 14, 18], ["mice", "SPECIES", 79, 83], ["mice", "SPECIES", 121, 125], ["mice", "SPECIES", 14, 18], ["mice", "SPECIES", 79, 83], ["mice", "SPECIES", 121, 125]]], ["Endostatin or NGR\u2010endostatin was injected at a dose of 20 mg/kg subcutaneously.", [["subcutaneously", "ANATOMY", 64, 78], ["Endostatin", "CHEMICAL", 0, 10], ["NGR\u2010endostatin", "CHEMICAL", 14, 28], ["Endostatin", "CHEMICAL", 0, 10], ["Endostatin", "SIMPLE_CHEMICAL", 0, 10], ["NGR\u2010endostatin", "SIMPLE_CHEMICAL", 14, 28], ["Endostatin", "TREATMENT", 0, 10], ["NGR\u2010endostatin", "TREATMENT", 14, 28]]], ["Nineteen hours after injection, tumor tissues (14 and 16 tumor samples from the respective groups) and representative normal tissues were removed surgically.", [["tumor tissues", "ANATOMY", 32, 45], ["tumor samples", "ANATOMY", 57, 70], ["tissues", "ANATOMY", 125, 132], ["tumor", "DISEASE", 32, 37], ["tumor", "DISEASE", 57, 62], ["tumor tissues", "TISSUE", 32, 45], ["tumor samples", "CANCER", 57, 70], ["normal tissues", "TISSUE", 118, 132], ["tumor tissues", "PROBLEM", 32, 45], ["tumor samples", "TEST", 57, 70], ["tumor tissues", "OBSERVATION", 32, 45], ["normal tissues", "OBSERVATION", 118, 132]]], ["This time point was chosen to minimize overwhelming serum levels from obscuring the tissue\u2010bound endostatin.", [["serum", "ANATOMY", 52, 57], ["serum", "ORGANISM_SUBSTANCE", 52, 57], ["endostatin", "GENE_OR_GENE_PRODUCT", 97, 107], ["tissue\u2010bound endostatin", "PROTEIN", 84, 107], ["overwhelming serum levels", "PROBLEM", 39, 64], ["the tissue\u2010bound endostatin", "TREATMENT", 80, 107]]], ["Tissues were snap frozen and homogenized in RIPA buffer containing proteinase inhibitors (PBS, 1% NP40, 0.5% sodium deoxycholate, 0.1% SDS, and 10 \u03bcg/mL PMSF), maintained at 4 \u00b0C for 45 minutes, and cleared by centrifugation.", [["Tissues", "ANATOMY", 0, 7], ["sodium deoxycholate", "CHEMICAL", 109, 128], ["NP40", "CHEMICAL", 98, 102], ["sodium deoxycholate", "CHEMICAL", 109, 128], ["PMSF", "CHEMICAL", 153, 157], ["Tissues", "TISSUE", 0, 7], ["NP40", "SIMPLE_CHEMICAL", 98, 102], ["sodium deoxycholate", "SIMPLE_CHEMICAL", 109, 128], ["PMSF", "SIMPLE_CHEMICAL", 153, 157], ["RIPA buffer", "TREATMENT", 44, 55], ["proteinase inhibitors", "TREATMENT", 67, 88], ["PBS", "TEST", 90, 93], ["0.5% sodium deoxycholate", "TREATMENT", 104, 128]]], ["Human endostatin concentrations in the serum and in tissue lysates were determined by ELISA (Cytimmune, College Park, MD).", [["serum", "ANATOMY", 39, 44], ["tissue lysates", "ANATOMY", 52, 66], ["Human", "ORGANISM", 0, 5], ["endostatin", "GENE_OR_GENE_PRODUCT", 6, 16], ["serum", "ORGANISM_SUBSTANCE", 39, 44], ["tissue lysates", "ORGANISM_SUBSTANCE", 52, 66], ["endostatin", "PROTEIN", 6, 16], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["Human endostatin concentrations", "TREATMENT", 0, 31], ["the serum", "TEST", 35, 44], ["tissue lysates", "TEST", 52, 66]]], ["The ELISA method showed similar sensitivity to both native endostatin and NGR\u2010endostatin (data not shown).", [["endostatin", "GENE_OR_GENE_PRODUCT", 59, 69], ["NGR\u2010endostatin", "SIMPLE_CHEMICAL", 74, 88], ["endostatin", "PROTEIN", 59, 69], ["NGR\u2010endostatin", "PROTEIN", 74, 88], ["The ELISA method", "TEST", 0, 16], ["similar sensitivity", "PROBLEM", 24, 43], ["native endostatin", "TREATMENT", 52, 69], ["NGR\u2010endostatin", "TREATMENT", 74, 88]]], ["Statistical significance was determined with a Student t test.Tumor Growth Inhibition Studies: Inhibition of Mouse Ovarian Carcinoma Growth in Athymic Nude Mice by Bolus Injection of NGR\u2010Endostatin ::: MATERIALS AND METHODSFemale athymic nude mice (age 4\u20136 weeks) were obtained from the National Cancer Institute and were acclimatized to local conditions for 1 week.", [["Tumor", "ANATOMY", 62, 67], ["Ovarian Carcinoma", "ANATOMY", 115, 132], ["Ovarian Carcinoma", "DISEASE", 115, 132], ["Bolus", "CHEMICAL", 164, 169], ["Cancer", "DISEASE", 296, 302], ["Tumor", "CANCER", 62, 67], ["Mouse", "ORGANISM", 109, 114], ["Ovarian Carcinoma", "CANCER", 115, 132], ["Nude Mice", "ORGANISM", 151, 160], ["Endostatin", "SIMPLE_CHEMICAL", 187, 197], ["athymic nude mice", "ORGANISM", 230, 247], ["Mouse", "SPECIES", 109, 114], ["Mice", "SPECIES", 156, 160], ["mice", "SPECIES", 243, 247], ["mice", "SPECIES", 243, 247], ["a Student t test", "TEST", 45, 61], ["Mouse Ovarian Carcinoma Growth", "PROBLEM", 109, 139], ["Athymic Nude Mice", "TREATMENT", 143, 160], ["Ovarian", "ANATOMY", 115, 122], ["Carcinoma", "OBSERVATION", 123, 132], ["Cancer", "OBSERVATION", 296, 302]]], ["Logarithmically growing mouse ovarian carcinoma cells (LM3) were harvested by trypsinization and suspended in fresh medium at a density of 1 \u00d7 107 cells/mL.", [["ovarian carcinoma cells", "ANATOMY", 30, 53], ["LM3", "ANATOMY", 55, 58], ["cells", "ANATOMY", 147, 152], ["ovarian carcinoma", "DISEASE", 30, 47], ["mouse", "ORGANISM", 24, 29], ["ovarian carcinoma cells", "CELL", 30, 53], ["LM3", "CELL", 55, 58], ["cells", "CELL", 147, 152], ["Logarithmically growing mouse ovarian carcinoma cells", "CELL_LINE", 0, 53], ["LM3", "CELL_LINE", 55, 58], ["mouse", "SPECIES", 24, 29], ["mouse", "SPECIES", 24, 29], ["Logarithmically growing mouse ovarian carcinoma cells", "PROBLEM", 0, 53], ["growing", "OBSERVATION_MODIFIER", 16, 23], ["mouse ovarian carcinoma cells", "OBSERVATION", 24, 53], ["fresh medium", "OBSERVATION_MODIFIER", 110, 122]]], ["Then, 100 \u03bcL of the single\u2010cell suspension were injected subcutaneously into the flanks of mice.", [["subcutaneously", "ANATOMY", 57, 71], ["flanks", "ANATOMY", 81, 87], ["flanks", "ORGANISM_SUBDIVISION", 81, 87], ["mice", "ORGANISM", 91, 95], ["mice", "SPECIES", 91, 95], ["mice", "SPECIES", 91, 95], ["the single\u2010cell suspension", "TREATMENT", 16, 42], ["flanks", "ANATOMY_MODIFIER", 81, 87]]], ["When the tumors became visible (5 days after inoculation), mice were randomized into groups.", [["tumors", "ANATOMY", 9, 15], ["tumors", "DISEASE", 9, 15], ["tumors", "CANCER", 9, 15], ["mice", "ORGANISM", 59, 63], ["mice", "SPECIES", 59, 63], ["mice", "SPECIES", 59, 63], ["the tumors", "PROBLEM", 5, 15], ["tumors", "OBSERVATION", 9, 15]]], ["The mice were treated with endostatin or NGR\u2010endostatin subcutaneously at a dose of 20 mg/kg per day for 12 days.", [["NGR\u2010endostatin", "CHEMICAL", 41, 55], ["mice", "ORGANISM", 4, 8], ["endostatin", "GENE_OR_GENE_PRODUCT", 27, 37], ["NGR", "SIMPLE_CHEMICAL", 41, 44], ["\u2010endostatin", "SIMPLE_CHEMICAL", 44, 55], ["mice", "SPECIES", 4, 8], ["mice", "SPECIES", 4, 8], ["endostatin", "TREATMENT", 27, 37], ["NGR\u2010endostatin", "TREATMENT", 41, 55]]], ["A control group of mice (n = 5 animals) was treated with sterile PBS under similar conditions.", [["mice", "ORGANISM", 19, 23], ["animals", "ORGANISM", 31, 38], ["mice", "SPECIES", 19, 23], ["mice", "SPECIES", 19, 23], ["A control group of mice (n = 5 animals", "TREATMENT", 0, 38], ["sterile PBS", "TREATMENT", 57, 68]]], ["All injections were given subcutaneously \u2248 2 cm away from the growing tumor mass.", [["subcutaneously", "ANATOMY", 26, 40], ["tumor mass", "ANATOMY", 70, 80], ["tumor", "DISEASE", 70, 75], ["tumor", "CANCER", 70, 75], ["All injections", "TREATMENT", 0, 14], ["the growing tumor mass", "PROBLEM", 58, 80], ["growing", "OBSERVATION_MODIFIER", 62, 69], ["tumor", "OBSERVATION", 70, 75], ["mass", "OBSERVATION", 76, 80]]], ["Tumor growth was monitored by periodic caliper measurements.", [["Tumor", "ANATOMY", 0, 5], ["Tumor", "CANCER", 0, 5], ["Tumor growth", "PROBLEM", 0, 12], ["periodic caliper measurements", "TEST", 30, 59]]], ["Tumor volume was calculated by the following formula: Tumor volume (mm3) = (a \u00d7 b2)/2, where a is the length in mm, and b is the width in mm (a > b).", [["Tumor", "ANATOMY", 0, 5], ["Tumor", "ANATOMY", 54, 59], ["Tumor", "CANCER", 0, 5], ["Tumor", "CANCER", 54, 59], ["Tumor volume", "TEST", 0, 12], ["Tumor volume", "TEST", 54, 66], ["Tumor", "OBSERVATION", 54, 59], ["length", "OBSERVATION_MODIFIER", 102, 108], ["width", "OBSERVATION_MODIFIER", 129, 134]]], ["Statistical significance between control and treated groups was determined with a Student t test.Inhibition of Human Ovarian Carcinoma in Athymic Nude Mice by NGR\u2010Endostatin\u2010Encapslated Alginate Beads ::: MATERIALS AND METHODSEndostatin\u2010encapsulated alginate beads were prepared as described previously.20 A control group of mice received vehicle\u2010encapsulated alginate beads on a similar schedule.", [["Ovarian Carcinoma", "ANATOMY", 117, 134], ["Ovarian Carcinoma", "DISEASE", 117, 134], ["Human", "ORGANISM", 111, 116], ["Ovarian Carcinoma", "CANCER", 117, 134], ["Nude Mice", "ORGANISM", 146, 155], ["mice", "ORGANISM", 325, 329], ["Human", "SPECIES", 111, 116], ["Mice", "SPECIES", 151, 155], ["mice", "SPECIES", 325, 329], ["mice", "SPECIES", 325, 329], ["a Student t test", "TEST", 80, 96], ["Human Ovarian Carcinoma", "PROBLEM", 111, 134], ["Athymic Nude Mice", "TREATMENT", 138, 155], ["Endostatin\u2010Encapslated Alginate Beads", "TREATMENT", 163, 200], ["METHODSEndostatin\u2010encapsulated alginate beads", "TREATMENT", 219, 264], ["vehicle\u2010encapsulated alginate beads", "TREATMENT", 339, 374], ["a similar schedule", "TREATMENT", 378, 396], ["Ovarian", "ANATOMY", 117, 124], ["Carcinoma", "OBSERVATION", 125, 134], ["alginate beads", "OBSERVATION", 250, 264]]], ["Alginic acid is a naturally occurring biopolymer that has been used as a matrix for entrapment and delivery of a variety of biologic agents.", [["matrix", "ANATOMY", 73, 79], ["Alginic acid", "CHEMICAL", 0, 12], ["Alginic acid", "CHEMICAL", 0, 12], ["Alginic acid", "SIMPLE_CHEMICAL", 0, 12], ["matrix", "CELLULAR_COMPONENT", 73, 79], ["Alginic acid", "PROBLEM", 0, 12], ["entrapment", "PROBLEM", 84, 94], ["delivery", "TREATMENT", 99, 107], ["a variety of biologic agents", "TREATMENT", 111, 139]]], ["Logarithmically growing MA148 cells were harvested by trypsinization and suspended in serum\u2010free medium at a density of 1 \u00d7 107 cells/mL.", [["MA148 cells", "ANATOMY", 24, 35], ["cells", "ANATOMY", 128, 133], ["MA148 cells", "CELL", 24, 35], ["cells", "CELL", 128, 133], ["MA148 cells", "CELL_LINE", 24, 35], ["Logarithmically growing MA148 cells", "PROBLEM", 0, 35], ["trypsinization", "TEST", 54, 68], ["MA148 cells", "OBSERVATION", 24, 35]]], ["Then, 100 \u03bcL of the single\u2010cell suspension were injected subcutaneously into the flanks of female athymic mice.", [["subcutaneously", "ANATOMY", 57, 71], ["flanks", "ANATOMY", 81, 87], ["flanks", "ORGANISM_SUBDIVISION", 81, 87], ["athymic mice", "ORGANISM", 98, 110], ["mice", "SPECIES", 106, 110], ["mice", "SPECIES", 106, 110], ["the single\u2010cell suspension", "TREATMENT", 16, 42], ["flanks", "ANATOMY", 81, 87], ["athymic mice", "OBSERVATION", 98, 110]]], ["When the tumors became visible (7 days after inoculation), mice were randomized into groups and were treated with endostatin\u2010encapsulated alginate beads (5 animals per group).", [["tumors", "ANATOMY", 9, 15], ["tumors", "DISEASE", 9, 15], ["tumors", "CANCER", 9, 15], ["mice", "ORGANISM", 59, 63], ["mice", "SPECIES", 59, 63], ["mice", "SPECIES", 59, 63], ["the tumors", "PROBLEM", 5, 15], ["endostatin\u2010encapsulated alginate beads", "TREATMENT", 114, 152], ["tumors", "OBSERVATION", 9, 15]]], ["Because alginate microencapsultion results in slow and sustained release in vivo, endostatin preparations were given once a week (total, four injections) in this study.", [["alginate microencapsultion", "CHEMICAL", 8, 34], ["alginate", "SIMPLE_CHEMICAL", 8, 16], ["endostatin", "GENE_OR_GENE_PRODUCT", 82, 92], ["endostatin", "PROTEIN", 82, 92], ["endostatin preparations", "TREATMENT", 82, 105], ["this study", "TEST", 157, 167], ["slow", "OBSERVATION_MODIFIER", 46, 50]]], ["Statistical significance between control and treated groups was determined with a Student t test.Determination of Vessel Density and Apoptosis ::: MATERIALS AND METHODSTo determine the effect of antiangiogenic treatments on vessel density and apoptosis, residual tumors were resected surgically and snap frozen in liquid nitrogen.", [["Vessel", "ANATOMY", 114, 120], ["vessel", "ANATOMY", 224, 230], ["tumors", "ANATOMY", 263, 269], ["tumors", "DISEASE", 263, 269], ["nitrogen", "CHEMICAL", 321, 329], ["Vessel", "TISSUE", 114, 120], ["vessel", "MULTI-TISSUE_STRUCTURE", 224, 230], ["tumors", "CANCER", 263, 269], ["a Student t test", "TEST", 80, 96], ["METHODSTo", "TREATMENT", 161, 170], ["antiangiogenic treatments", "TREATMENT", 195, 220], ["vessel density", "PROBLEM", 224, 238], ["apoptosis", "PROBLEM", 243, 252], ["residual tumors", "PROBLEM", 254, 269], ["liquid nitrogen", "TREATMENT", 314, 329], ["Vessel", "ANATOMY", 114, 120], ["Density", "OBSERVATION", 121, 128], ["Apoptosis", "OBSERVATION", 133, 142], ["vessel", "ANATOMY", 224, 230], ["density", "OBSERVATION", 231, 238], ["apoptosis", "OBSERVATION_MODIFIER", 243, 252], ["residual", "OBSERVATION_MODIFIER", 254, 262], ["tumors", "OBSERVATION", 263, 269]]], ["Cryostat sections (10 \u03bcm) of tumors were fixed in cold acetone, air dried, then treated with PBS containing 1% BSA to block nonspecific binding (background).", [["Cryostat sections", "ANATOMY", 0, 17], ["tumors", "ANATOMY", 29, 35], ["tumors", "DISEASE", 29, 35], ["BSA", "CHEMICAL", 111, 114], ["acetone", "CHEMICAL", 55, 62], ["Cryostat sections", "MULTI-TISSUE_STRUCTURE", 0, 17], ["tumors", "CANCER", 29, 35], ["acetone", "SIMPLE_CHEMICAL", 55, 62], ["BSA", "SIMPLE_CHEMICAL", 111, 114], ["Cryostat sections", "TEST", 0, 17], ["tumors", "PROBLEM", 29, 35], ["PBS", "TREATMENT", 93, 96], ["block nonspecific binding (background)", "PROBLEM", 118, 156], ["tumors", "OBSERVATION", 29, 35]]], ["Sections were then incubated with a 1:50 dilution of an anti\u2010CD31 (mouse) monoclonal antibody conjugated to phycoerythrin (MEC 13.3; BD PharMingen, San Diego, CA).", [["anti\u2010CD31", "GENE_OR_GENE_PRODUCT", 56, 65], ["mouse", "ORGANISM", 67, 72], ["phycoerythrin", "SIMPLE_CHEMICAL", 108, 121], ["anti\u2010CD31 (mouse) monoclonal antibody", "PROTEIN", 56, 93], ["phycoerythrin", "PROTEIN", 108, 121], ["BD PharMingen", "PROTEIN", 133, 146], ["mouse", "SPECIES", 67, 72], ["mouse", "SPECIES", 67, 72], ["an anti\u2010CD31 (mouse) monoclonal antibody", "TREATMENT", 53, 93], ["phycoerythrin", "TEST", 108, 121], ["MEC", "TEST", 123, 126]]], ["After a 1\u2010hour incubation at room temperature, sections were washed thoroughly with PBS and then examined with an Olympus BX\u201060 fluorescence microscope.", [["sections", "ANATOMY", 47, 55], ["PBS", "TREATMENT", 84, 87], ["an Olympus BX", "TEST", 111, 124], ["fluorescence microscope", "TEST", 128, 151]]], ["Images (7\u201310 fields per section) were captured by the Metamorph program for analysis.", [["Images", "TEST", 0, 6], ["analysis", "TEST", 76, 84]]], ["Detection of apoptosis was carried out by using an In Situ Cell Death Detection Kit (Boehringer Mannheim, Indianapolis, IN) following the manufacturer's protocol.", [["Cell", "ANATOMY", 59, 63], ["apoptosis", "PROBLEM", 13, 22], ["the manufacturer's protocol", "TREATMENT", 134, 161], ["apoptosis", "OBSERVATION", 13, 22]]], ["Parts of the tumor samples were also fixed in 10% neutral buffered formalin and processed for histology.20", [["tumor samples", "ANATOMY", 13, 26], ["tumor", "DISEASE", 13, 18], ["formalin", "CHEMICAL", 67, 75], ["tumor samples", "CANCER", 13, 26], ["formalin", "SIMPLE_CHEMICAL", 67, 75], ["the tumor samples", "TEST", 9, 26], ["histology", "TEST", 94, 103], ["tumor", "OBSERVATION", 13, 18]]]], "PMC7393014": [["An event is serious (based on the ICH definition) when the patient outcome is:", [["ICH", "DISEASE", 34, 37], ["patient", "ORGANISM", 59, 66], ["patient", "SPECIES", 59, 66], ["the ICH definition", "TEST", 30, 48], ["serious", "OBSERVATION_MODIFIER", 12, 19]]]], "PMC7232074": [], "PMC7480210": []}